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The following corrections were made to my Masters thesis in 
accordance with the specifications of the 3 examiners and the 
changes were approved by my supervisor Prof. E.H.Harley: 
Several general corrections were made to the entire thesis: 
- uM, ug symbols were changed to pM and pg. 
- °C replaced all 'C symbols. 
- Argininosuccinate synthetase, canavanine-resistance, 
tetrahydrobiopterin, nitric oxide, nitric oxide synthase 
were referred to by their abbreviated forms after their 
inital definition. 
- The possessive form of "it" was corrected from "it's" to 
"its". 
- The purpose of the error bars was defined in figures 22, 
23, 38, 40, 42, 44, 46. 
-The use of the non-standarq abbreviations for co1 , NO£ , 
ca2 + , Mgu etc • was corrected. 
- The Y-axis scale on figures 9, 11, 22, 31 and 40 were 
redefined as suggested. 
- Product names such as Falcon, Southern, Luria, Sephadex 
were capitalised. 
- Bacterial names and restriction enzymes were italisized. 
- The incorrect spelling of cycloheximide was altered 
throughout the thesis. 
- DNA marker names and sizes were given where appropriate •. 
The following specific corrections were also made: 
Spelling errors: 
pg 43: aperture. 
pg 50/61: electrophoresed. 
pg 51: thiocyanate, isoamyl alcohol. 
pg 112: iron-protoporphyrin, carbon monoxide. 
pg 115: relaxation. 
pg 123: hydroxyl. 
pg 127: in turn. 
pg 128: peroxynitrite. 
pg 129: threatening. 
pg 134: transcarbamylase. 
pg 138: aqueous, whereas. 
pg 139: solvent. 
pg 142: isocratic. 
pg 158: fumarate. 
pg 165: ice cold. 
pg 177: ketoglutarate. 
pg 195: immunology. 
- The section entitled " Development of amino acid 
separation tecniques" was more appropriately entitled 
"evaluation of amino acid separation techniques". 
pg 8: References to the G->A mutation were more correctly 
referred to as G->A transitions. 
pg 10/18: The figure from reference [1] was found to be 
incorrect and was altered accordingly. 
pg 17: The appropriate sentence was restructured. 
pg 21: Phosphate was changed to pyrophosphate. 
pg 24: This figure was reproduced to improve the quality, 
the bacterial names were put into italics and the 
full names of the bacteria were given. 
pg 25: The number of remaining ASS exons was corrected. 
pg 27: It was noted on the figure that the sequence given in 
this figure is +3 base pairs when compared to the 
Genbank sequence used throughout the rest of the 
study. The figure was also reprinted to improve the 
quality. 
pg 28: References were given to the various forms of 
evidence. 
pg 36: The description of atypical citrullinemia was 
redefined. 
,~-
pg 37: The reference to Table 2 was corrected and the 
description of the range of mutations altered. A 
sentence was included to explain why the exact 
frequencies of the various mutations have not been 
given. 
pg 40: The process in which the diagnosis of citrullinemia 
was achieved was more accurately detailed. 
pg 42: F535 was characterised in more detail. 
pg 43: The concentrations of the various antibiotics were 
given as mgjml. 
pg 45: The method of maintaining the specific activity in 
this experiment was clarified. 
pg 46: The origin of the· pASl plasmid was referenced. 
pg 50: Liquid scintillation spectrometer. 
pg 52: "Solubility" was changed to "dissolution". 
pg 55: The correct PCR program was inserted. 
pg 57/58: Reference 45 was relocated to indicate it as the 
reference for Smai cloning. 
pg 58: The reasoning behind the incubations in the 
transfection of competent cells was simplified. 
pg 59: The reference to the alpha fragment of the 
beta-galactosidase gene was corrected and the 
description of the "larger" plasmids" improved upon. 
The description of the PEG precipitation was 
rewritten to clarify the process. 
pg 60: The volume of the DNA sample and the molarity of the 
Tris.HCl solution were given. 
pg 61: "Respective" mixes. 
pg 69: "attack" was replaced with "approach". 
pg 75: "results not shown" was added. 
pg 77: It was stated that the original primers were not 
designed with "oligo" and that a Hot-start was only 
employed with the new set of primers. 
pg 79: A more accurate quantitation of the number of ASS 
target molecules was given, and the quantity of DNA 
used in the magnesium titration was also indicated .. 
pg 84: "Possibility" was substituted for " hypothesis". 
pg 87: The reasoning behind the use of Smai in the cloning 
reaction was clarified with regards to the prevention 
of plasmid religation. 
pg 89: The DNA was digested with Psti and ECoRI, and an 
uncut pUC18 band was indicated in figure A. 
pg 96: 1-1.5 fold and "up to a 0.5 fold decrease". 
pg 99: The term Km/Vmax mutant was found to be incorrect and 
consequently the term "alte~ed" was used. 
pg 103: The logic behind the role of glycine in the folding 
process was rewritten, and the evidence that the 
mutation was not a sequencing artifact was given. 
pg 104: The figure references were corrected and "whole 
cell" studies were performed. The possibilty that 
the mutation may cause the protein to become 
unstable and become more rapidly degraded was 
included in this discussion. 
pg 115: The abbreviation for acetylcholine was corrected and 
the abbreviation for soluable guanylate cyclase was 
given. 
pg 123: The remnant sentence was removed. 
pg 134: The unknown function of BH~, referred to 
cytokine-induced Ba+specifically. 
pg 146: Radioactive emission. 
pg 147: The purpose of the dashed argininosuccinate lines 
was explained. 
pg 150: The program was descibed in the methods section and 
was referred to in this figure. 
pg 156: The numbers of the various figures were corrected. 
pg 157: The last sentence was corrected as suggested. 
pg 162: The description of the "dilution effect" was 
clarified. 
pg 172: It was clarified in the text as to the reasoning 
behind the shortened incubation time for F500 and 
the length of the incubation was given in the graph 
legend. 
pg 173/176: References to peak Z were corrected to peak Y. 
The X-axis was also labelled. 
pg 178: The number of the diagram showing urea formation was 
corrected. 
pg 185: The correct incubation times were given for the 
nitric oxide assay and the assay given in the 
methods section was referred to as the finalised 
assay. 
The following points were not corrected: 
pg 19: Table 1 was not a composite table and was taken 
entirely from reference 11. 
pg 20: Glutamate is correct in this context. 
n . 
pg 32: The word used was pre-traplat1onal not 
pre-transcriptional as suggested. 
pg 34: A figure showing the areas of homology between the 
various mammalian species was not available. 
pg 60: KGB buffer was defined on page 48. 
pg 71: A diagram of the various primers indicated what 
fragments they produced. 
pg 82: Although the figure could not be altered, the legend 
was changed to indicate that the two gels are the 
same indicating that the concentrations given in 
figure 17B also represent 17A. 
pg 93/98: As with all the results sections a brief summary 
of the experimental procedure was given to explain 
certain parts to the experiment. The brief 
introduction to ASS activation was shortened as 
recommended but was included to explain the 
rationale of the experiment. 
pg 116: The sentence was corrected but the suggested 
correction changed the meaning of the sentence. 
pg 118: The sentence refers to the neurons in the pituritary 
gland rather than neurons and the pituritary gland. 
pg 130-132: It is important to realise that NO~itself may 
not be the biological agent but that other redox 
forms may play a significant role, that is why 
the section was included. A description of the 
p53 gene seemed unnecessary in this context. 
pg 159: The section referred to was only a brief 
introduction and an explaination of the mode of 
action of cycloheximide and valine was 
inappropriate. These discussions were given in 
detail when the experiments were discussed. 
pg 163: At this stage cellular supernatant fractions were 
being collected, the cells were precipitated at a 
later stage with TCA. 
Pg 167: The logic behind the statment was that the method of 
collecting the counts was inadequate and therefore 
the results unreliable. 
pg 195: 300 dpm does equate to 2.4nM, as the labelled 
metabolite was mcijmmol rather than Cijmmol (given 
in the methods). 
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ABSTRACT: 
A citrullinemic fibroblast cell line was used in this study 
to investigate two biochemical pathways involving citrulline. 
In the first section, the genetic mutation responsible for 
the argininosuccinate synthetase (-ASS) deficiency (1-5% 
activity) in this cell line was investigated. PCR analysis of 
the ASS eDNA revealed that the mRNA coding region (1236bp) 
was intact, showing no signs of major rearrangements. The ASS 
eDNA (1307bp) was cloned and sequenced and showed the 
presence of a single base mutation at position 1045bp, which 
represented a G->A transition. This mutation resulted in a 
glycine -> serine amino acid substitution at position 324\ in 
the ASS subunit protein sequence. Although this glycine 
residue ~as not found to occur in any potential substrate 
binding sites, it was shown to be highly conserved among 
species, indicating a possible role of this amino acid in ASS 
catalytic activity. In the second section, the presence of 
the nitric oxide pathway in fibroblasts was investigated. 
Inducible nitric oxide synthase activity was assayed by 
measuring the production of 14c-citrulline from 14c-arginine 
after cytokine stimulation. By using the citrullinemic cell 
line (ASS deficient) any citrulline that may be produced by 









fibroblasts have the potential to synthesise nitric oxide, 
although a more sensitive assay system may need to be 
employed ( longer 
detection). 
cytokine activation, nitrite/nitrate 
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INTRODUCTION: CITRULLINE METABOLISM, THE INS AND OUTS. 
Citrulline is a basic amino acid that is not directly 
utilised for the production of protein, but rather plays a 
role in the synthesis of endogenous arginine and ureagenesis, 
the process by which waste nitrogen is converted to urea and 
excreted from the body [1]. The enzymes that are responsible 
for the metabolism of citrulline include 
synthetase and argininosuccinate lyase, 
urea cycle shown in figure 1. 
argininosuccinate 
two enzymes of the 
UREAGENESIS AND ENDOGENOUS ARGININE SYNTHESIS. 
The major source of circulating citrulline is supplied by the 
intestine which converts glutamine into the urea precursors -
ammonia and citrulline [1,2,3], both of which are secreted 
into the portal circulation (figure 2). Although the liver 
and a few other tissues possess the enzymes that are able to 
synthesize citrulline [1,4], extra-intestinal citrulline is 
not normally found in the circulation [3]. Under abnormally 
low citrulline concentrations in the blood however, it has 
been found that citrulline storage pools in the cerebrospinal 
fluids and skeletal muscle can be stimulated to release 
citrulline [3]. 
The major site of ureagenesis is in the liver, where 
ornithine is used directly to produce the citrulline 
necessary for the urea-cycle to proceed [4,5]. The 
circulating intestinal citrulline passes straight through the 
liver, with little uptake being evident [3]. 
TOOH FH 
C·O 'NAGS (CH2 )2 + I •1 W ___. 
S CH·NH·C·CH 
I I 3 
CoA COOH PI 
Glutamic Acetyl CoA 
acid 
N-acetyl· 
glutamic acid Carbamyl phosphate 
Ornithine 
Arginine 
• NH 2 
I • 




I NH COOH 
<fH213 II • I 
I AL I I 










CH·NH2 ">-C ·NH -CH 
(CH2b COOH 
c.tt-COOH JH-NH Argininosuccinic 




FIGURE 1: UREA CYCLE. 
The substrates, products and co-factors required 




argininosuccinate lyase, CPS = carbamyl phosphate synthetase, 
NAGS == N-acetylglutamate synthetase, OTC = ornithine 
transcarbamylase. This figure was a modification from the 













l }--Aspartate Kidney 
NH/ ~rginine 
Alanine _.;,NH + NH + Arginine 
l _../ ?-- l ( - \._ ~·uREA _... ( 
N(+-+-- amino acids Glutamate Aspartate 
Liver 
(deaminating) 
FIGURE 2: The pathway of waste nitrogen synthesis from amino 
acids. 
Diagrammatic representation of the participation of the 
intestine , kidney and the liver in the utilisation of 
citrulline [1]. 
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The fate of circulating citrulline under normal conditions 
resides in its utilisation by the kidney, in the production 
of endogenous arginine for protein synthesis. It has been 
reported that up to 83% of the citrulline released from the 
intestinal tract is taken up by the kidney, most of which is 
converted to arginine [3]. The kidney is thus an important 
organ in the metabolism of citrulline. 
However, the kidney is probably not the only organ with the 
ability to extract and use large amounts of citrulline. In a 
study performed on rats whose kidneys had been removed [3], 
the amount of circulating citrulline rose by only 17% thirty 
minutes after kidney removal, instead of the expected 80%. 
This result suggested that under these conditions, other 
systems are brought into operation to compensate for the 
arginine loss and the excessive citrulline build-up. Several 
pathways were proposed in this study [3] such as the 
utilisation of citrulline by the liver or the use of enzymes 
in other tissues. 
The brain is able to participate in citrulline metabolism as 
it possesses both argininosuccinate synthetase and 
argininosuccinate lyase enzymes, allowing for the synthesis 
of arginine from citrulline [1,3]. other tissues and 
individual cell types (fibroblasts [1,6] and lymphoblasts 
[1]) that possess these two urea cycle enzymes are also 
capable of producing endogenous arginine for protein 
synthesis and other metabolic pathways. 
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NITRIC OXIDE PATHWAY. 
In the past, citrulline was only known to be associated with 
ureagenesis and arginine 
discovery of the nitric 
synthesis. However, since 
oxide pathway, an important 
the 
new 
source of citrulline has been discovered. The nitric oxide 
pathway involves the metabolism of arginine by nitric oxide 
synthase to produce equal quantities of No· and citrulline. 
The No· produced by this pathway is the active metabolite, 
participating in signal transduction and the immune defense 
system. The citrulline is probably released into the 
circulation where it is utilised by other tissues for 
arginine synthesis. Citrulline may in fact play a direct role 
in the perpetuation of the NO.response, since extracellular 
arginine (0.2-0.4mM) [7] is essential for nitric oxide 
synthase activity. Thus in tissues that possess the necessary 
urea cycle enzymes (ASL and ASS), a constant level of 
arginine for No"production can be maintained. 
CITRULLINEMIA. 
Citrullinemia is one of the diseases associated with 
defective citrulline metabolism and is caused by 
argininosuccinate synthetase deficiency. The disease is an 
autosomal inherited metabolic disorder characterised by 
elevated ammonia and citrulline levels in the urine, plasma 
and cerebral spinal fluids and often leads to retardation and 
in severe cases, death [1]. 
The cause of the argininosuccinate synthetase deficiency has 
been studied in several cases of citrul1inemia [1,8,9,10), 
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revealing that the mutations leading to enzyme inactivity are 
heterogenous. The mutations range from gene-rearrangments to 
single base mutations that are scattered along the length of 
the argininosuccinate synthetase coding region. These 
mutations also have a variety of effects from complete gene 
inactivation to reduced levels of mRNA production and protein 
inactivation. 
THESIS AIM. 
The purpose of this thesis was to study several aspects of 
citrulline metabolism, using normal and mutant ·fibroblast 
cell lines in order to gain insight into elements of the urea 
cycle in these cells and to assess their ability to 
synthesize nitric oxide. Each section contains a review and a 
detailed introduction explaining the aims and rationale 
behind each set of experiments. A brief overview is given 
below. 
The first section of the study involves the investigation of 
the mutation responsible for the argininosuccinate synthetase 
deficiency in the citrullinem.ic fibroblast cell line F25. The 
purpose being to gain insight into the catalytic mechanisms 
of argininosuccinate synthetase, which are ill-defined at 
present. Molecular biology techniques were employed to 
.investigate this mutation at the gene level. 
The second section investigates whether activation of the 
nitric oxide pathway can be demonstrated in fibroblasts. The 
argininosuccinate synthetase deficient cell line F25 was used 
in the study, allowing for the correlation of citrulline 
15 
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accumulation in these cells, to NO production under specific 
conditions. 
In an attempt to optimize the conditions necessary for 
studying the nitric oxide pathway in fibroblasts, other 
aspects of urea cycle metabolism in fibroblasts were 
investigated. Ornithine transcarbamylase activity as well as 




CITRULLINEMIA: THE PIN-POINTING OF A POINT MUTATION. 
1.1 REVIEW: ARGININOSUCCINATE SYNTHETASE 
METABOLISM. 
CITRULLINE 
1.1.A: ARGININOSUCCINATE SYNTHETASE - THE PROTEIN. 
A.i: Expression of Argininosuccinate synthetase. 
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Argininosuccinate synthetase (ASS) is one of five enzymes of 
the urea cycle (shown in figure 3) and is responsible for the 
catalysis of the following reversible reaction: 
ATP + citrulline + aspartate -> argininosuccinate + AMP 
<- + PPi 
This reaction occurs in the cellular cytoplasm, as do the 
reactions catalysed by argininosuccinate lyase (ASL) and 
arginase. The reactions cataylsed by the other urea cycle 
enzymes: carbamyl phosphate synthetase (CPS) and ornithine 
transcarbamylase (OTC), occur in the mitochondrial matrix 
[11]. 
In the liver, ASS is produced in large quantities as a 
component of the complete urea cycle, that serves to dispose 
of ammonia. However, much lower levels of ASS are found in 
peripheral tissues that do not possess the full complement .of 
urea cycle enzymes. Table 1 [11] shows the levels of ASS 
activity found in various rat and human tissues. In these 
peripheral tissues, ASS in combination with ASL serves to 
synthesize arginine from citrulline [12]. This arginine is 
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S CH·NH·C·CH 
I I 3 
CoA COOH PI 
Glutamic Acetyl CoA 
acid 
N·SC6tyl· 































Arginine I • 
(CH2)3 NH COOH I II • I 
CH·NH 2 ">--C ·NH -CH 
I AL I I 
COOH NH CH2 
· I I 











CH·NH 2 Arginlnosuccinic 




FIGURE 3: UREA CYCLE. 
The substrates, products and co-factors required 




argininosuccinate lyase, CPS = carbamyl phosphate synthetase, 
NAGS = N-acetylglutamate synthetase, OTC = ornithine 
transcarbamylase. This figure was a modification from the 
figure given in reference [1]. 
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TABLE 1: ASS ACTIVITY IN MAMMALIAN TISSUES. 
SOURCE: SPECIFIC ACllVITY: 
(nmol/hr/mg) at 38'C 
IRAT:I 
UVEA 1386.0 +/- 95 
KIDNEY 667.0 +/-55 
SMALL INTESTINE 68.3 +I- 2.5 
LARGE INTESTINE 35.3 +/- 3.4 
BRAIN 50.6 +/- 4.6 
LUNG 21.7 +/- 2.1 
SPLEEN 10.5 +/- 0.6 
I HUMAN: I 
UVEA 1080.0 +/- 174 
FIBROBLAST(MGF1139) 81.2 +/- 5.3 
FIBROBLAST(MGF591) 192.5 +/-19 
The active human ASS enzyme of ~83000Da in size, exists as a 
tetramer of four identical subunits (42,800Da each) of 412 
amino acids each [13], with the two pairs of subunits linked 
via s-s bonds [~4,15]. It has an unusually high content of 
basic amino acids resulting in a pi of 9 [~3] and appears to 
undergo no post-translational modification [16]. 
A.ii: ASS enzymology. 
The exact nature of the catalytic mechanisms and the amino 
acid residues involved in the active site of this enzyme 
have not yet been clearly defined. However, the following 
~nformation is available: The enzymatic reaction proceeds in 
a two-step manner as follows [~7]: 
A1) citrulline + MgATP -> citrulline-AMP + MgPPi + 2H+ 
B2) citrulline-adenylate + aspartate -> argininosuccinate 
+ AMP. 
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This two-step reaction occurs in an ordered manner, shown 
below in figure 4 with the sequential addition of the 
substrates: MgATP, citrulline, aspartate, followed by an 
ordered release of the products: argininosuccinate, MgPPi, 
AMP [18,19]. No products are released until all the 
substrates have bound to the enzyme [19]. 
Al B2 
E--+ EA--+ EAB--+ EABC--+ EIPC_. EPQR --•E + Q + P + R 
FIGURE 4: Proposed kinetic scheme of the argininosuccinate 
synthetase reaction [19]. 
E = ASS, A = MgATP, B = citrulline, C = aspartate, 
I = citrulline-adenylate, P = PPi, Q = argininosuccinate, 
R = AMP. 
The first reaction (A1) represents the activation of 
citrulline by ATP to form a tightly bound 
enzyme-citrulline-adenylate complex [17]. Although the 
citrulline-adenylate complex can be formed in the absence of 
the enzyme-bound aspartate, aspartate increases the rate of 
production of this complex 600-fold. Glutamine synthetase 
also exhibits similar enhancement, with the rate of formation 
of g-glutamyl phosphate from glutamine and ATP being 
increased 35-fold in the presence of NH3 [17]. 
The PPi formed in this reaction (A1), is not released at this 
stage, but remains tightly bound to the enzyme. This is 
unusual as amino acid activation normally proceeds with an 
amino acid dependant ATP-PPi exchange [14]. It is only after 
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condensation of aspartate with the iso-ureido group of the 
citrulline-adenylate complex that argininosuccinate is formed 
as PPi and AMP are released in the second step of the 
reaction (82) [19]. Kumar, Lennane and Ratner [15] suggested 
that upon condensation with citrulline, aspartate causes a 
conformational change, which results in the weakening of the 
binding affinity between ASS and PPi. This then allows the 
release of the pyrophosphate group. 
The active ASS protein exists as a tetramer, with one active 
site per subunit. Contained within each subunit there exists 
a cysteine residue that has been shown to be essential for 
catalytic activity (all four cysteines are required) [18]. 
Each subunit of the tetramer also contains an arginine 
residue that is essential for ATP and PPi bindi~g and that 
for optimum catalysis all four active sites must'be occupied 
by either ATP or PPi [15]. Arginine residues 153 and for 157 
have been implicated in ATP binding through modification 
studies, and these residues occur in a region that has 
homology with other ATP-binding domains for other enzymes 
[ 9 ] • Enzymes such as aspartic and ornithine carbamyl 
transferases, as well as glutamine and carbamyl phosphate 
synthetase, possess arginine residues that are .important in 
binding anionic co-factors and other substrates [15]. 
ASS is activated by the presence of divalent cations. 
One role of these cations is the formation of complexes 
shown that with ATP. However, it has also been 
the synthetase requires the binding of an additional 
uncomplexed Mg2• ion to achieve maximum activ~ty. The 
-f 
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function of this additional cation is not yet known. It could 
either be involved in the catalytic mechanism or fulfill a 
structural role [20]. Glutamate synthetase, carbamyl 
phosphate synthetase, pyruvate kinase as well as several 
other enzymes also require an additional uncomplexed metal 
ion, but at present its function in these enzymes is also 
unknown [ 20]. 
A.iii: ASS regulation at the protein level. 
ASS displays negative co-operativity 





molecule to an oligomeric protein with two or more catalytic. 
sites, causes additional substrate molecules to bind with 
diminished affinity at the other catalytic sites [14]. This 
mechanism enables an effective kinetic response over a wide 
range of substrate concentrations. Due to the amplitude of 
the kinetic response exhib~ted by this enzyme, it suggests 
that negative homotrophic behaviour may play a significant 
role in regulation of ASS activity [14]. 
In kinetic studies on the human liver ASS enzyme, it has been 
demonstrated that ASS, like many other synthetases is 
inhibited by ADP and AMP. These nucleotides act as 
competitive inhibitors of ATP-binding when aspartate and 
citrulline are at saturating concentrations. However, this 
effect is diminished at lower non-saturating concentrations 
of citrulline and aspartate and affinity data suggest that 
this is due to the affinity of the enzyme for the inhibitors 
decreasing at the lower substrate concentrations. This 
suggests that a 
affinity for the 
to note that the 
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conformational change causes the loss of 
ADP and AMP nucleotides. It is interesting 
affinity of the enzyme for ATP remained 
unchanged over the concentration range of citrulline and 
aspartate [14]. 
Comparisons of amino acid sequence and eDNA sequence data of 
enzymes from various organisms, makes it possible to indicate 
regions that may be important for enzyme function by their 
high degree of homology among the various organisms. 
Comparisons have been done between various organisms for the 
ASS enzyme and although they show large differences at the 
overall amino acid primary sequence level (E.colijman = 26% 
homology, ratjman = 97%, yeast/human = 49%), several regions 
of high homology have been located - figure 5. Using the 
information about the presence of a cysteine and an arginine 
residue at the active site, these conserved areas were 
evaluated as possible active sites. Although no cysteine 
residues were seen in the~e regions, three possible reactive 
arginines were found to occur in the subunit. Using copmputer 
modelling programs to locate possible substrate binding 
domains, two of the highly conserved regions showed 
substrate-binding capabilities [18]. 
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FIGURE 5: Comparison of the ASS-subunit amino acid primary 
sequences [18]. 
The ASS amino acid sequences from the following organisms 
were aligned: Human, Escherichia coli, Saccharomyces 
cerevisiae, Methanosarcina barkeri and Methanococcus 
vannielii ( archeobacteria), revealing several areas of 
homology. The boxed areas indicate areas of high homology. 
The under-lined regions are possible substrate binding sites 
within the ASS subunit and the symbols indicate possible 
reactive arginine residues (one arginine per subunit is 
involved in ATP/ADP binding). The mutated glycine residue in 
F25 is indicated by a * symbol. 
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1.1.B: ARGIHIHOSUCCIHATE SYNTHETASE - THE GENE. 
B.i: Location and gene product. 
The actively transcribed human ASS gene has been located to 
the q34 region of chromosome 9 [1] and is 63 kB in size. Some 
controversy seems to have developed over the years as to the 
nu~ber of exons in the active gene, with researchers 
reporting between 11 and 16 [1,9,16,21,23]. However, the 
consensus at the moment seemas to be that there are 16 exons. 
The first two exons code for untranslated regions and are 
alternatively spliced [21]. In most human cell lines exon 1 
and 3 are spliced together (type B mRNA), deleting the second 
exon. This alternative splicing however, seems to be species 
specific with baboon liver expressing 99% type A mRNA (exon 
1-2-3) while human liver 99% type B mRNA (exon 1-3), but the 
levels vary a little between human cell types [21]. The 
biological significance of this alternative splicing has not 
yet been elucidated [16]. The other 13 exons encode a mRNA of 
1600 bases, that has an open reading frame of 1236 
nucleotides [1]. Exon 3 possesses the translational start 
site for the production of a 412 amino acid protein subunit. 
B.ii: Pseudogenes. 
There are 14 different pseudogenes·of the ASS gene, and they 
are located at multiple loci in the genome. These include two· 
loci on chromosome 9, where the active gene is located, two 
on the X chromosome and one on theY chromosome [22]. Seven 
of these pseudogenes have been investigated and they are all 
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less than 2Kb in length (as opposed to the expressed gene of 
63Kb), belong to the second class of pseudogenes (intronless) 
and represent processed pseudogenes [21,22,23]. These 
pseudogenes are highly homologous to the mRNA encoded by the 
active gene, with one of 
94% homology with the ASS 
the sequenced pseudogenes showing 
eDNA [23]. Figure 6 shows the 
comparison between the eDNA from the active gene and three of 
the pseudogenes, demonstrating the high degree of homology 
between the sequences. As can been seen in this figure, most 
of the differences are single base changes or small 
insertions and deletions. No 
occurred. 
major rearrangements have 
Due to the structure and sequence of these processed 
pseudogenes it has been proposed that these copies arose 
through a mature mRNA intermediate, that was then 
reintegrated into the genome. This could have arisen through 
the action of retroviruses or transposons. Possibly multiple 
copies arose from a single reverse transcription event 
followed by duplications and then integration [23]. 
ASS pseudogenes are not unique to humans, but have also been 
found in the genomic DNA of chimpanzees. From this evidence 
and by analysing the mutation rates of the pseudogenes, it 
has been postulated that the pseudogenes evolved some 10-20 
million years ago, before the divergence of the great apes 
from the hominids [23]. 
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FIGURE 6: A comparison between the nucleotide sequence of 
human ASS eDNA and human ASS pseudoqenes [ 23] • 
A comparison of the nucleotide sequence of human ASS eDNA 
with the sequences of human ASS pseudogenes As-1, AS-3 and 
AS-7. The eDNA sequence is shown here as well as the bases 
that differ in the respective pseudogenes. • represents 
similar base differences between AS-1 and AS-3. Base 3 on 
this diagram represents base 1 on sequences derived from 
Genbank. 
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Strong evidence suggests that there is only one active locus 
and that none of these other ASS-like genes give rise to the 
enzyme product. This evidence includes the genetic 
characteristics of the metabolic disease citrullinemia (ASS 
deficiency) which is an autosomal recessive disorder, 
suggesting one active locus [1]. Mutational analysis of 
cultured fibroblasts with defects in the structural gene, 
have shown that all the detectable mRNA was derived from one 
locus [1,9]. studies on probing for gene duplication have 
also all been negative [13]. 
B.iii: Gene regulation. 
Two independant mechanisms of ASS gene regulation have been 
elucidated so far. One is the arginine-mediated repression 
that has been demonstrated in some cultured cell lines: 
hamster fibroblasts, human lymphoblasts and the human 
squamous cell carcinoma cell line RPM1 2650 [1,24,25]. This 
mechanism is evident by the increase in ASS enzyme activity 
when the cells are incubated for > 96 hours in arginine-free 
medium (0.6mM citrulline) [25]. The range of ASS activation 
in the absence of arginine, is between 3-60 fold depending on 
the cell type [26]. 
The other mechanism of regulation of ASS at the gene level is 
seen in canavanine resistant (CanR) cultured cells. These 
cells are resistant to the toxic effects of canavanine (an 
arginine analog) and show different regulatory ASS features 
from the wild type ASS enzyme. · The ASS activity in these 
cells is 200 fold increased relative to the parental cell 
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line, this level being on a par with the ASS activity found 
in normal liver cells [1]. The enzyme activity in CanR cells 
is also unresponsive to the arginine-mediated repression 
mentioned above. At this stage it has been postulated that 
the mechanism that is responsible for increased ASS activity 
in CanR cells is the same as that in liver cells and may be 
responsible for the tissue-specific levels of expression in 
the various cell lines [27]. 
B.iii.a: Arginine-mediated repression. 
It was initially proposed that the increased activity in CanR 
cells was due to the loss of the arginine-mediated repression 
seen in other cultured cell lines. This confused the issue 
when investigators were trying to elucidate the ASS gene 
regions responsible for the arginine-mediated repression 
using CanR cells [24,25]. Boyce et al [26] used constructs of 
the 5'untranslated regions of ASS and the CAT gene (reporter 
gene) and were able to approximately locate the area 
responsible for the arginine-negative feed-back mechanism. 
However, they clearly demonstrated that this element was 
separate from the element involved in the increased levels of 
ASS activity in CanR cells. 
Since the elucidation of the two separate mechanisms, a 
number of studies have been performed on the two regulatory 
mechanisms. With regards to the arginine-mediated repression 
several facts have emerged: Firstly, the increase in ASS 
activity in the absence of arginine and the presence of 
citrulline is not due to citrulline activating the ASS locus, 
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but is due to arginine-regulation of ASS activity. Secondly, 
arginine-mediated repression · of ASS occurs at the 
pre-translational level, by controlling ASS mRNA levels and 
is ASS-specific (does not effect ASL) [26]. 
Using ASS-CAT promotor fusion constructs, Boyce et al [26] 
demonstrated that the arginine-regulatory unit was contained 
in 150bp 5' to the start of exon 1, in the region of the 
transcriptional start site. This is similar to other systems 
that are regulated by trans-acting factors, where the binding 
sites of the trans-acting factors are found within 300bp of 
the transcriptional start site on the DNA. 
Originally, it was proposed that the alternative splicing of 
exon 2 played a role in this arginine-repression in the 
different cell types. Exon 2 contains three arginine-codons 
and it was proposed that by a mechanism of attenuation 
involving Arg-tRNA, the stability of the ASS could be 
altered, resulting in the varied ASS activities under 
different conditions [1,13]. Regulation through tandem codons 
for a regulatory amino acid is known in bacterial amino acid 
operons, which are regulated by attenuation and in other 
regulatory mechanisms that operate in yeast and the SV40 
virus [13]. However, Boyce et al showed this idea to be 
redundant due to the absence of exon 2 in the above mentioned 
arginine-reactive constructs [26]. 
A sequence that is more likely to be relevant 
repression is TGTGAACGC, at position -137 to 
to arginine 
-129. This 
sequence is similar to an element found in promotor regions 
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of yeast genes that are derepressed during amino acid 
starvation. Deletion of this sequence in plasmid-constructs 
resulted in loss of arginine repression (1]. 
Other regulatory motifs are also found in the 5' untranslated 
promotor region and ·these include: TATAA at -30 [18] and 
multiple GC boxes or hexanucleotide core sequences for SP1 
binding. An octomeric 
identified in ASS and 
sequence of AGAAGTGA at -470 was also 
is also 
factor VIII and albumin. These 




house-keeping genes (GC elements) and genes that are 
expressed in a tissue-specific manner (TATAA and octomeric 
sequence) [1,16]. 
B.iii.b: Canavanine - resistance. 
CanR cells have been derived from a variety of cell lines. 
These cells manage to avoid the toxic effects of canavanine 
by increasing the synthesis of arginine, therby diluting the 
effects of the arginine analog [26]. 
The basis of CanR is at present not completely understood. 
CanR cells express up to 200 fold increased levels of ASS 
activity and this is directly correlated with an increase in 
cytoplasmic ASS mRNA [24] rather than to an alteration in ASS 
anzyme kinetics [28,29]. No major genetic rearrangement has 
occurred in these cells and gene-duplication as a way of 
explaining the increase in mRNA levels has also been excluded 
[29,30]. CanR is a stable feature suggesting the occurence of 
a genetic mutation [1]. 
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The mechanism that governs the increase in mRNA production in 
CanR cells acts at the pre-translational level, this could 
involve increased transcription, increased RNA stability or 
altered nuclear RNA processing [1]. 
In RPM! 2650 cells (a squamous carcinaom cell line), where 
there are as few as three copies of ASS mRNA per cell and the 
CanR variants express at least 500 copies, Boyce and Freytag 
[27] showed that the half-life of each set of mRNA species 
(CanR and parental mRNA) is almost identical (12-24 hours). 
This result indicates that a change in cytoplasmic mRNA 
stability is not the mechanism responsible for the CanR, 
although an increase in the stability of the nuclear ASS RNA 
cannot be excluded [29]. Transport of ASS RNA from the 
nucleus to the cytoplasm is also not altered in these mutant 
cells. These results suggest that the mechanism operating 
here is either at the level of initiation of transcription, 
elongation or at some point prior to polyadenylation [27]. it 
has been reported that changes in elongation rates can affect 
mRNA stability and therefore affect gene expression [31]. 
Cellular hybridisation experiments have demonstrated that the 
CanR mechanism involves a positive trans-acting factor and 
that increase levels of ASS mRNA are not due to the loss of a 
repressor [26,27]. This trans-acting factor has been shown to 
be limiting, ASS specific and operational in the nucleus 
[32]. 
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CanR cells are not responsive to arginine levels. Two 
scenarios are possible in the explaination of this finding: 
One being that the positive trans-acting factor is dominant 
over the arginine-repression mechanism and the other being 
that these cells produce enough arginine to become insenstive 
to the extracellular levels of arginine [26]. 
The DNA element that binds the positive trans-acting factor 
does not appear to form part of the ASS promotor, which is 
where the arginine-repression occurs. Instead it has been 
proposed that the element is intragenic, occurring within one 





factor increases in efficiency rather than 
a change in affinity for the factor. Perhaps 
recognises a unique DNA secondary structure 
The importance of establishing the mechanism responsible for 
the increased ASS activity in CanR cells lies in the fact 
that these cells show the same level of ASS activity and the 
high level of ASS mRNA that occurs in liver cells. In fact it 
has been proposed that the mechanism responsible for the high 
ASS activity in hepatocytes is the same as that in CanR 
cells. Further evidence in support of this idea is that a 
dominant, positive acting factor that operates in the 
nucleus, has also been shown to be operative in hepatocytes 
in the production of high levels of cytoplasmic ASS mRNA 
[27]. The conclusion that CanR/ASS regulation in hepatocytes 
operates at the post-transcriptional level fits in very well 
with other regulatory systems operating predominantly or 
exclusively in the liver, including 
transferrin and phosphoenolpyruvate 
[27]. 
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regulation of : albumin, 
carboxykinase activity 
It has been speculated that this mechanism is linked to 
cell-differentiation and that CanR cells represent a more 
differentiated cell type than the parental cell line. In 
other words the mutation that has occurred in these cells has 
activated a mechanism that forms part of 
cell-differentiation, probably towards liver differentiation 
[27]. 
It is clear that more work needs to be done to specifically 
locate the mechanism responsible for the increased activity 
of ASS in hepatocytes and CanR cells. It is important to 
elucidate this mechanism since it could contribute to the 
treatment of patients suffering from citrullinemia, which is 
a disorder resulting from the partial or complete loss of ASS 
activity. 
B.iii.c: 3' Regulatory sequences. 
Using comparisons between the eDNA sequence data of ASS from 
four mammalian species: murine, rat, bovine and human, two 
significant regions of homology have been found in the 3' 
untranslated region. One is 57bp 3' to the termination 
sequence and consists of 74% A+T in a stretch of 42bp. The 
other occurs 50bp further downstream, with a 50% A+T content. 
Both of these areas share an almost 100% homolgy between the 
four species. A+T rich regions have often been associated 
with rapid turnover of short-lived mRNA species, such as 
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those involved in the inflammatory response. However, the 
AUUUA motif that is particularly associated with these mRNAs 
is not present in ASS. It has also been shown that the 
3'untranslated regions may play a role in translational 
efficiency, as has been shown in ~-interferon and others. The 
-fact that these areas are highly conserved suggests that 
these regions must have some functional importance, however 
no other genes have been identified so far that have closely 
related sequences to these found in ASS [16]. 
1.1.C: CITRULLINEMIA. 
C.i: Disease definition. 
Citrullinemia is an autosomal recessive disorder caused by 
the partial or total loss of argininosuccinate synthetase 
activity. This disease is characterized by an accumulation of 
citrulline in the blood (at least 40 fold in the plasma), 
cerebral spinal fluid (100 fold elevation) and in the urine. 
It is also accompanied by an elevation of the concentration 
of ammonia in the blood (hyperammonemia) [1]. 
The classic neonatal form of this disease is characterized by 
mental retardation, hyperammonemia and early death [11]. The 
infants seem unaffected at birth, but become irritable and 
lethargic in the first few days of extrauterine life, showing 
signs of a depressed neurological state. Convulsions may 
occur followed by coma and death within the first week of 
life. Metabolic acidosis, hypoglycemia and hypocalcemia can 
occur and small microscopic brain lesions from the 
degradation of nerve cells and myelin are observed. Delayed 
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myelin formation and the presence of enlarged glial cells 
with intracellular lipoid accumulation have been seen in some 
cases [1]. 
There are several other forms of citrullinemia: subacute, 
asymptomatic and atypical. These forms are loosely defined 
and basically reflect the stage of onset of the symptoms, 
with the subacute type presenting with a gradual onset of 
neurological symptoms; tremors, seizures, within the first 
weeks/months of life. Asymptomatic types present with 
elevated citrulline levels in the relevant fluids, but 
present no other symptoms, at least in early childhood. The 
atypical type shows elevated ammonia and citrulline levels, 
with no apparent liver dysfunction, while slurred speech and 
delirium may occur without obvious neurological damage [1]. 
It is interesting to note that the disease shows a male 
predominance, with a male:fe~ale ratio of 10:3 [1]. 
c.ii: Citrullinemic ASS mutations. 
Several assay systems exist for the kin~tic analysis of ASS, 
however they are not frequently used for the analysis of 
citrullinemic patient cell lines, due to the relatively low 
level of activity of ASS in normal cultured cells 
(fibroblasts and lymphocytes) (table 1). However, one kinetic 
study [13] was performed comparing a normal and citrullinemic 
liver extract. The results showed a sigmoidal kinetic 
dependance on the citrulline concentration with an increased 
Km for citrulline in the patient, when compared to the normal 
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hyperbolic kinetic dependance in the control ASS. The thermal 
stapility of crude extracts of ASS in the patient was also 
decreased when compared to the control. The kinetics of ASS 
in another citrullinemic patient was also studied and 
revealed an increased Km for citrulline (25-200 fold 
increase) and as~artate (200 fold) [1]. The normal Km for 
citrulline in human liver= 0.03mM [1]. 
Most analyses have been performed at the molecular level, 
investigating the patient DNA and mRNA. Using molecular 
biology techniques a full range of mutations have been 
associated with this disease, ranging from large deletions 
to single base changes. Table 2 [9] shows some of the 
mutations that have been identified. 
TABLE 2: SUMMARY OF CITRULUNEMIC MUTATIONS 
A: Single base changes in ASS eDNA. 
Au.ELE: NORMAL: MliTANT: 
G14-> S gGC(Giy) aGC(Ser) 
5180-> N AgC(Ser) AaC(Asn) 
R157-> W CgC(Arg) CaC(His) 
R304->W cGG(Arg) tGG(Trp) 
G324 -> S gGT(GiV) aGT(Ser) 
R363-> W cGG(Arg) tGG(Trp) 
G390-> R gGG(Giy) aGG(Arg) 
B: ASS eDNA deletions. 






*The result of a splice junction mutation in intron 15 [9].· 
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This molecular heterogeneity is in sharp contrast to many 
other disorders such as Tay-Sachs disease, cystic fibrosis 
and Gaucher disease where only a few mutations are 
responsible for a large proportion of the mutant alleles [9]. 
The exact frequencies of the various mutations in ASS have 
not as yet been detailed since large population studies have 
not been performed. 
Due to the presence of a large number of pseudogenes with 
high percentage homologies to the active gene [23], the 
Southern-blot technique is not often used to look for gross 
gene abnormalities. Instead S1-nuclease protection assays 
[10], mRNA analysis [9] and sequencing of the patient eDNA 
are preferentially used to characterise patient defects [9]. 
One of the more common defects is that of abnormal RNA 
splicing [10] giving rise to abnormal mRNA products. This can 
arise from single base substitutions within the splice 
acceptor sites at the ends of introns [8] and often leads to 
a protein reading frame shift, causing the production of an 
abnormal protein. The interesting point about these 
abnormally spliced mRNA molecules is that they are very 
stable, even if entire exons have been deleted [9]. 
Single base substitutions have also been found in several 
citrullinemic patient mRNAs and they are fairly scattered 
along the length of the mRNA. Table 2 shows some of the 
single base 
with regards 
changes, which are at this stage uninformative 
to locating key regions of ASS regulation or 
catalytic activity. 
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One of the important points to emerge from the analysis of 
citrullinemic patient eDNA, is that the 3' terminus of the 
protein is essential for ASS enzymatic function and is 
important for maintaining stability of the ASS protein [8]. 
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1.2: INTRODUCTION. 
The aim of the experiments in this section of the study, was 
to establish the cause of the ASS deficiency in the human 
fibroblast cell line F25. This cell line was established in 
1984 from a patient who died within the first week of life, 
after presenting with the clinical symptoms of citrullinemia. 
An inital diagnosis of ASS enzyme deficiency was achieved 
using a citrulline uptake assay which was later confirmed 
using an assay based on the complementation between ASL 
deficient fibroblasts and ASS deficient cells [33], the basis 
of which is discussed in section 1.4. The results of these 
two assays are shown in figure 9 and 11 respectively and 
reveal the extent of the ASS enzymatic deficiency that was 
initially found in the F25 cell line (1-5% of control 
activity). The purpose of the present study was to establish 
the cause of this ASS enzyme deficiency at the molecular 
level. 
Mutations that can cause enzyme deficiencies can be 
characterised at several levels: 1) Protein analysis, which 
investigates the changes in ezyme kinetics (Km,Vmax) or 
alterations to the secondary and tertiary structure of the 
protein. 2) Genetic analysis, to establish the mRNA sequence 
and consequently the amino acid squence of the protein. the 
latter allows for the identification for large deletions in 
the coding region of the gene, point mutations or promotor 
defects in altered gene expression. 
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Kinetic analysis of ASS is normally performed on liver 
extracts, as hepatocytes possess the highest ASS activity. In 
peripheral tissues, including fibroblasts, the enzyme 
activity is much lower, 10-100 times lower (table 1) and is 
therefore more difficult to assay accurately [11]. In the 
study of F25, the problem of low activity is further 
compounded by a recorded 1-5% ASS activity of normal (figure 
9). It has also been documented that the ASS Vmax values of 
control fibroblasts vary quite extensively, as seen in table 
1 [11], making accurate assessments of patients' results very 
difficult. Due to these problems, accurate kinetic analysis 
of the ASS enzyme in the F25 cell line was not performed, 
although a crude assessment was attempted later in the study. 
Instead the mutation was investigated at the genetic level. 
At the DNA level, mutations associated with citrullinemia can 
manifest themselves in the form of gene rearrangements or 
promotor defects that render the gene inactive. At the mRNA 
level an inactive gene product can result from splicing 
mutations that result in frame shifts in the transcribed 
protein. Small deletions, insertions or simply substitutions 
of nucleic acids in the mRNA transcript coding region may 
cause incorrect protein folding or alter an essential active 
site amino acid, which in turn affect the quantity and 
quality of the protein product. 
Southern-blotting, PCR {polymerase chain reaction) and DNA 
sequencing were utilised in this section of the study to 
analyse the ASS gene at both the DNA and mRNA levels to 
locate the mutation responsible for citrullinemia in the F25 
42 
cell line. 
Crude kinetic experiments were performed on ASS from F25 as 
already mentioned, and the activation of the ASS promotor in 
the absence of arginine was also investigated. These 
metabolic studies were performed to try and gain insight into 
the consequences of the mutation that was eventually found in 
the F25 ASS eDNA. 
1. 3: MATERIALS AND METHODS. 
l.J.A: TISSUE CULTURE. 
The following fibroblast cell lines were used throughout the 
ASS study: 
F25 = ASS deficient. 
F535 = ASS deficient ( a cell line derived from the younger 
brother of F25 as part of this study on citrullinemia) 
F199 = ASL deficient. 
F500,F527,F488,F489,F699,F688 =control cell lines 
( no urea-cycle defects). 
These cell lines were maintained with Dulbecco's modified 
Eagles medium (DMEM) (Gibco) supplemented with 10% foetal 
calf-serum (FCS) (Delta bioproducts) and incubated at 37°C 
with C02 -5% and 90% humidity. The cell culture medium was 
replaced every four days and the cells were maintained in the 
absence of antibiotics. Cell cultures were tested on a 
regular basis for the presence of mycoplasma. At confluency 
the flasks were trypsinised and the resulting cell suspension 
split between three flasks. 
1.3.B: ARGININOSUCCINATE SYNTHETASE ENZYME ACTIVITY 
ANALYSIS. 
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B.i:3H-phenylalanine - 14c-citrulline dual label uptake. 
Confluent flasks were trypsinised and the cell suspension 
volume increased to 5ml with the addition of BME (Basal 
medium Eagle) (Flow laboratories) containing 5% FCS and 
Penicillin(30mgjml), streptomycin(50mgjml) and Neomycin 
(25mgjml) (PSN). The cell number of each culture was 
determined using a coulter counter-Zf (settings: 
amplification = 2, threshold = 22, aperture current = 2) and 
100000 cells aliquoted into lml wells (Falcon 24 well 
plates). Additional BME was added and the cells incubated 
overnight at 37~, 5% co2and 90% humidity. 
The medium was removed from each of the wells and replaced 
with 0.5ml of the following mixtures: 0.5)1Ci 3H-phenylalanine 
(55Cijmmol) (Amersham) and 0.3)1Ci 14C-citrulline (58mCijmmol) 
(Amersham) in 0.5ml medium Z (15mM Na Hepes, 145mM NaCl, 5mM 
KCl, lmM Mgso4 , lmM CaC12 , 8. 3mM g'l ucose (pH 7 . 3) ) • The 
trays were incubated at 37°C for 4 hours in the absence of , 
After the incubation period the medium was removed and the 
cells washed 3 times with ice cold 5% trichloro-acetic acid 
(TCA) toprecipitate proteins. The precipitated proteins were 
dissolved in 500)11 o .1M NaOH and 400)11 of the protein 
solution added to scintillation fluid (Hionic-Fluor) for 
radioactivity counting. Counts were expressed as cpm/100000 
cells. DPM were calculated by taking into account the 
efficiency of counting 3H and 14c by the Beckman LS 3801 
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scintillation counter: 14c in 14c window = 72% and 3H in the 3H 
window = 42% 1 14c in 3H window = 1S% and the background 
counts. 
Protein determination. 
A fraction of the remaining protein solution (SOul) was used 
to measure the amount of cellular protein present in each 
well. A solution of 2ml distilled water and 0.4ml Biuret 
solution (Biorad) [34] was made and 2ml aliquoted into each 
curvette. A standard protein curve was constructed by 
measuring the absorbance at 590nm of SOul of the following 
BSA (bovine serum albumin) concentrations mixed with the 
Biuret solution: 50)1g/ml 1 lOOpgjml 1 200pgjml, 400pgjml. These 
results were graphically represented by absorbance 590nm 
verses protein concentration on the x-axis. The concentration 
of the samples (SO)ll) of interest were determined from their 
absorbance values according to the standard protein curve. 
These results give an indication of the variation of cell 
number between the various wells and can be used to give a 
more accurate measure of the incorporation 
into the acid precipitable material when 
expressed as cpmj~g protein. 
B.ii: Complementation assay. 
of radioactivity 
the results are 
For the complementation assay, 100000 cells of F25 and F199 
(ASS deficient and ASL deficient) were co-cultured in 3ml 
wells and allowed to grow to confluency overnight. As 
controls, 200000 fibroblasts of F500, F25 and F199 were 
plated separately into 3ml wells. The overnight BME medium 
45 
was replaced with 2ml of medium Z containing lpCi of 
14c-citrulline (58mCijmmol) (Amersham) and the cells were then 
incubated at 37°C in the absence of C02 for 6 hours. The 
medium was removed and the amount of radioactivity 
accumulated in the cellular precipitate determined as above. 
B.iii: Argininosuccinate synthetase activatiop. 
Fibroblasts {400000) of the following cell lines: F500 
(control), F25 and F535 were plated into 3ml wells and 
incubated overnight in BME (5% FCS). The medium was removed 
and replaced with 3ml of one of the following mixtures: 
a) Arginine-free DMEM, 0.6mM L-citrulline, PSN. 
b) Arginine-free DMEM, 0.6mM L-citrulline, 5% FCS, PSN. 
c) DMEM (0.5mM Arginine), 10% FCS, PSN. 
After 48 hours the medium was removed , replaced with 3ml of 
the same medium and incubated for a further 48 hours (to 
replace exhausted nutrients and remove waste products). The 
ASS activity was then assayed by incubating the cells in 
1.5ml medium z containing 0.5pCi 14c-citrulline, for 4 hours. 
The medium was removed, the cells washed and the amount of 
radioactivity incorporated into the cellular protein 
determined as above. 
B.iv: Argininosuccinate synthetase kinetic analysis. 
Fibroblasts (400000) (F25 and F699) were incubated in 
Arginine-free DMEM (0.6mM L-citrulline, PSN) for 96 hours 
(one medium change). The medium was then removed and the 
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dependance of ASS activity on the concentration of citrulline 
assayed. The cells were incubated in medium z containing 
14c-ci trull ine 
o.025mCijmmol 
at a 
( 0. 5pCi 
constant specific 
14c-citrulline I mmol 
activity of 
L-citrulline), 
with the total citrulline concentration being either 20pM, 
40pM, 60pM, BOpM or lOOpM. The ASS activity was then assessed 
over a 4 hour time period by measuring the incorporation of 
14c into acid precipitable material under the different 
substrate concentrations. 
1.3.C: ARGININOSUCCINATE SYNTHETASE DNA ANALYSIS. 
C.I: ASS plasmid amplification and isolation. 
The plasmid pASl [24] contains a full length copy of the ASS 
eDNA, inserted at a Psti restriction endonuclease site in the 
pBR322 vector. This plasmid was used as a probe in the 
Southern-blot analysis of the ASS gene and as a positive 
control in the development of the PCR technique for the 
amplification of the mutant ASS mRNA. 
E.coli (strain DHalpha) containing the plasmid pASl were 
cultured in the presence of tetracycline (15pgjml) on agar 
plates and then 1.5ml overnight cultures of the colonies were 
established in Luria Broth containing tetracycline (15pg/ml). 
The plasmid DNA was extracted by the alkaline-lysis method 
[35,36,37] discussed below: Bacterial cell pellets were 
resuspended in GTE (50mM glucose, lOmM EDTA, 25mM Tris. HCl 
(pH 8)) and lysed in the presence of 0.2M NaOH, 1% SDS 
(sodium dodecyl sulphate). 3M potassium acetate (pH 4.8) was 
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added to precipitate proteins, host chromosomal DNA and SDS, 
4
; which were then remove by centrifugation. The supernatant was 
treated with RNAse (lOmgjml) and the plasmid DNA recovered 
after phenol/chloroform extraction by ethanol precipitation 
(2 volumes 100% ethanol at -70°C for 20 minutes). The final 
pellet was vacuum dried and dissolved in TE (lOmM Tris.HCl 
(pH 8), lmM EDTA (pH 8)). 
C.ii: Extraction of cellular genomic DNA. 
Confluent flasks of cultured fibroblasts were washed with two 
3ml washes of saline to remove incubation medium and then 
incubated in the . presence of trypsin for 5 minutes. The 
dislodged cells were collected and washed again with two 
washes of saline. The pelleted fibroblasts were resuspended 
in 0.3ml of digestion buffer (O.lmgjml proteinase K, 0.5% 
SDS, lOmM Tris (pH 8), lOOmM NaCl, 25mM EDTA (pH 8)) and 
incubated for 18-24 hours at 55 °C in a shaking incubator 
(0.3ml digestion buffer per 3xlOA7 cells) [38]. 
Proteins were removed by phenol/chloroform/ isoamyl alcohol 
extraction [38] and the DNA preferentially precipitated with 
0.2 volumes 10M ammonium acetate and 2 volumes 100% ethanol 
(20 minutes at 70 °C) (RNA requires longer precipitation 
times). Residual salts were removed from the DNA pellet with 
a 70% ethanol wash and the final vacuum dried pellet 
re-dissolved in TE (aided by gentle shaking at 55 °C 
overnight). Residual RNA was removed by 
samples with DNAse-free RNAse (lOmgjml) for 
the RNA-free DNA precipitated with 
incubation of the 
1 hour, 37 °C and 
ethanol after 
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phenol/chloroform extraction [38]. 
C.iii: Southern-blotting. 
C.iii.a: Radioactive labelling of the pAS1 probe. 
For Southern-blotting purposes, the ASS plasmid probe. was 
radioactively labelled by a random-priming method using 
random hexamers as primers for the Klenow fragment of DNA 
polymerase 1 [35]. 10ng-600ng of plasmid DNA was linearised 
with BamHI(10U) in 0.5X KGB buffer (50mM potassium glutamate, 
12.5mM Tris.Acetate, 5mM magnesium Acetate, 25mgjml BSA, 1mM 
2-mercaptoethanol), in a reaction volume of 6pl, for 1-2 
hours at 37 °C. The fragments were heat denatured by boiling 
for 10 minutes followed by snap-cooling. Random-hexamers 
(2pl), 3pl ATG dNTP's (5mM) and 50pCi (5pl) p32 -dCTP were 
added to the denatured, linear DNA (20pl reaction volume) and 
incubated in the presence of 4U of Klenow for 1 hour at 37°C 
to produce the complementary labelled strand. The labelling 
reaction was halted with the addition of 4pl of 0.1M EDTA. 
The labelled probe was separat~d from unincorporated p32-dCTP 
by size-eclusion chromatography using a Sephadex G-50 column 
(3cm)[38].The sample was placed onto the column and fractions 
eluted with 150pl of TE (pH 8), 15 fractions were collected. 
1.5pl of each fraction was added to 4ml scintillation fluid 
and the radioactivity quantified in a liquid scintillation 
detector. Figure 7 shows the typical elution profile from ~he 
Sephadex G-50 column, with the labelled probe eluting first 
followed by the unincorporated p32-dCTP. The labelled probe 
fractions containing the highest radioactivity were pooled 
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FIGURE 7: Separation of p32labelled DNA probe from 
unincorporated p32-dCTP. 
A random-primed p32labelled pAS1-ASS probe was separated 




random-primed mixture was layered on top of the column and 
150)11 fractions eluted with TE. 4).11 of each fraction was 
added to 6ml scintillation fluid and the radioactivity 
content determined (Beckman LS 60001 scintillation counter). 
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The specific activity of the probe was calculated as follows: 
(cpm of pooled fractions) x 100 1 0.4* 
[DNA - pg] 
* = counting efficiency of the liquid scintillation 
spectrometer. 
The probes that were used for the Southern-blots had a 
specific activity of between 1x10A7 and 1x1QA8 dpm/pg. 
C.iii.b: Transfer and hybridisation. 
Cellular genomic DNA (10pg) was digested with restriction 
enzymes EcoRI, Hindiii and Psti for 8 hours and 
electrophoresed on a 1% agarose gel (20x15cm) (Amersham). The 
alkaline-transfer method was used to transfer the DNA 
fragments onto a Hybond N+ nitrocellulose membrane [39] over 
a 16 hour period. 
Non-specific binding sites on the membrane were blocked by 
prehybridisation with 0.25% Blotto (skim milk powder) and 
0.06% sodium pyrophosphate (Na-PP), in 0.1% SDS and 6xSSC 
" (0.9M NaCl, 0,09M sodium citrate) for several hours at 65°C. 
The labelled ASS plasmid probe was denatured by boiling, 
added to the prehybridisation solution and then incubated 
with the membrane for 24 hours at 65°C. 
The non-specifically bound probe was removed from the 
membrane by a series of washes: 
1x 6xSSC, 0.1%SDS, 0.06%Na-PP room temp. - 15 mins. 
1x 6xSSC, " " 65 °C - 15 mins. 
1x 3xSSC, " " 65 °C - 15 mins. 
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The membrane was finally vacuum dried and autoradiographed 
with the aid of intensifying screens. After 2-5 days at -70~, 
the film was developed. 
1.3.0: ARGININOSUCCINATE SYNTHETASE mRNA ANALYSIS. 
D.i: Total RNA extraction. 
Total RNA was extracted from confluent fibroblasts using the 
Single-Step guanidium thiocyanate extraction procedure [38]. 
Briefly, lml of solution D (4M guanidium thiocyanate, 25mM Na 
citrate (pH 7), O.lM 2-mecaptoethanol, 0.5% sarcosyl) was 
added to each flask of cells a~d the lysed cell components 
scraped from the base of the flasks. 2M NaAc (pH 4), 
water-saturated phenol and chloroform/isoamyl alcohol were 
added sequentially and the solution incubated on ice for 15 
minutes. Protein and much of the DNA was removed by 
centrifugation at lOOOOg ahd the RNA precipitated from the 
aqueous phase with an equal volume of isopropanol and 
incubation at -70°C for 30 minutes. The RNA pellet was again 
treated with solution D (0.3ml) and reprecipitated with an 
equal volume of isopropanol to ensure the removal of all the 
protein. The final pellet was washed 3 times with 70% ethanol 
to remove all traces of guanidium thiocyanate as this 
interferes with the synthesis of eDNA. The final pellet was 
dissolved in 200~1 water, lOpl removed for quantitation and 
500pl 100% ethanol was then added to the rest, for storage at 
0 -70 c. Total RNA was quantified by measuring the absorbance 
of the diluted 10~1 sample at 260nm. 
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Large flasks (75cm2 ) of cultured fibroblasts were used in the 
extraction to maximise yields, giving on average 45pg 
RNA/flask. Good quality RNA was found to be essential for the 
synthesis of full length eDNA and to check this, 5flg of total 
RNA was separated on a 1.2% agarosejformaldehyde gel and 
stained briefly with ethidium bromide. The quality of the RNA 
was confirmeq by strong, clear 28s and 18s rRNA bands ·(38]. 
Quicker confirmation of quality RNA was determined from the 
200-300nm scan showing a well-defined peak at 260nm with a 
260/280 ratio of greater than 1.8. All solutions were treated 
with diethylpyrocarbonate (DEPC) (200fll/100ml solution) to 
destroy RNAse. 
D.ii: eDNA synthesis. 
ASS mRNA was converted into double-stranded eDNA by a two 
step process: a) Reverse-transcription, resulting in 
cDNA-mRNA hybrids, followed by b) the polymerase chain 
reaction (PCR). PCR allows the synthesis of the second DNA 
strand and the subsequent amplification of the 
double-stranded eDNA product. 
D.ii.a: Reverse transcription. 
The mRNA contained in the total RNA sample was converted into 
cDNA-mRNA hybrids using AMV reverse transcriptase and oligo 
dT primers [40,41]. SOU of AMV (Boehringer Mannheim) and 
0.5pg oligo dT were used to reverse transcribe 10pg of total 
RNA. The RNA samples and added oligo dT primers were 
initially heated to 95°C to ensure complete denaturation and 
dissolution of the RNA, prior to the addition of the other 
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additives: 1 x RT buffer (5x = 250mM tris.HCl (pH S.3), 300mM 
KCl, 15mM MgCl2 ) 0.5mM of each dNTP, 5mM dithiothreitol, DEPC 
treated water, ~g acetylated BSA, 5U RNAsin and SOU AMV 
reverse trancriptase (lOOpl total reaction volume). The 
reaction was performed at 42°C for 1 hour. Three cycles of 
this reaction were performed to increase the cDNA-mRNA hybrid 
yield. At each cycle the hybrids were denatured by heating to 
95°C and then SOU of AMV as well as 5U of RNAsin were added 
and the incubation at 42°C continued. 
D.ii.b: Amplification of double-stranded ASS eDNA. 
Oligo-dT primed reverse transcription produces mRNA-cDNA 
hybrids of all the mRNA species in the sample. To produce and 
amplify ASS double-stranded eDNA specifically, the polymerase 
chain reaction was used to produce the second strand of the 
ASS eDNA specifically, with the aid of ASS gene-specific 
primers. The principles of the PCR reaction are represented 
in figure s. 
Several sets of ASS specific primers were designed to be 
utilised in the amplification of the ASS eDNA and these are 
discussed in more detail in the results section. The basic 
PCR reaction used in all the reactions was as follows: 
lOOul reaction volume: 
lOx reaction buffer (500mM KCl, lOOmM Tris.HCl (pH S.3), MgC12 
10-70mM), forward and reverse primers (lOOpmoles of each 
primer), 0.2mM of each dNTP, DNA template (lfg- lpg), Taq 
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FIGURE 8: The polymerase chain reaction. 
A diagrammatic representation of the principles of the 
polymerase chain reaction (PCR) [38]. 
54 
55 
The following three step program was implemented in the 
amplification of the 1307bp fragment of ASS eDNA preceded by 
an additional Hot-start [42]. The Hot-start involves the 
addition of all the reagents on ice (except enzyme) followed 
by the heating of the reaction mixture to > 65 °C before the 
addition of the enzyme. This minimises non-specific annealing 
of the primers and helps to prevent primer-dimer formation. 
1) 95°C -1.5 minutes DENATURATION STEP 
Add enzyme and mineral oil 
2) 55 °C -1 minute ANNEALING 
72 °C -7 minutes EXTENSION 39 cycles 
93 °C -1 minute DENATURATION 
3) 55 °C -1 minute ANNEALING 
72 •c -10 minutes EXTENSION 
The three-step program used in the amplification of the three 
500bp overlapping ASS eDNA fragments was as follows: 
1) 95 °C -1.5 minutes 
2) 42 °C or 48 °C or 50 °C - 1 minute 
72 °C - 2 minutes 39 cycles 
93 °C - 1 minute 
3) 42 °C or 48 °C or 50 °C - 1 minute 
72 °C - 10 minutes 
The products of each PCR amplification were assessed on a 2% 
agarose (Amersham) gel or a 4% wide range low-melting point 
agarose gel (NEN products), stained with ethidium bromide and 
visualised under UV. 
To establish the optimised magnesium concentration for each 
set of primers, a magnesium titration was performed. This 
involved the amplification of the template at various 
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magnesium concentrations: 1 - 6mM, to establish the most 
suitable concentration. 
D.iii: Purification of PCR products. 
PCR products were separated from unincorporated primers, 
primer-dimers, free dNTPs and non-specific products by two 
methods: a) "Magic PCR preps" [43] (Promega) purification 
from low melting point agarose, or b) "Qiaex" [44] (Qiagen) 
extraction from normal agarose. 
D.iii.a: 0 Magic prep0 • 
The "Magic prep" purification system [43] allowed for the 
rapid purification of PCR products that had been excised from 
low-melting point agarose (NEN products). The agarose 
fragment was melted at 70 °C and then mixed with an 
ion-exchange resin that binds DNA present in the agarose 
(through weak ionic interactions). The resin was loaded onto 
a small column, the agarose and ethidium eluted with a quick 
80% isopropanol wash and the DNA eluted in 50pl of TE 
[43].When smaller volumes were required the DNA was 
precipitated with 1/10th volume 3M Na acetate (pH 5.2) and 2 
volumes 100% ethanol (-70°C for 20 minutes) and then washed 
with 70% ethanol. The DNA prepared in this way was used for 
cloning and subsequent reamplification of PCR fragments. 
D.iii.b: 0 Qiaex0 • 
Larger PCR products that were separated 
gels (due to the separation limitations 
low-melting point agarose), were purified 
on normal agarose 
of the available 
from gel slices 
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using the "Qiaex" purification kit from Qiag'en [44]. This 
involved the binding of DNA to silica beads, the removal of 
agarose and ethidium and the elution of the DNA fragments 
with TE. The 1% agarose gel fragment was solubilised with the 
addition of QX1 (3M Nai, 4M NaCl04 , 10mM Tris.HCl(pH 7), 10mM 
sodium thiosulphate) and the Qiaex bead suspension followed 
by incubation at 50°C for 10 minutes.The DNA-Qiaex suspension 
was centrifuged and the pellet washed with QX2 (8M NaCl04 , 
10mM Tris.HCl (pH 7)) to remove the agarose and contaminating 
dyes and QX3 (70% ethanol, 100mM NaCl, 10mM Tris.HCl (pH 
7.5)) to remove the sodium perchlorate. The pellet was 
thoroughly dried and the DNA pellet eluted from the resin by 
incubation with TE at room temperature for 5 minutes. This 
elution was repeated to increase the recovery yield (60%). 
D.iv: Cloning of eDNA PCR products. 
Fibroblast eDNA amplified through PCR, was cloned into a 
plasmid vector and then sequenced to establish if the ASS 
mutation occured at the level of the mRNA. Cloning involves 
several steps: enzymatic manipulation of vector and insert, 
transfection of competent cells and selection of 
recombinants. 
D.iv.a: Blunt-end ligation. 
The cloning method used was i'bl unt-end" 1 igation [ 4 5] and was 
performed as follows: The purified PCR product was 
blunt-ended ("polished") with the Klenow fragment of E.coli 
DNA polymerase 1 and the addition of 0.55mM dNTPs and 5mM Mg2+ 
at 37°C for 1 hour. The mixture was then denatured at 65°C to 
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inactivate the Klenow fragment. 
The plasmid vector pUC18 DNA was linearised with Smai (12Ujpg 
plasmid DNA), which produces blunt-ended fragments. The 
"polished PCR fragment and the plasmid vector were then mixed 
in a proportion of 5:1 {500ng/100ng) and incubated with T7 
ligase overnight at room temperature to ligate the two 
fragments together. Smai was also included in the ligation 
reaction to prevent the re-ligation of the "empty" plasmid 
[45]. This does not effect the ligation of insert and vector 
however, as this ligation does not regenerate a Smai site. 
D.iv.b: Transfection of competent cell.s. 
Competent E.coli ceils (strain DH5 alpha) were prepared [46] 
and stored at -70°C until needed, at which point they were 
thawed on wet ice. 100~1 of cells were incubated on ice in 
the presence of 8pl of ligation mixture for 45 minutes, heat 
shocked at 37°C for 45 seconds and further incubated at 37°C 
for 1 hour in Luria Broth. 100-200pl of cells were then 
plated onto agar plates, containing 50pgjml Ampicillin and 
coated with 40~1 of X-gal (5-Brom-4-chlor-3-indolyl-B-D 
-galactopyranosid) {20mgjml) (dissolved in dil'nethylformamide) 
and 4ul IPTG (isopropyl-B-D-thiogalactopyranosid) {200mgjml 
in water), and incubated at 37~C overnight [35,38]. 
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D.iv.c: Selection of recombinant clones. 
pUC18 possesses two genes of importance in the selection of 
recombinants: An ampicillin resistance gene, which allows 
only those cells that carry the plasmid to grow in the 
presence of ampicillin, and the ex. -fragment of the 
~-galactosidase gene. This gene fragment allows bacterial 
cells containing the plasmid to cleave X-gal into galactose 
and X, which is a blue dye. The Smai site lies on the plasmid 
lies within the ~-fragment and thus if an insert is ligated 
at this site, the galactosidase gene is disrupted and the 
cells cannot cleave X-gal, producing white colonies. However, 
if the plasmid religates without the insert, the cells 
produce blue colonies [35,38]. 
1.5ml overnight cultures were established from white colonies 
on the amp-X-gal-IPTG plates and the alkaline-lysis method 
was used to extract plasmid DNA from the cultures [36]. A 
quick size test was performed to screen for plasmid"s 
containing inserts. Samples were evaluated on a 1% agarose 
gel and those plasmids that showed a 25-50% size increase 
were recultured and the DNA purified [36]. Contaminating RNA 
was removed by incubation with RNAse (lOmgjml), 
phenol/chloroform extraction and reprecipitation with 
ethanol. The plasmid DNA was then precipitated specifically 
by the addition of 6.5% PEG-8000 and 0.4mM NaCl to the dried 
DNA pellet. After incubation on ice for several hours, the 
precipitate was collected by centrifugation, ethanol washed 
and dissolved in TE (20pl). These purified samples were 
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digested with EcoRI and Psti (4U of each in 1x KGB) to excise 
the inserts and analysed on a 1% agarose gel for the presence 
of the correctly sized insert fragment. Purified DNA from 
insert positive colonies was then further analysed in the 
following sequencing reactions. 
D.v: Sequencing. 
Cloned ASS PCR products were sequenced using the Pharmacia T7 
sequencing kit that utilises the Sanger-dideoxy method of 
sequencing. 
The PEG/NaCl purified DNA (20pl) from the positive clones was 
denatured by the addition of 2pl of a solution of 2N NaOH and 
2mM EDTA. The NaOH was then neutralised with 8pl 1M Tris.HCl 
(pH 4.5) and the denatured DNA precipitated with 1/10 volume 
3M Na 
-70 °C). 
acetate and 2 volumes 
The pellet was 
100% ethanol ( 20 minutes at 
washed with 70% ethanol and 
vacuum-dried, and then the insert annealed to a sequencing 
primer by heating 2pl primer (10pmoles), DNA, 2pl annealing 
buffer (1M Tris.HCl (pH 7.6), 100mM MgC12 , 160mM DTT) and 
10pl distilled water to 65°C, then allowing the solution to 
cool slowly to room temperature [37]. 
Following the annealing reaction, the annealed. primer was 
extended in a brief labelling reaction by T7 DNA polymerase, 
to incorporate dATP-s35 into the first few nucleotides of the 
second strand. The reaction was initiated with the addition 
of 3pl labelling mix-dATP (dCTP, dGTP, dTTP-1.375mM, 333.5mM 
NaCl) and ~1 dATP-s35 (5pCi) on ice followed by 2U of T7 
sequenase, at which point the samples were incubated at room 
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temper~ture for 2.5 minutes to allow the labelling reaction 
to proceed. After 2.5 minutes, the labelling reactions were 
terminated by the addition of 4.5pl of labelling reaction to 
each of 4 tubes: G A T c, containing 2.5pl of the respective 
dideoxy nucleotide mixes. These termination reactions were 
incubated at 37 °C for a further 5 minutes and the reactions 
halted with the addition of 5).11 stop solution {0.3% 
Bromophenol Blue, 0.3% Xylene Cyanol, 10mM EDTA (pH 7.5), 
97. 5% deionised formamide) .• 
The products of chain termination were then denatured at 95°C 
for 3 minutes and electrophoresed {4 adjacent lanes) on a 6% 
acrylamide, 8M urea denaturing gel for several hours. The gel 
was run at 75W, fixed in 5% acetic acid/10% methanol/0.5% 
glycerol to remove the urea, dried under vacuum at 80°C and 
exposed to B-max x-ray film (Amersham). 
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1.4: RESULTS. 
1.4.A: ENZYME ANALYSIS. 
Preliminary diagnostic tests on the F25 patient revealed 
elevated ammonia and citrulline levels in the urine and 
plasma. This finding suggested a dificiency in either the ASS 
or ASL enzymes. Two experiments were primarily performed on 
this cell line to confirm the diagnosis of citrullinemia i.e: 
ASS deficiency, a dual-label uptake and a complementation 
assay. These experiments were repeated in this study ·to 
confirm the diagnosis before proceeding to molecular biology 
studies on ASS. 
Firstly, a dual-label ( 3H-phenylalanine and 14c-citrulline) 
uptake experiment was performed on the cultured fibroblasts. 
When ASS and ASL are both operating optimally, the 
fibroblasts are able to convert 14c-citrulline into 
14c-arginine, which is then incorporated into 14c-protein at the 
same rate as controls. The purpose of the second label, 
3H-phenylalanine, is to control for variation in cell number 
and cell viability, since all cells should incorporate 
~-phenylalanine at the same rate regardless of any urea cycle 
defects. The ratio of formation of 14c: 3H protein gives a 
more accurate representation of the utilisation of citrulline 
since it adjusts for cell differences. 
F25, three control cell lines (F500, F489, F488), an 
ASL deficient cell line (F199) and F535 
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(which is a cell line derived from the affected sibling of 
F25), were used in the initial dual label experiment. 
Fibroblasts were incubated in medium z containing 
3M-phenylalanine and 14c-citrulline for 4 hours and the amount 
of radioactivity incorporated into acid precipitable material 
was then assessed. The incubations were performed in medium Z 
as this medium is arginine free, which forces the cells to 
utilise the labelled amino acids for protein synthesis and 
therefore increases the amount of label incorporated into 
cellular protein. 
Figure 9A shows the amount of 3H-protein formed by each cell 
line, reflecting that all the cells formed similar levels of 
3H-protein. This indicates that the cells were healthy and 
that there were no major differences in cell number between 
the various cell lines. Figure 9B shows the amount of 
14c-protein formed reflecting the utilisation of citrulline 
and quite clearly shows the poor use of citrulline by F25 
when compared to the controls. In fact a 20 fold decrease can 
be seen between this cell line and the controls. Again when 
looking at the ratio's of 14c-proteinj3H-protein, (figure 9C) 
which adjusts for the slight variation in cell number, it is 
clear that F25 has a deficiency in citrulline uptake or 
citrulline metabolism. The ratio for a normal cell line is 
0.05, while F25 has a ratio of 0.003. It must be noted that 
there is a large variation in the 
by controls, when different 
utilisation of citrulline 
control cell lines and 
experiments are compared ( incorporation of 2000 to 38000 
14c-cpm into 14c-protein figures 9 and 23). 
H3-C14 DUAL LABEL UPTAKE 
A: H3·PROTEIN FORMATION 
B: C14-PROTEIN FORMATION 
3510 
PZS P535 PUJ P411 Pstl P41' P25 P535 Pm P411 Pstl P-
C: C14/113 RATIO 
..... 
FIGURE 9: Dual-label uptake assay: The determination of 
ASS / ASL activity. 
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Fibroblasts (100000 cells) were incubated in 0.5ml medium Z 
containing 0.5pCi 3H-phenylalanine and 0.3pCi 14c-citrulline 
for 4 hours. The medium was removed and the cellular proteins 
precipitated with 5% TCA. The acid precipitable material was 
dissolved in 0.5ml O.lM NaOH and 400pl counted to determine 
the quantity of 3H and 14c-protein formed. F25/F535 = 
citrullinemic patients, F199 = ASL deficient, F500, F489, 
F488 =controls (no urea cycle defects). The error bars 
represent the range of results seen in the triplicate wells. 
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However, F25 always remained within the range of 1-5% of the 
controls. F535 also shows very low utilisation of citrulline 
as was expected, since citrullinemia is an inherited 
metabolic disorder and so the mutation in both cell lines 
should be the same. 
At this stage however, it was not possible to determine from 
the experiment whether the defect in F25 was with the ASS or 
ASL enzymes, as can be seen with the behaviour of F199, the 
ASL deficient cell line in figure 9B. This cell line gives 
almost identical results to F25 in the utilisation of 
14c-citrulline, due to its inability to convert 
argininosuccinate to arginine. 
After establishing a defect in citrulline metabolism, a 
second experiment, a complementation assay, was performed to 
investigate which enzyme was defective. This assay was 
developed by Davidson et al [33] and relies on cellular 
communication between cells in the exchange of substrates. 
They demonstrated that ASS deficient cells and ASL deficient 
cells could complement each other in the utilisation of 
citrulline. This was shown to occur through the formation of 
gap-junctions between the cell types, when grown in 
co-culture. These junctions allowed the co-culture to 
successfully use citrulline for the production of arginine 
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FIGURE 10: The principles of the ASS 1 ASL complementation 
assay. 
Fibroblasts are able to communicate through gap junctions, 
allowing the exchange of metabolites between cells. Using 
these gap junctions (-----) ASS and ASL deficient cells are 
able to complement each other through the exchange of 
argininosuccinate and arginine, to allow both cell types to 
utilise citrulline for arginine synthesis. 
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To establish if a cell line is ASS deficient, specimen cells 
would be co-cultured with ASL deficient cells anq the 
utilisation of 14c-citrulline assessed. If formation of 
14c-protein by the co-culture was comparable with the control, 
then complementation had occurred and the specimen cells were 
ASS deficient. 
F25 and F199 (ASL deficient) were incubated separately a~d as 
a co-culture in the presence of 14-c-citrulline. Figure 11 
shows the results, reflecting the inability of these two cell 
lines to metabolise citrulline independantly, while when in 
co-culture they can convert the same amount of 14c-citrulline 
into 14c-protein as the control cell line. The ability of 
these two cell types to co-operate indicates that the defect 
in F25 lies in the ASS enzyme rather than an ASL deficiency. 
1.4.B: DNA ANALYSIS: SOUTHERN-BLOTTING. 
After the confirmation that ASS was defective i~ the F25 cell 
line, the first step in the identification of the ASS 
mutation at the gene level, was to check for any gross 
abnormalities in gene structure i.e: 
I 
rearrangements, 
insertions or deletions. DNA from the patient cell lines F25 
and F535, as well as from a control fibroblast cell line, 
F527, were digested with Psti and EcoRI restriction 
endonucleases and Southern-blotted. 
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FIGURE 11: ASS I ASL complementation assay. 
F25 (ASS deficient), Fl99 (ASL deficient) and F500 (control). 
fibroblasts {200000 cells) were incubated for 4 hours in• 
medium z containing 1 pci 14c-citrulline to assay their ASS 
and ASL activities ( 14c-citrulline->14c-arginine->14c-protein). 
F25 and Fl99 {100000 cells of each) were co-cultured and 
incubated in the above medium to assess their combined 
ASS/ASL functions. The cellular protein fractions were 
collected and the 14c-cpm in these fractions recorded. 
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material; Incorrect stringency of washing; Low specific 
activity of the radioactive probe, caused by too much initial 
DNA. Figure 12 shows the best result. 
Although a number of differences in the restriction banding 
patterns between control and the mutant cell lines can be 
seen, conclusions are difficult to draw from these results as 
the picture is complicated by the presence of 14 pseudogenes. 
These pseudogenes areintronless and show up to 93% homology 
with the coding region of the active ASS (figure 6) [25]. It 
is because of this homology that the Southern-blot is 
difficult to interpret, since the differences highlighted in 
figure 12 may reflect mutations in the pseudogenes rather 
than the active ASS gene itself. 
1. 4. C: mRNA ANALYSIS. 
C.i: PCR - eDNA analysis. 
To avoid the problems with the ASS pseudogenes, it was 
decided to approach the problem from a different angle, that 
being the analysis of the coding region of ASS, by 
investigating the ASS mRNA. Fortunately the pseudogenes are 
not transcribed so they cannot interfere in this analysis 
[23]. mRNA analysis allows one to address the following 
questions: 1) Is a transcript produced from the gene ? 2)Is 
it of the expected size? 3) Is it of the correct 
quantity? 
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f535 f2s fsoo fs3s f2s fsoo f53s f2s fsoo 
* 
* 
._Psti- .. EcoRI -... ... Hindiii-.... 
FIGURE 12: ASS DNA analysis - Southern-blot. 
Genomic DNA from F25, F535 and f500 (control) was digested 
with Psti, Hindiii 
onto Hybond N+ and 
and EcoRI restriction enzymes, 
probed with p32 labelled pASl-ASS 
blotted 
DNA ( 
10 "' 7 dpmjpg) . Observed differences in the restriction 
patterns of control ASS (F500) and the citrullinemic DNA (F25 
and F535) are indicated by * symbols. 
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4) Is the sequence of the mRNA 
convenient way of investigating the 
mRNA is to look at the eDNA copy, a 
as expected? The most 
nature of a particular 
DNA copy of the mRNA, 
which is much .more stable and more readily manipulated than 
mRNA. This involves the production of cDNA-mRNA hybrids to 
the total mRNA and then the production and amplification of a 
specific double-stranded eDNA (specific mRNA), with the use 
of specific primers in a polymerase chain reaction (PCR). 
From here the size and sequence of the mRNA can be analysed. 
cDNA-mRNA hybrids were created for the following cell 
lines: FSOO-control, F25 and F535. The amplification of ASS 
specific eDNA was then performed using the following sets of 
ASS specific primers: 
PRIMER 1A-22mer 5'-3'=G,AMACAGATTCCAGACGCCGG (P1A) 







PRIMER 5-18mer 5'-3'=CCACAGGAAAGGGGAACG (PS) 
PRIMER 6-18mer 5'-3'=GGTGCCTGCTGGGGTCTC (P6) 
Figure 13 shows 
the fragment 
the binding positions of these primers and 
sizes that they produce , when used in 
appropriate PCR reactions. 
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Sequence of ASS from 1 to 1547 
10 20 30 40 P1A 50 60 P18 70 
CGAGCCCGAG TGGTTCACTG CACTGTGAAA ACAGATTCCA GACGCCGGGA ACTCACGCCT CCAATCCCAG 
~ 80 90 100 110 120 130 140 
ACGCTATGTC CAGCAAAGGC TCCGTGGTTC TGGCCTACAG TGGCGGCCTG GACACCTCGT GCATCCTCGT 
150 160 170 180 190 200 210 
GTGGCTGAAG GAACAAGGCT ATGACGTCAT TGCCTATCTG GCCAACATTG GCCAGAAGGA AGACTTCGAG 
220 230 240 250 260 270 280 
GAAGCCAGGA AGAAGGCACT GAAGCTTGGG GCCAAAAAGG TGTTCATTGA GGATGTCAGC AGGGAGTTTG 
290 300 310 320 330 340 350 
TGGAGGAGTT CATCTGGCCG GCCATCCAGT CCAGCGCACT GTATGAGGAC CGCTACCTCC TGGGCACCTC 
360 370 380 390 400 410 420 
TCTTGCCAGG CCCTGCATCG CCCGCAAACA AGTGGAAATC GCCCAGCGGG AGGGGGCCAA GTATGTGTCC 
430 440 PS 450 460 470 480 490 
CACGGCGCCA CAGGAAAGGG GAACGATCAG GTCCGGTTTG AGCTCAGCTG CTACTCACTG GCCCCCCAGA 
500 510 P3 520 530 540 550 560 
TAAAGGTCAT TGCTCCCTGG AGGATGCCTG AATTCTACAA CCGGTTCAAG GGCCGCAATG ACCTGATGGA 
570 580 590 600 610 620 630 
GTACGCAAAG CAACACGGGA TTCCCATCCC GGTCACTCCC AAGAACCCGT GGAGCATGGA TGAGAACCTC 
640 650 660 670 680 690 700 
ATGCACATCA GCTACGAGGC TGGAATCCTG GAGAACCCCA AGAACCAAGC GCCTCCAGGT CTCTACACGA 
710 720 730 740 750 760 770 
AGACCCAGGA CCCAGCCAAA GCCCCCAACA CCCCTGACAT TCTCGAGATC GAGTTCAAAA AAGGGGTCCC 
780 790 800 810 820 830 840 
TGTGAAGGTG ACCAACGTCA AGGATGGCAC CACCCACCAG ACCTCCTTGG AGCTCTTCAT GTACCTGAAC 
850 860 870 880 890 900 p~ 910 
GAAGTCGCGG GCAAGCATGG CGTGGGCCGT ATTGACATCG TGGAGAACCG CTTCATTGGA ATGAAGTCCC 
920 _ P6 930 940 950 960 970 980 
GAGGTATCTA CGAGACCCCA GCAGGCACCA TCCTTTACCA TGCTCATTTA GACATCGAGG CCTTCACCAT 
990 1000 1010 1020 1030 1040 1050 
GGACCGGGAA GTGCGCAAAA TCAAACAAGG CCTGGGCTTG AAATTTGCTG AGCTGGTGTA TACCGGTTTA 
1060 1070 1080 1090 1100 1110 1120 
CGGCCTAGCC CTGAGTGTGA ATTTGTCCGC CACTGCATCG CCAAGTCCCA GGAGCGAGTG GAAGGGAAAG 
1130 1140 1150 1160 1170 1180 1190 
TGCAGGTGTC CGTCCTCAAG GGCCAGGTGT ACATCCTCGG CCGGGAGTCC CCACTGTCTC TCTACAATGA 
1200 1210 1220 1230 1240 1250 1260 
GGAGCTGGTG AGCATGAACG TGCAGGGTGA TTATGAGCCA ACTGATGCCA CCGGGTTCAT CAACATCAAT 
1270 1280 1290 1300 1310 ~ 1320 1330 
TCCCTCAGGC TGAAGGAATA TCATCGTCTC CAGAGCAAGG TCACTGCCAA ATAGACCCGC GTACAATGAG 
1340 P2 1350 1360 1370 1380 1390 1400 
GAGCTGGGGC CTCCTCAATT TGCAGATCCC CCAAGTACAG GCGCTAATTG TTGTGATAAT TTGTAATTGT 
1410 1420 1430 1440 1450 1460 1470 
GACTTGTTCT CCCCGGCTGG CAGCGTAGTG GGGCTGCCAG GCCCCAGCTT TGTTCCCTGG TCCCCCTGAA 
1480 1490 1500 1510 1520 1530 1540 
GCCTGCAAAC GTTGTCATCG AAGGGAAGGG TGGGGGGCAG CTGCGGTGGG GAGCTATAAA AATGACAATT 
1550 1560 1570 1580 1590 1600 1610 
AAAAGAG 
FIGURE 13: Positions of the ASS-specific PCR 1 sequencing 
primers. 
Diagrammatic representation of the relative positions of the 
primers used in the amplification of ASS fragments from pASl 
and cellular ASS eDNA. PlA - P2 = 1334bp, PlB - P2 = 1307bp, 
PlB - PJ = 460bp, P2 - P4 = 480bp, P5 - P6 = 510bp. * = ASS 
translation start codon, I = termination codon. 
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C.i.a: Amplification of pASl ASS insert. 
Due to the low level of expression of ASS in peripheral 
tissues compared to hepatocytes [1,11] (lower cytoplasmic 
levels of mRNA), as well as the report that some cell types 
contain as few as three ASS mRNA molecules per cell [27], it 
was necessary to optimise the PCR conditions to amplify ASS 
eDNA from a very small starting concentration. In order to 
achieve this, the plasmid pAS1 was used as a template in the 
preliminary studies of PCR optimisation. As mentioned earlier 
this plasmid contains a complete copy of the ASS mRNA 
inserted into a pUC18 vector. 
PCR program design. 
several factors had to be taken into consideration when 
designing the PCR program. Firstly, a fragment of at least 
1236bp needed to be amplified (coding region of ASS [1]) for 
complete ~nalysis, and secondly the ASS mRNAjcDNA template 
was expected to be rare amon9 the mRNA species. 
The p~ogram that was used to amplify the complete ASS coding 
region as well as additional 5' sequence (1334bp), consisted 
of 40 cycles of the following: denaturation for 1 minute at 
93°C, 1 minute at 55°C to anneal the primers and 7 minute 
extensions at 72 °C. 2-3 minute extension times are normally 
used to amplify 400-700bp fragments, so 7 minutes ensures the 
1334bp product is completed. 
A step program of 15 cycles of 5 minute extensions followed 
by 15 cycles at 6 minute extensions, then 10 cycles at 7 
minutes was also attempted, but was found to be inadequate 
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(extensive DNA smearing was produced on agarose gels). The 
step program takes into account the decrease in Taq 
polymerase enzyme activity after extended incubations at high 
temperatures [47], allowing longer extension times as the 
enzyme activity decreases. The previously mentioned program 
of 40 cycles of 7 minute extensions was however, found to be 
more successful. The decrease in enzyme activity was 
compensated for by the initial addition of 2.5U of Taq 
polymerase (Stratagene), followed by a further 2.5U at 20 
cycles. 
For the formation of the shorter 400-SOObp products discussed 
below, a shorter extension time of 2 minutes was chosen and 
additional enzyme was not added. However, 40 cycles was still 
performed due to the expected rarity of the template. 
PCR reactions used to amplify the 1307bp and the 3 500bp 
fragments were initiated with a Hot-start, so as to ~imit the 
formation of primer-dimers [42], and all the reactions were 
completed with a final extension of 10-15 minutes to ensure 
that all the products were completely extended. 
It is important to note that all PCR reactions (plasmid and 
cellular) were monitored for 
of a blank reaction mix 
contamination, by amplification 
per PCR reaction. This blank 
contained all the PCR components excluding DNA template, and 
thus should not produce any amplified product unless one of 
the components 
only recorded 
is contaminated. PCR positive reactions were 
when the blank was negative i.e: no 
contamination detected: 
15 
Amplification of pASl ASS fragment 1334bp/1301bp. 
Initially an attempt was made to amplify the entire coding 
region of the ASS eDNA, 1334bp, using PRIMER 1A and PRIMER 2. 
Using an initial target template 
magnesium titration was performed 
concentration necessary for the 
concentrations of 1 and 2mM 
concentration of 0.9ng, a 
to determine the optimal 
PCR reaction. Magnesium 
found to be the most 
the plasmid insert, when 
temperature, 7 minute 
were 
effective in the amplification of 
using 40 cycles, 55 °C annealing 
extensions and 5U of Taq polymerase (2.5U Taq, 20 cycles -
2.5U Taq, 20cycles) (results not shown). 
To test the sensitivity of this amplification, further 
dilutions of the plasmid were made and used as PCR templates. 
0.09ng-90fg template concentrations were examined. Bands. of 
the correct size (1334bp) were amplified from a starting 
concentration of 0.09ng to 0.9pg but no lower. This result 
implies that the limit of amplification and detection using 
this method and primer pair 
molecules of target sequence 
is amplification from 6x10A5 
(1334bp). Taking into account 
that as few as three mRNA molecules of ASS mRNA may be 
present per cell [27], that RNA is extracted from 
approximately 10A6 cells and the amounts of RNA used in the 
eDNA and PCR reaction, the sensitivity needs to be lower than 
10,...4 molecules. 
Although the bands were visible, band intensity decreased 
with the more dilute samples and smearing became more intense 
(figure 14). 
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90 9 0.9pg 
. /smearing 
FIGURE 14: Amplification of pAS1-ASS: 1334bp, using P1A and 
P2. 
ASS eDNA from pAS1 was amplified using primers PlA and P2 
(1334bp). [Mg] = lmM, 55 °C annealing temperature, 7 minute 
extensions, 40 cycles, 2.5U Taq polymerase 1 20 cycles. The 
amplifications from 90pg - 0.9pg of ASS eDNA are shown here 
and demonstrate the increasing smearing as the initial 
template concentration is decreased. 
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Several possibilities were investigated for the reasons 
behind the smearing and poor yield: contamination in the 
buffers, contaminated primers, incorrect dNTP concentration, 
enzyme overlpading, incorrect annealing temperature, 
differing buffer requirements. All these possibilities were 
eliminated as the reasons behind the smearing. 
Originally these primers were designed without the aid of 
computer programs for primer design, so when the "OLIGO" 
computer program became available the structure of the two 
primers was examined in more detail to establish any 
detrimental complementarity. Figure 15 shows the results of 
this analysis. Self-annealing of PRIMER lA, as well as the 
annealing between PRIMER lA and PRIMER 2 would probably 
result in the formation of primer-dimers. This information 
could readily explain the smearing mentioned earlier, as it 
probably represents primer-dimer formation and the 
concatamerization of these products. Due to the abundance of 
primers in the reaction mixture, primer-dimers will be 
preferentially formed when very dilute amounts of target DNA 
are present [48]. This would in turn explain explain the 
present sensitivity limitations. 
To test this hypothesis and try to improve the PCR 
sensitivity, new primers were designed that had minimal 
primer-dimer formation, possessed no self-complementarity and 
had compatible annealing temeratures: PRIMER lB and PRIMER 2 
(fragment size: 1307bp). As well as the alteration of primer 
structure, a Hot-start [42] procedure was adopted to minimise 
formation of primer-dimers. 
PRIMER 1A 
5' GAAAAC 
II I l 
3' GGCCGCAGACCTTAGA j 
5' 3' 
GAAAACAGATTCCAGACGCCGG 
I I I I 
GGCCGCAGACCTTAGACAAAAG 
3' 5' 






FIGURE 15: Primer-dimer formation. 
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"OLIGO" analysis of PlA and P2, showing the complementarity 
between PlA and P2 and the self-complementarity within PlA 
that may dead to the formation of primer-dimers. The 
formation of significant amounts of primers-dimers lowers the 
efficiency of a PCR reaction and is generally avoided. 
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Although the two primers show no complementarity, it has been 
postulated that Tag polymerase can still form primer-dimers 
from the two primers, by stabilizing the juxtaposition of the 
primers, allowing extension to occur [48]. This will occur in 
dilute template solutions, so it is necessary to limit the 
formation of these dimers as much as possible. The Hot-start 
method involves the addition of polymerase, Mg2+ or primers 
only after the rest of the PCR cocktail has been heated to 
greater than 70 °C. This prevents the formation of 
non-specific annealing, by allowing primer extension only at 
higher temperatures [42,48]. 
A magnesium titration using the new primer pair - PRIMER 1B 
and PRIMER 2 (DNA template concentration of 0.9ng)(40 cycles, 
55°C annealing, 7 minute extensions and additional 2.5U Tag 
at 20 cycles), revealed two magnesium optima: 1 and 5mM 
(figure 16). Target concentrations of 0.09ng-0.09fg were then 
used as templates for these primers. Figure 17A shows the 
results, reflecting the successful amplification of a clear 
uand from a starting concentration of 9fg. This figure 
represents approximately 6x10AJ molecules of target DNA. This 
should be sensitive enough to detect any eDNA if it is 
produced in the F25 cell line. 
To establish the absolute lower limits of this amplification, 
0.1pCi p32-dCTP was added to the PCR ·mix, to enable newly 
synthesized strands to be radioactively labelled, allowing 
for a more sensitive means of detection. 
1 2 3 4'5 
~1307bp 




A magnesium titration for the amplification of 1307bp of ASS 
eDNA from pASl using PlB and P2. [Mg] = 1 - 5mM, 55 °C 
annealing temperature, 7 minute extensions at 72 °C, 40 
cycles, 2.5U Taq polymerase (Stratagene) 1 20 PCR cycles. A 
Hot-start was also performed. 
A 
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Amplification of 1307bp of ASS from pASl using PlB and P2, 
from initial DNA concentrations of 0.09ng - 9fg. [Mg] = lmM, 
55°C annealing temperature, 7 minute extensions, 40 cycles, 
2.5U Taq polymerase 1 20 cycles, Hot-start, and o.~Ci 
p32 -dCTP was included to improve detection sensitivity. 
A) An ethidium stained agarose gel of the PCR products. B) An 
autoradiograph of the same gel showing the successful 
amplification from ASS DNA concentrations in the 0.09ng 
0.9fg range. 
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The samples were electrophoresed and the gel 
autoradiographed. Figure 178 shows the result, indicating a 
faint PCR band of the expected size (1307bp) amplified from a 
starting concentartion of 0.9fg - 6x 1Q A2 molecules of ASS 
eDNA! 
Amplification of pAS1 ASS fragments: 460-510bp. 
Due to the length of the ASS eDNA and the initial difficulty 
with the amplification of the total eDNA from the cell lines 
and the plasmid, it was decided to amplify shorter, 
overlapping fragments of the ASS eDNA. The eDNA coding region 
was divided into three fragments of +/- 500bp each using 
primers P1B+P3, P2+P4, P5+P6 shown in figure 13. 
Again optimal conditions were established for each set of 
primers and the optimal conditions are shown in table 3: 
TABLE 3: PLASMID PCR SPECIFICATIONS. 
PRIMER PAIR: ANNEALING TEMP: No. CYCLES: [Mg2+ mM] : . FRAGMENT SIZE(bp) : 
P18 + P3 42
6
C 40 2,3,4 460 
P2 + P4 48°C 40 2 480 
P5 + P6 50°C 40 3 510 
All reactions were performed using the reaction profile of 40 
cycles, 2.5U Taq polymerase and 2 minute extension times as 
described in the methods section. Strong clear bands were 
observed with each subset and the various fragment sizes are 
shown in figure 18. The sensitivity also allowed 
amplification from 9fg of initial template DNA. 
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FIGURE 18: Fragmented ASS amplification from pASl. 
Amplification of fragmented ASS eDNA from the ASS eDNA insert 
of pASl. A = P2-P4: 480bp, B = P5-P6: 510bp, C = Pl-P3: 
460bp, D = P1B-P2: 1307bp. Refer to table 3 for the details 
of these PCR reactions. 
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After establishing 
amplification of the 
important to establish 
the optimal conditions for the 
various plasmid fragments, it was 
if these conditions would be altered 
in the presence of the elements from the reverse trancription 
mix. This is relevant as the reverse transcriptase mix 
contains dNTPs that could readily affect the PCR reaction. To 
test this possibility, a plasmid dilution was made in the 
reverse transcriptase mix and an aliquot used for the PCR 
reaction P2+P4. The results showed a shift in the magnesium 
requirements, with the optimum shifting from 2mM to 3mM and 
4mM. This factor was taken into consideration when amplifying 
cellular eDNA from reverse transcription mixes, using the 
higher magnesium optima for the PCR reactiqns. 
c.i.b: Amplification of cellular eDNA. 
The initial aim was to amplify the entire ASS eDNA of the 
patient and control fibroblast cell lines and then compare 
their sequences. However due to the problems with the initial 
set of primers PRIMER lA and PRIMER 2, it was decided to 
amplify the three overlapping fragments, as mentioned above. 
Fragmented cellular ASS eDNA: 460-510bp. 
Reverse transcribed RNA (lpg) from 
(control) were used as templates for 
F25, F535 and F500 
the PCR reactions as 
described in the plasmid section using PRIMER1B-PRIMER3, 
PRIMER5-PRIMER6 and PRIMER2-PRIMER4. The results are shown in 
figure 19A and show the successful amplification of the three 
PCR fragments in all three cell lines. The expected sizes of 
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510bp (P5+P6), 460bp (P2+P4) and 480bp (Pl+P3) were obtained 
in all three cell lines. 
The results of these amplifications provide several useful 
pieces of information about the F25, F535 mutation. Those 
being that ASS mRNA is produced in the citrullinemic cell 
lines and it is of the expected size, indicating that no 
major deletions or insertions are present in this ASS mRNA. 
The three PCR fragments produced for each cell line were used 
in the cloning and sequencing reactions discussed in section 
c.ii. 
Amplification of cellular ASS eDNA: 1307bp. 
After the synthesis of a newly designed PRIMERlB, synthesis 
of full length cDN~ from the three fibroblast cell lines was 
attempted. Using the optimal conditions for 1307bp plasmid 
amplification (PlB and P2 (lOOpmoles of each), 40 cycles, 
55°C annealing, 7 minute extension time, enzyme top-up (2.5U) 
at 20 cycles) F25,F535 and F500 (control) eDNA was used as 
the PCR template. eDNA samples were initially denatured at 
95 °C for 2 minutes and snapped cooled on ice prior to 
addition to the PCR reaction to ensure complete denaturation 
of the cDNA-mRNA hybrids. Figure 19B gives the results, 
showing the successful amplification of the 1307bp fragment 
in the control and F25 cell lines. The 1307bp fragment was 
also successfully amplified from F535 eDNA. This result 
confirms the earlier result of the presence of a full length 
coding region in the ASS deficient cells (F25, F535), with 









ASS eDNA was amplified from 2 citrullinemic patient cell 
lines (F25 and F535) and a control cell line (F500). (A) 
represents fragmented ASS amplification where A = P2-P4: 
480bp fragment, B = P5-P6: 510bp and c = Pl-P3: 460bp 
fragment. 1 = F25, 2 = F535, 3 = F500. (B) shows the 
amplification of 1307bp of ASS eDNA from F25 and F500. The 
eDNA solutions were primarily denatured at 95°C for 5 minutes 
prior to addition to the PCR reaction which was initiated 
with a Hot-start. The following PCR conditions were used: 
[Mg] = lmM, 55°C annealing temperature, 7 minute extensions, 
40 cycles, 2.5U Taq polymerase (Stratagene)/20 cycles. 
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Unfortunately, these results give no indication of the 
relative amounts of mRNA produced in these cells. 
C.ii: Cloning and sequencing. 
C.ii.a: Cloning. 
PCR products can be sequenced directly or cloned and then 
sequenced. Cloning has an advantage in that large amounts of 
material can be generated for sequencing purposes from small 
quantities of starting material. The disadvantage of cloning 
is that a number of clones must be sequenced to distinguish a 
true mutation from a random Taq polymerase error. The cloning 
route was chosen for the sequencing of the three overlapping 
PCR fragments synthesised from F25. 
Smai "blunt-end" ligation was chosen as the method of 
inserting the PCR fragment into the pUC18 vector [45]. One of 
the general disadvantages of "blunt-end" ligation, is that it 
tends to result in a relatively high plasmid religation 
background level. The Smai method lowers the 
self-religated vectors by the inclusion of 
percentage of 
Smai in the 
ligation mix , to keep the vector "open". It can however, 
only be used if the PCR insert fragment does not possess an 
internal Smai site. Further refinements such as removing the 
5' phosphate groups from the vector or increasing the 
insert:vector ratio, can be performed to further reduce the 
high background levels. 
With regards to the cloning of the three PCR fragments of 
F25, it was found that when the insert:plasmid ratio was 5:1, 
5 positive clones out of 15 white colonies were produced. 
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Although the background was quite high, enough clones were 
produced for sequencing purposes, so no refinements were made 
to the cloning procedure. The following controls were used to 
assess the method: cell competancy check, Smai efficiency in 
preventing plasmid religation and efficiency of ligase to 
religate the plasmid in the absence of Smai. Using these 
controls, it was found that all stages of the cloning 
experiment were operating effectively. 
Initial screening of white colonies 
for shifts in the size of the 
was performed by looking 
intact plasmid on gel 
electrophoresis, as compared to insert negative plasmid, as 
can be seen in figure 20A. These provisional positives were 
digested with EcoRI and Psti to cut out the insert from the 
multiple cloning site of the plasmid vector and the fragments 
separated on a 2% agarose gel. Positive colonies were taken 
as those that contained the 460bp, 480bp or 510bp fragments 
(figure 20B). 
C.ii.b: Sequencing. 
Three of the positive clones from each separate cloning 
experiment for F25 were sequenced to ensure that any detected 
mutations were not Taq polymerase or sequencing errors. The 
PCR fragments were sequenced in both directions using their 
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FIGURE 20: Selection of ASS recombinant plasmids. 
ASS PCR products were cloned into pUC18 vectors and amplified 
in competent DH5 alpha E.coli cells. Plasmid extracts were 
prepared by alkaline-lysis [38,39] and then analysed for the 
presence of the ASS inserts. (A) = plasmid extracts prepared 
from white colonies (blue-white selection) from the cloning 
of F25 ASS P2-P4 fragment into pUC18. Plasmids containing 
inserts showed size shifts on a 1% agarose gel (T )· (B)= 
plasmids showing size shifts were digested with Psti and 
EcoRI to confirm the presence of the 480bp fragment. 
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The first 900bp of the ASS eDNA from F25 i.e: P1-P3 and P5-P6 
fragments showed no sequence divergence from the published 
human sequence available from Genbank [13]. However, the 
fragment P2-P4 revealed five base changes, as shown below: 
1040 1064 
reference: TATACCGGTTTACGGCCTAGCCT 
F25 , .••.•. A . .•. CT . •• AC ••••• 
These base changes then result in the alteration of four 
consecutive amino acids: 
320 330 
reference: A E L V Y T G L R P s P E 
F25 . . . . . • S F W H . . . 
These results were shown in all three clones of the 
P2-P4 fragment, indicating that the changes are unlikely 
to be Taq polymerase errors. It is very unusual to have 
so many base changes in one area, so to confirm these 
results the P2-P4 fragment of F535 was also cloned and three 
clones sequenced. The sequences again revealed the same 
five base changes, showing that the original result was not 
a sequencing artifact. 
In order to understand the significance of these mutations, 
the F25 1 F535 mutant amino acid sequence was compared to 
several other ASS sequences available on Genbank: human, 
mouse and bovine. The following interesting result was found: 
320 330 
Human A E L v y T G L R p s p E 
F25 . s F w H . . . . . . . . 
Mouse . G F w H . . . . . . . . 
Bovine: . . . . . . G F w H . 
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This comparison showed that the mutant sequence showed more 
homology to the mouse and bovine sequences rather than to the 
documented human sequence [13]. This finding is very unusual 
and suggests that the human ASS sequence on Genbank is 
incorrect . To investigate this hypothesis , the P2-P4 PCR 
fragment from F500 , a control fibroblast cell line '· was 
cloned and three clones sequenced. This "normal" sequence was 
then compared to the Genbank sequence: 
1040 1064 
reference: TATACCGGTTTACGGCCTAGCCT 
F500 ••••••••••• CT ••• AC ••••• 
This result demonstrates that the sequence on Genbank is not 
representative of a normal human ASS eDNA sequence. Taking 
this into account, the F25 mutations were reassesed by 
comparison with our control fibroblast cell line F500. The 
results are shown in figure 21 which represents the 
autoradiograph of the two sequences, and summarised below: 
1045 
F500(control): TATACCbGTTTACGGCCTAGCCT 
F25 ••••• • A •••••••••••••••• 
324 324 
GLYCINE -> SERINE 
This G->A transition at 1045bp in the F25 ASS eDNA causes 
the amino acid change: Gly -> Ser at position 324 in the F25 
subunit protein sequence. This mutation is not a Taq 
polymerase error or a sequencing artifact and represents a 
true ASS mutation present in the mRNA coding regions of both 
F25 and F535. 
.,.AG 
~GG 
G A T C G A T C 
FIGURE 21: Sequence comparison of F25 (ASS deficient) 
and F500 (control). 
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The three overlapping ASS eDNA PCR fragments from F25 and 
F500 were sequenced using P2, P3, P4, P5 and P6 primers and 
their sequences compared. A single base difference between 
F25 and F500 was found at position 1045bp, which represented 
a G->A transition mutation in the F25 ASS eDNA. 
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1.4.0: ARGININOSUCCINATE SYNTHETASE ACTIVATION. 
The molecular experiments have answered several questions 
regarding the mutation in the F25 citrullinemic cell line 
i.e: an ASS mRNA transcript is produced in these cells and it 
is of the expected size, however the coding region of this 
transcript contains a single point mutation ( position 
1045bp), resulting in a Gly->Ser amino acid change in the 
subunit protein sequence. 
However, this may not be the only mutation responsible for 
the ASS deficiency in F25. At present no information has been 
gathered regarding the amount of ASS mRNA produced i.e: is 
the promotor defective ? 
As mentioned in the review, it has been reported that in some 
cultured cell lines ASS is regulated at the transcription 
level by extracellular arginine concentrations . It is known 
that arginine acts at the ASS promotor of these cells to 
depress the levels of cytoplasmic ASS mRNA produced. When 
arginine is removed from the medium the levels of cytoplasmic 
ASS mRNA increase 360 fold depending upon the cell type. At 
present this phenomenon has not been demonstrated in human 
fibroblasts. To investigate the presence of this regulatory 
mechanism in cultured fibroblasts and to investigate the 
possibility of a defect in the promotor region of ASS in F25, 
the activation of ASS in the absence of arginine was 
researched. 
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F25, F535 and control fibroblast cell lines F500, F699 and 
F688 wer~ incubated in the presence of arginine-free (0.6mM 
citrulline) medium, 0.05mM arginine· (0.6mM citrulline) or 
0.6mM arginine medium for 96 hours [25] (medium was changed 
at 48 hours to replenish glucose levels and remove waste 
products) in an attempt to activate transcription from the 
ASS promotor. The medium was removed and the cells incubated 
in the presence of medium Z (arginine-free) for 20 minutes to 
allow for the metabolism of any intracellular arginine. The 
cells were then incubated in the presence of 14c-citrulline 
(medium Z) to study the effects of pre-incubation (96 hours) 
on the activity of the ASS enzyme in the various cell lines. 
Figure 22 gives the results of this experiment. 
The histogram represents the amount of 14c-radioactivity 
incorporatedj400ug of cellular protein, rather than per cell 
number, as it was found that cell protein levels varied 
significantly between the different media, in patients and 
the controls after the 3-step experiment. This variation 
could have been a result of two factors, one being that due 
to the inability of the ASS and ASL enzymes to co-operatively 
produce enough arginine for protein production in the 
absence of extracellular arginine, cellular proteins were 
being degraded to allow the production of essential proteins. 
The other possibility being that significant cell death was 
occuring in the wells free of extracellular arginine, again 
because ASS and ASL cannot synthesize the necessary quantity 
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FIGURE 22: ASS activation. 
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F25, F535 (citrullinemic cell lines) as well as F500, F699 
and F688 (controls) were pre-incubated in medium containing 
varying amounts of arginine (0, 0.05, 0.5mM) for 96 hours .. 
After the incubation period the ASS activity was assayed by 
measuring the incorporation of 0.5pCi ·~-citrulline into 
~-protein over a 4 hour period in medium z. The cellular acid 
precipitable material was collected (0.5ml) and the 
radioactivity content determined. The results were expressed 
as 1~-cpmj400pg protein to correct for observed differences 
in cell numbers. The error bars indicate the range of results 
shown in the triplicate wells. 
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To investigate the first possibility, the media from the 48 
hour and 96 hour incubations was analysed on the amino acid 
analyser to look for differences in the levels of amino 
acids. Significant protein degradation should result in an 
increased level of certain amino acids. 
However, no such differences were noted between the 3 
different media after the 48 hour incubation periods. Upon 
closer examination of the cells during the actual ASS 
activation experiment, a notable decrease in cell number was 
evident in the arginine-free medium. Cell death probably 
explains the drop in cell number more accurately. This must 
be kept in mind when investigating ASS mRNA levels. 
Figure 22 shows 
unresponsive to 
regulation of ASS 
that control fibroblasts 
extracellular arginine 
activity. This result has 
are relatively 
levels in the 
also been shown 
in several other repeat experiments, with ASS activity only 
increasing between 1-1.5 fold in the presence of 0.05mM 
arginine and decreasing by up to 0.5 fold in the complete 
absence of arginine. The decrease may be a reflection of the 
lack of growth factors that would normally be supplied in the 
foetal calf serum. 
lines show 
definite 
very different results, 
7 fold increase in ASS 
The citrullinemic cell 
with F25 showing a very 




with a 4 fold increase in the presence of 0.05mM 
(5%FCS). These results are mimicked to a large 
the F535 line, showing a 6 fold increase in the 
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absence of arginine. These results have also been repeated 
and although results vary, F25 shows definite increases in 
ASS activity when incubated in the absence of arginine: 5-15 
fold increase. The variation is probably due to experimental. 
variation in the utilisation of citrulline by cultured 
fibroblasts as reported by Baumgarten [49]. These results 
could represent several possibilities : 1) In light of 
reported evidence that ASS promotor activity is regulated 
by arginine in other cultured cell lines [1,24,25,26], there 
could be a promotor defect in the F25 and F535 cell lines, 
making them sensitive to the arginine regulation. 2) The 
other possibility is that this reflects an isotopic dilution 
effect, with intracellular arginine diluting the 14c-Arginine 
formed by ASS from 14c-citrulline, leading to lower 14c-protein 
incorporation results in the cells incubated for 96 hour in 
media containing 0.6mM or 0.05mM arginine. 
As a test for this activation hypothesis , the ratio of 
14c-citrulline : 3H-arginine uptake was measured after the 
different incubation conditions to assess any dilution 
effects in both the F25 and F500 cell lines (labels were 
incubated in separate wells). If true activation was occuring 
in F25, the 14c: 3H ratio should be expected to increase 5-15 
fold in the cells incubated for 96 hour in the absence of 
arginine, reflecting the increased ASS enzyme activity. 
However, identical 14c:~ ratios were found in cells fed in 
the presence and absence of arginine for 96 hour. The 
"activation" shown in F25 and F535 (figure 23) therefore 
probably relects an isotopic dilution effect of unlabelled 
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arginine on 14c-arginine, rather than true ASS transcription 
activation. 
No obvious dilution effect was seen in the control 
fibroblasts. This can however be explained by the ASS 
activity in these cells. 0.6mM L-citrulline is included in 
the arginine-free incubation medium, which enables control 
cell ASS/ASL activity to produce significant intracellular 
arginine levels over the 96 hour period. The arginine pool 
size in these cells must be very similar to that of cells 
incubated in the presence of arginine (96 hours) as no 
significant isotopic dilution effect is observed. In the 
citrullinemic cell lines F25 1 F535, the 1-5% residual ASS 
activity is presumably unable to compensate for the decrease 
in the intracellular arginine pool over the 96 hour period, 
leading to the pronounced dilution effect when comparing 
cells incubated in arginine-free to 0.5mM arginine medium. 
1.4.E: KINETIC ANALYSIS OF ARGININOSUCCINATE SYNTHETASE. 
Although the enzyme kinetics were not originally studied, due 
to the very low levels of ASS activity in the citrullinemic 
cell lines, the increased 14c-citrOlline (5-15 fold) 
incorporation found in these cells after intracellular 
arginine depletion (96 hours in arginine-free medium), made 
it possible to study citrulline metabolism more readily. Thus 
an attempt was made to study the kinetics of ASS in a control 
and citrullinemic F25 cell lines. Ideally, cell-free assays 
are performed to accurately assess the parameters of an 
'~ ' } 
I 
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Figure 23: ASS kinetic analysis. 
The kinetic parameters (Vmax and Km) of the ASS enzyme from 
F25 (citrullinemic patient) and F699 (control) were analysed 
by measuring ASS activity a citrulline concentration range of 
10-100pM in a whole cell assay. ASS activity was measured by 
determining the incorporation of 14c-citrulline (constant 
specific activity) of 25~Cijmmol) into 14c-protein over a 4 
hour period, in the presence of the unlabelled L-citrulline. 
The error bars represent the range of results seen in the 
triplicate wells. 
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This would bring the Km for citrulline into the range of 
4-6mM, which was not covered in the present study. The result 
obtained in figure 23 would be compatible with either an 
increase in Km or a decrease in Vmax, and there is 
insufficient activity in these cells to be able to perfqrm an 
accurate discrimination between these two possibilities. 
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1.5: DISCUSSION. 
1.5.A: GLYCINE -> SERINE MUTATION. 
Little is known about the amino acid residues involved in the 
catalytic activity of ASS, therefore analysis of kinetic 
mutants may help to elucidate the nature of the active site. 
For this reason the nature of the mutation responsible for 
the ASS deficiency in the F25 cell line, from a citrullinemic 
patient, was investigated. 
A genetic analysis of the mutation responsible for the 
reduced ASS activity (1-5%) in the F25 cell line was 
performed. This involved the investigation of possible 
genetic rearrangements at the DNA level, and the analysis of 
the coding region of the active ASS gene (q34 chromosome 9). 
The results of these studies showed that a mRNA transcript 
was produced from the ASS locus in the abnormal cell line, 
and the coding region was of the correct size. This indicates 
that no abnormal RNA splicing was occurring. Upon analysis of 
this coding region, a single point mutation was found at 
position 1045bp, a G->A transition which results in an amino 
acid change Gly->Ser at position 324 in the subunit protein 
sequence. 
The possibility that perhaps a contaminating nuclear 
pseudogene was actually sequenced was eliminated due to 
the fact that only one base mismatch was detected. ASS 
pseudogenes show a very high homology with the ASS mRNA, 
as can been seen from figure 6 other point mutations 
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would also be expected. This G->A transition was not the 
result of a Taq polymerase error or a sequencing artifact 
since the same mutation was found on sequencing 6 separate 
clones. Instead it represents a true mutation in the coding 
region of the ASS eDNA in both the F25 and F535 cell lines. 
The consequences of this mutation on the catalytic activity 
of ASS are difficult to determine exactly as little is known 
about the tertiary structure of the protein or the active 
site amino acids. Some analysis of the protein has been 
performed by the comparison of the primary structure between 
various species (figure 5) [18].Several areas of homology 
have been determined through this analysis and two of these 
have the properties of possible substrate-binding sites, 
however glycine 324 is not located in any of these regions. 
It is important to note that glycine 324 is highly conserved 
between species, indicating that it may have an important 
role in ASS protein function. The importance of this glycine 
residue was further confirmed by the observation of a 
Gly->Ser 324 mutation in three other unrelated cases of 
citrullinemia, in a study performed by Kobayashi et al [9] 
that investigated 53 cases of the disease. 
Glycine is a small, neutral amino acid that is important in 
protein folding, as it is easily accommodated in turns and 
protein interiors. Serine on the other hand is hydrophilic 
and would thus be most commonly found on the surface of 
proteins. This change in hydrophobicity and size could 
interfere with the folding of the protein, altering the 
active site itself or the ability of the subunits to form a 
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tetramer. The single ASS subunits possess some activity [1], 
so an inability of the subunits to form a tetramer may be a 
possible explanation for the residual activity in F25. A 
change in protein folding may also effect protein stability, 
decreasing the half life of the ASS enzyme. 
Limited kinetic analysis of ASS was performed on both control 
and F25 cell lines (figure 23). The kinetic curve of the 
control gave a typical Michaelis-Menten reaction curve with 
an approximate Km of 20pM, which is in close agreement with 
that reported for liver [1]. However, F25 gave no 
interpretable curve, which would be consistent with F25 
representing a Km mutant, although the results were in no way 
conclusive. It is possible that the Gly->Ser mutation may 
have decreased the enzyme affinity for citrulline, thus 
markedly reducing enzyme activity under normal physiological 
concentrations of citrulline. More informative results on the 
kinetics of this enzyme in F25 could be obtained from the 
analysis of purified ASS from this patient. The whole cell 
studies performed here only give an indication of the kinetic 
parameters, they are by no means ideal. 
This mutation alone may not completely explain the decrease 
in activity of ASS in F25. Citrullinemia is a rare autosomal 
recessive disorder, thus requiring both ASS alleles to be 
mutated. Homozygosity is unusual in the case of rare 
disorders unless consanguinity has occurred earlier in the 
family history. The more likely situation is that of compound 
heterozygosity, different mutations on each ASS allele. This 
has been found to be the case in most of the studies 
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performed on citrullinemic patients [9]. 
Regarding the situation with F25, the results may suggest 
either a homozygous mutation or compound heterozygosity. Due 
to the presence of the G-A mutation in effectively six clones 
(three from F25, three from F535) it is likely that at this 
locus the mutation is homozygous. However, it is possible 
that only one allele is actually synthesised in these mutant 
cells, that being the one containing the G-A mutation. In 
this case the patient would be a compound heterozygote, with 
the other mutation representing a "promotor" defect on the 
other allele, where the amount or stability of ASS mRNA is 
affected. 
It has been reported that in some cultured cell lines, ASS 
activity is regulated by an arginine-mediated negative feed 
back mechanism [24,25,26]. This regulation occurs at the 
pre-translation level and involves the control of ASS mRNA 
levels. The DNA element responsible for the mediation of the 
arginine-repression of ASS activity has been shown to occur 
within 150bp upstream from the transcription start-site i.e: 
within the promotor region [26]. In lymphoblasts, HeLa and KB 
cells a 3-60 fold increase in ASS activity is noted when the 
cells are incubated in the absence of arginine [26], with the 
increase directly linked to an increase in ASS mRNA levels. 
An attempt was made to demonstrate this regulatory pathway in 
fibroblasts and to observe any abnormalities in the 
citrullinemic cell lines, by looking for ASS activation after 
incubation in arginine-free medium for 96 hour [25]. No ASS 
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activation was noted for control cell lines, however 5-7 fold 
activation was seen in the citrullinemic cell lines (figure 
23). This result would have been consistent with a promotor 
defect resulting in the increased sensitivity of th ASS 
promotor to arginine, as is observed in other cultured cells 
[24,25,26]. However, this apparent increase in ASS activity 
was found to be due to an isotopic dilution effect of 
intracellular arginine pools on 14c-protein formation, rather 
than true ASS activation. Thus according to the experiments 
performed in this study, the ASS promotor in fibroblasts is 
unresponsive to exogenous arginine levels and no evidence was 
collected regarding a promotor defect in F25. A more accurate 
means of assessing arginine repression of transcription from 
the ASS promotor, would be to study the levels of ASS mRNA 
produced when the cells are incubated in the presence and 
absence of arginine. 
To elucidate the nature of the F25/F535 defect more clearly, 
several other studies need to be performed: The genetics of 
the parents must be analysed to establish if the affected 
children are homozygotes or compound heterozygotes. Levels of 
ASS mRNA produced in F25 must also be ascertained to 
establish if there is a promotor defect in these cells. This 
can be achieved by Northern-blotting or radioactive PCR 
techniques. The exact consequences of the Gly->Ser mutation 
in F25 can only be determined by a combination of experiments 
to establish the mutations effects on substrate binding, 
protein folding and subunit association. 
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1.5.B: GENBANK ERROR. 
During the investigation of the citrullinemia mutation, it 
was found that the human ASS sequence [13] deposited in the 
Genbank database possessed a set of 4 incorrect bases. This 
conclusion was derived in two ways, one being that a sequence 
of a control fibroblast cell line differed from the Genbamk 
human sequence and the other being that the amino acid 
sequence of the Genbank human entry differed significantly 
from the sequence of other species (section 1.4.C.ii.b). 
This result can be interpreted in terms of the discovery that 
the cells that were originally sequenced by O'Brien et al 
[13] were actually mutant cells. The human cells were CanR 
RPM! 2650 cells, utilised because of their increased 
expression of ASS mRNA, making it easier for eDNA prepartion, 
cloning and sequencing. As mentioned in the review on ASS, 
the mechanism of CanR has been shown to have similarites to 
the regulatory mechanism responsible for the high ASS 
activity in hepatocytes [27]. This mechanism may also be 
involved in the tissue-specific expression of ASS activity. 
Through the research on canR cells more information about 
this possible ASS regulation mechanism is being investigated. 
At this stage, it is known that CanR results in increased 
levels of ASS cytoplasmic mRNA, that the mechanism 
operates at the pre-translational level and that a 
dominant positive trans-acting 
[1,27,30,32]. It is not certain 
factor is involved 
where this trans-acting 
0 
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factor binds and it has been postulated that perhaps the 
sequence is present in one of the exons [26]. 
It is the information that the 
high activity in liver cells 
sequence involved in CanR and 
may be intragenic, that makes 
the "mistake" in the Genbank sequence very relevant. Perhaps 
these 4 base changes occur in the DNA element involved in 
this regualtory mechanism and are responsible for the 
increased ASS expression in these CanR cells. Before any 
further speculation was made in this respect, a thorough 
literature search produced a paper (9] published some 10 
years after the human ASS sequence was originally published. 
This paper by the original authors admitted that the 4 base 
changes identified in this thesis were actually the result of 
a "sequencing error". However, it is hard to understand how 
O'Brien et al (13] could have made such a mistake in reading 
the sequence, since they sequenced three separate clones. It 
is therefore imperative that the original CanR clones are 
re-sequenced before these results are ignored. 
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SECTION 2 
INVESTIGATION OF THE NITRIC OXIDE PATHWAY IN FIBROBLASTS. 
110 
2 .1 REVIEW: THE NITRIC OXIDE PATHWAY. 
2.1.A: INTRODUCTION. 
The nitric oxide pathway represents the following reaction: 
L-arginine -----------> L-citrulline + NO 
nitric oxide synthase 
This reaction was only discovered six years ago in 1987 [50], 
when it was found that the elusive endothelium relaxing 
factor, involved in relaxation of vascular smooth muscle 
cells, was in fact the unstable, free radical nitric oxide 
(Nd) [51,52]. Since this finding, NO.has been shown to be 
involved in many aspects of mammalian physiology from host 
immune defense mechanisms to neuronal stimulation. Nitric 
oxide is the smallest molecule, lightest and first gas known 
to act as a biological messenger in mammals [53]. 
The detailed nature of the production of N~ from L-arginine 
is shown in figure 24 [54] and demonstrates the unusual 
metabolic route, although still speculative at this stage. 
Another aspect of nitric oxide is that it was found to be an 
intermediate in the production of nitrates in the mammalian 
system [55]. Reduction of nitrates to nitrites is involved in 
the production of nitrosamines which are potent carcinogens 
[55,56], thus an understanding of the NO" pathway may have 
implications in understanding the process of carcinogenesis. 
The key behind the diversity of functions of this gas is the 
enzyme that produces it: nitric oxide synthase (NOS). It has 
been demonstrated that there are at least two isoforms of 
this enzyme: constitutive (eNOS) and inducible (iNOS). 
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_FIGURE 24: The metabolic route proposed for the formation of 
NO'from L-arginine by nitric oxide synthase [55]. 
A five step (1-5) reaction scheme for the conversion of 
L-arginine to NO~ nitrate, nitrite and citrulline by nitric 
oxide synthase. 
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The specific distribution of the two isoenzymes and the 
different mechanisms of regulation allow NO.to fulfill such 
varied functions. Both isoenzymes catalyse the same reaction, 
both are dioxygenases, cytosolic and utilise the same 
cofactors: tetrahydrobiopterin (BH4 ), NADPH, FAD and FMN 
[57,58,59,60]. However, they differ extensively in their 
dependance on ca2•and in the amount of nitric oxide that they 
produce. The two enzymes share a 51% amino acid sequence 
homology [60], differing largely in the region of the 
predicted calmodulin binding site [61]. The subunits of the 
inducible form are slightly smaller in size (125-135kDa) to 
that of the constitutive enzyme (150-155kDa) and appear to be 
active in the dimeric form rather than monomers (eNOS) [58]. 
The use of both FAD and FMN as co-factors is unusual, with 
only one other mammalian enzyme in this category: 
NADPH-cytochrome P-450 oxireductase [61]. The FAD and FMN 
cofactors of this enzyme (P-450) allow the one-electron 
reduction of hemoproteins by stabilizing the resultant 
radical, formed within the oxireductase. It is possible that 
NOS utilises a similar mechanism in the synthesis of No: 
Another similarity between P-450 and NOS is the presence of 
ironprotoporphyrin lX, with cysteine as the ferric (111) iron 
ligand [62]. An interesting point that deserves further 
investigation relates to one of the hi-products of the P-450 
reaction- carbon monoxide (CO). One of the major functions 
of P-450 is the donation of electrons to the heme-oxygenase 
enzyme which breaks down heme. When P-450 donates electrons 
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to heme-oxygenase co is liberated. Evidence has been gathered 
[63] that supports the notion that co is also a neuronal 
messenger, involved in the regulation of cyclic GMP levels. 
Thus the structural similarity between P-450 and NOS may 
refect their involvement in the production of a new class of 
neurotransmitters. 
2.1.B: CONSTITUTIVE NITRIC OXIDE SYNTHASE. 
The constitutive form of NOS has been detected in vascular 
endothelial cells and cerebellar neurons and is dependant 
upon ca2+ (l00-500nM) [60], calmodulin and oxygen activity 
[64]. The constitutive form is a rapid response enzyme 
involved in signal transduction, producing small bursts of NO 
-
in response to changes in ca2•concentrations. The NO"produced 
by this enzyme acts as an unusual neurotransmitter [65], 
involved in the stimulation of guanylate cyclase activity 
[51]. Most neurotransmitters are amino acids or peptides, 
which are stored in specific vessicles and on release 
interact with specific receptors on the surface of cells 
[63]. NO.operates very differently, simply diffusing from one 
cell to another once synthesized in the cytoplasm [53,66]. 
B.i: Endothelial cells. 
In vascular endothelial cells NO is involved in vascular 
muscle relaxation [60]. Blood vessels are dilated by 
neurotransmitters such as acetylcholine and norepinephine, 
that cause the muscle layer to relax or contract. As 
mentioned above, neurotransmitters normally act through 
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receptors on the surface of muscle cells, However, no such 
receptors were found for acetylcholine. Acetylcholine 
receptors were in fact found on the surface of vascular 
endothelial cells that line the vascular muscle cells [63]. 
The mechanism of action was found to involve another 
neurotransmitter: NO' (refer to figure 25) [60,63,67]. When 
acetylcholine binds to the receptors on the endothelial cells 
it causes an influx of ca2• into the cell, which binds to 
calmodulin. This complex in turn binds to eNOS and activates 
it [63] to produce small amounts of NO' in the presence of 
oxygen [67]. Due to the fact that this enzyme is 
constitutively produced, a rapid response of NO' can be 
produced upon activation. 
NO'is lipid soluble and quickly diffuses across all membranes 
to the smooth muscle cells [64]. Here the No· free radical 
binds to the heme co-factor (Fe-thiel centre) of guanylate 
cyclase, causing a structural change that activates the 
enzyme more than 50 fold [60,62,63]. Guanylate cyclase then 
causes an increase in cGMP levels which results in the 
relaxation of the vascular smooth muscle cells, and an 
overall decrease in blood pressure [60,62,63]. No' has also 
been shown to operate as a neurotransmitter in the relaxation 
of smooth muscle cells in the gastrointestinal tract, the air 
passages [53] and in the relaxation response of the urethra 
[68]. 
FIGURE 25: The synthesis and action of nitric oxide in 
endothelial cells [60]. 
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The signal transduction pathway of endothelium-dependant 
vascular relaxation. ACh = acetylcholine, cGMP = cyclic GMP, 
NOS = nitric oxide synthase, sGC = soluable guanylate 
cyclase, (+) = stimulation. 
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It is interesting to note that the drugs that are used to 
treat angina (nitroglycerine and its derivatives) act by 
being metabolised to No·, which then causes the dilation of 
blood vessels [55,69,70,71]. 
B.ii: Neurons. 
In cerebellar neurons the excitory neurotransmitter glutamate 
has also been shown to function through the production of No· 
[63]. The effects of glutamate are mediated 
types of activated channels, one of 
through several 
which is a 
N-methyl-D-aspartate (NMDA) receptor [72]. This receptor 
controls a post-synaptic, voltage-dependant slow calcium 
channel. When glutamate binds at these receptors (NMDA) (see 
figure 26}, it causes the opening of the calcium channels. 
The calcium binds to calmodulin, which in turn activates 
eNOS. The No"that is produced activates guanylate cyclase 
[63]. 
NMDA-type receptors have been implicated in the triggering of 
long-term potentiation (LTP} (the strengthening of synapses 
through use) which is proposed to be an important memory 
mechanism. Because NMDA receptor activation is involved in 
both LTP and NO" production, the possibility of NO' being 
involved in this memory mechanism was investigated [70]. LTP 
involves the post-synaptic neuron signalling the pre-synaptic 
neuron to release more neurotransmitter. The intracellular 
retrograde messenger needed to convey this message was found 




FIGURE 26: Nitric oxide production in neurons [63]. 
Neuronal nitric oxide is synthesised and released in response 
to the binding of glutamate to the NMDA receptor. Binding 
causes the influx of calcium ions into the neuron, this 
calcium binds to calmodulin which in turn activates eNOS to 
produce No·. 
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B.iii: Other eNOS locations. 
eNOS has been located in the pituitary gland, in neurons that 
synthesize and release vasopressin and oxytocin [63,73]. In 
the adrenal gland it has been found in neurons that stimulate 
the release of adrenalin from adrenal cells [63]. In light of 
these observations it has been proposed that No'is involved 
in the control of hormone activity. 
Constitutive, ca2~dependant NOS has also been reported in the 
brain [9,63] with the majority of the eNOS being located in 
the neurons (63]. 
Mast cells have been implicated in inflammation, allergy, 
parasitic infection as well as other processes. Bissonnette 
et al [74] showed that at least 34% of the cytotoxicity of 
peritoneal mast cells can be attributed to the production of 
No'. NO· production by these cells does not require protein 
synthesis and has more similarity to endothelial cell NO 
synthesis (involves eNOS) than to macrophage No'production 
(involves iNOS, see below). Due to this similarity and the 
fact that mast cells are often found near nerve termini and 
vasculature, it 
participate in 
has been proposed that mast cells 
the vascular changes that occur 
pathological responses. 
2.1.C: INDUCIBLE NITRIC OXIDE SYNTHASE. 
may also 
during 
This isoenzyme (iNOS) is inducible at the gene level, with 
transcription being activated in response to cytokine 
stimulation [60,61,71]. Several hours of cytokine stimulation 
are necessary to activate the ca2+ independent iNOS 
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[55,61,63], however once this protein has been induced it 
produces large amounts of No: iNOS has been detected in 
macrophages [54,58,61], neutrophils [71] and smooth muscle 
cells [74,75,76]. 
The No· that is produced by iNOS participates in the host 
immune defense system against invading organisms and tumour 
cells. iNOS was first 
responsible for some of 
cells. Since then it 
discovered in macrophages where it is 
the cytotoxic effects of these 
has also been shown to exist in a 
variety of other cells where it supposedly operates in a 
similar way. The production of NO.metabolites (nitrates and 
nitrites) upon cytokine stimulation has been shown to occur 
in EMT6 and TA3 murine adenocarcinomas cell lines [54], 
murine fibroblasts [77], rat hepatocytes, rat kupffer cells 
[69], endothelial cells [78], and leukocytes [50]. 
When micro-organisms enter the body, lymphoblasts are 
activated by accessory cells presenting foreign antigens 
[50] • In response they produce cytokines such as 
~-interferon, which activate the macrophages to attack the 
micro-organisms see figure 27 [71]. Macrophages are further 
stimulated by interf.eron in conjunction with other molecules 
such as tumour necrosis factor (TNF) and lipopolysaccharide 
(LPS) [55]. By binding to the macrophage cell surface 
~-interferon activates the transcription of iNOS and results 
in the production of large amounts of No·. The exact method 
of transcription induction by these cytokines is at present 
unknown, although protein kinase c has been directly linked 
to this signalling process [79]. 
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FIGURE 27: Nitric oxide involvement in non-specific host 
immune defence mechanisms [50,63]. 
When microorganisms enter the system, lymphocytes 
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are 
stimulated to produce cytokines such as interleukin (IL-l), 
tumour necrosis factor (TNF) and gamma-interferon (Y-IFN). 
These molecules induce the transcription of iNOS in the 
macrophages. The nitric oxide synthesised by this enzyme 
diffuses out of the macrophages into microorganisms and 
tumour cells. It inhibits cell growth by binding to Fe-thiol 
centres of enzymes involved in DNA replication and energy 
production. 
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It has been demonstrated that ~ -interferon stimulates the 
activity of guanosine-triphosphate cyclohydrolase 1 (5-100 
fold increase ) [80], which catalyses the key step in the 
synthesis of BH4 [71,77,81]. B~ has been shown to be an 
essential co-factor of the inducible isoenzyme of NOS, less 
so in the case of the constitutive form ,which shows a 
variable 2-9 fold activation in the presence of this 
co-factor [57,59,60,73] • In the case of eNOS, Wolff and 
Datto [73] suggested that some eNOS sources may retain a 
tightly bound form of B~, which confers activity in the 
absence of exogenous BH4 , explaining the variability in 
results. 
It has been reported that BH4 participates in the initial 
step of the L-arginine ---> No· reaction , resulting in the 
N-hydroxylation of arginine [77]. Some controversy surrounds 
the involvement of BH4 in this enzymatic reaction, with some 
groups reporting that B~ participates directly [73] and 
others suggesting that its effect is indirect (in the case 
of cerebrallar eNOS) [58]. It is possible that BH4 stimulates 
NOS activity by an allosteric mechanism [73]. 
It has also been reported that B~ acts as a co-factor of 
indoleamine 2,3dioxygenase (IDO), which is also strongly 
induced by cytokine stimulation [82]. IDO is involved in the 
degradation of the essential amino acid tryptophan and 
is thought to play some role in cytokine induced 
host defense mechanisms. How the actual NOS gene 
is activated to synthesize 
stimulation still remains a 
NOS mRNA upon cytokine 
mystery, although IDO and BH 
1.22 
may be involved. 
Other than human macrophages the stimulation of BH+ synthesis 
by ~-interferon and LPS has been shown to occur in human 
fibroblasts [82], murine fibroblasts [77,81] and a number of 
human tumor cell lines [80]. In murine fibroblasts this 
increase in BH4 synthesis has recently been directly linked 
to the production of NO' from L-arginine [77]. It is not known 
if in other human cell lines an increase in pteridine 
synthesis by cytokines results in the production of No·. 
Returning to the inducible NO' response, the NO' that is 
produced by the iNOS diffuses out of the macrophages and 
binds to Fe-thiol centres of the bacterial/tumor cell 
enzymes, causing the formation of iron-dinitrosyl-dithiolate 
complexes [62]. NO" only has a half-life of 6-30 seconds 
[50,64] as it reacts with oxygen to form nitrate and nitrite 
[59,63], thus the target cells have to be fairly close to be 
affected. In binding to the Fe-S group NO alters the 
3-dimensional structure of the active site and prevents 
enzyme activity. Enzymes that are normally affected are those 
involved in DNA replication and mitochondrial respiration 
(complex 1 and 11, aconitase and ribonucleotide reductase) 
[83]. Depending upon the activity of the affected enzyme, 
either the bacterial/tumor cell growth will be slowed or the 
cell will die (figure 27) [51]. 
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At the site of infection available arginine is quickly 
converted to NO"and citrulline as a consequence of macrophage 
stimulation. However, further arginine that enters the site 
is then kept limiting by the action of arginase so as to 
prevent the prolonged synthesis of No: This control mechanism 
is necessary as large amounts of NO' damage cells in a 
non-specific manner, preventing the healing process. In this 
respect No'production has also been linked to the inhibition 
of platelet aggregation [63,71,75,84]. The control of the NO' 
pathway thus hinges around the control of available arginine, 
requiring a delicate balance between the ARG -> ORN and 
ARG -> No' reactions of arginine metabolism. It has been 
estimated that in activated macrophages, 70% of Larginine is 
metabolised by arginase and the remaining 30% by the NO.route 
[ 7] • 
In addition to the above cytotoxic effects, NO' reacts with 
superoxide to form peroxynitrite, which once protonated forms 
nitrogen dioxide and the hydroxyl radical. These radicals are 
extremely cytotoxic and may also be involved in combatting 
invading organisms [64]. 
2.1.0: REGULATION OF NOS. 
The cytotoxic effects of macrophages have been shown to be 
highly L-arginine dependant, requiring an extracellular 
concentration of greater than 0.25mM arginine for maximal 
activity (Km = 37flM) [7]. Bogle et al [7] demonstrated that 
an increase in the transport of L-arginine into the 
macrophage occured upon macrophage activation and that 
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arginine availability was rate-limiting in the production of 
No·. This arginine dependance has also been shown in smooth 
muscle cells' iNOS [76]. These results suggest a regulatory 
step, independant of direct NOS regulation and that selective 
inhibition of cellular arginine uptake may be a mechanism of 
reducing macrophage cytotoxicity. L-lysine and L-ornithine 
have been shown to directly inhibit NOS activity at 
concentrations higher than 5mM [7]. 
Castillo et al [56] recently showed that there exists 
significant compartmentalisation of arginine metabolism 
within the whole body. There was shown to be a definite 
barrier between the hepatocytes and the plasma, as well as 
compartmentalisation within the liver itself (associated with 
urea cycle enzyme distribution). The functional importance of 
this compartmented metabolism of arginine has not been 
elucidated, but it may play a role in the activity and 
regulation of the No"-pathway. This also has relevance to NOS 
inhibitors as the compartmentalisation may effect their 
efficiencies. 
Helper-T-lymphocytes TH1 and TH2 produce different 
.lymphokines that often act antagonistically. TH1 produces 
IFN-¥ and IL-2, while TH2 synthesises IL10, IL-4 and IL-5. 
IFN-lr inhibits proliferation of TH2 cells, while IL-4 and 
IL-10 inhibit IFN-t secretion. It has also been shown that 
IL-4 and IL-10 affect the cytotoxic effects of macrophages, 
by preventing the induction of NO. production by IFN-K , when 
cells are pretreated with these lymphokines [85]. 
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What makes the situation of NOS regulation more complex is 
that one cell type may contain both types of NOS (iNOS and 
eNOS), producing No· for very different functions 
. 
l.e: 
endothelial cells [60,78] and macrophages [86]. This 
presumably requires complex regulatory mechanisms. 
N-nitro-L-arginine, N-amino-L-arginine and N-methyl-
L-arginine have been shown to reversibly inhibit NOS [68]. 
However, eNOS is most effectively inhibited by 
N-nitro-arginine, while iNOS is preferentially inhibited by 
the methyl and amino derivatives [66,87]. Using these various 
inhibitors one would be able to selectively affect one 
isoform without seriously affecting the production of NO"by 
,the other isoenzyme. 
2.1.E: OTHER NOS ISOFORMS. 
The classification of two isoforms of NOS made it easier to 
understand the complex roles of NO~as a neurotransmitter and 
an immune defense mechanism. These enzymes are sufficiently 
different to explain how they can be regulated independantly, 
especially with regards to ca2•dependancy. However, as NOS is 
being isolated from other sources, it appears that the 
situation is more complex. Evans et al [88] purified a 
cytokine-inducible form of NOS from rat liver (predominantly 
in hepatocytes) and showed that although it is not dependant 
upon ca2+ , it is stimulated in the presence of calmodulin, 
which is very unusual [88]. The NO.produced by this enzyme 
seems to be involved in the suppression of protein synthesis 
and protection of the liver against damage [88,89]. 
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Although the eNOS enzyme found in endothelial cells operates 
in the same way as the neuronal eNOS, it has been shown that 
these two enzymes are distinct isoenzymes [88], being 
generated from different genes. Neuronal eNOS (nNOS) is 
totally cytoplasmic, while endothelial eNOS (eNOS) is often 
associated with membranes and has slightly smaller subunits 
[59,86]. It has now been found that iNOS, nNOS and eNOS are 
derived from independant genes that form part of a gene 
family [86]. 
2.1.F: NITRIC OXIDE AND DISEASE. 
It has already been mentioned that the production of nitric 
oxide has to be tightly controlled as large amounts produce 
detrimental effects. In fact several neuronal diseases have 
been attributed to defects in the NO" pathway i.e : 
Huntington's and Alzheimers diseases [63]. 
One way that neuronal damage is caused is by the prolonged 
activation of NMDA receptors, which causes an excessive 
influx of calcium resulting in the production of large 
• amounts of NO. The action of NO" in turn results in a 
continual high level of cGMP, which appears to 
eventually result in neuronal damage. Strangely enough it 
has been shown that the neurons that contain the NOS are 
protected while the adjacent neurons are damaged [63]. 
Due to this new understanding of the role of nitric oxide in 
neuron activity drugs that inhibit the No· pathway 
such as N-monomethyl-L-arginine (L-NMMA) are now being 
used to treat strokes [63]. 
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It has been proposed that No"may also be involved in cerebral 
injury when ischemic or ,hypoxic brain tissue is reperfused 
with oxygen, see figure 28. Ischemia depolarises the neuronal 
membranes causing the release of glutamate from synaptic 
vesicles. This release activates the influx of calcium into 
the cells, which in turn activates an oxygen-dependant NOS. 
This enzyme synthesizes No· from arginine when oxygen is 
readmitted to the brain during reperfusion. Ischemia also 
causes the induction of superoxide production by xanthine 
oxidase. Superoxide then reacts with No· to form the 
peroxynitrite anion (ONoo·). ONoo· is fairly stable, enabling 
it to diffuse over several cell diameters, however once 
protonated it decomposes to form two very destructive 
cytotoxic oxidants: nitrogen dioxide and the hydroxyl 
radical, which result in cerebral damage [60,64]. The 
formation of these radicals is shown below: 
NO 
. 
02 oNoo· + ----> 
ONoo· + H+ ----> ONOOH 
ONOOH -----> N02 +·oH 
N02 -t•oH ----> No-3 + H+ 
However, peroxynitrite can also cause damage by reacting with 
sulfhydryl groups [90] and metal ions to form a potent 
nitrating agent [64]. From the evidence of the reaction of 
superoxide with No· it is possible that these two molecules 







FIGURE 28: Superoxide-mediated cerebral injury after 
reperfusion [64]. 
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Ischemia allows calcium to enter into the endothelial cells, 
which stimulates eNOS to produce NO at maximal rates when the 
tissue is reperfused with oxygen. However, when the tissue is 
reoxygenated superoxide (02-) may also be produced by 
mitochondria, neutrophils and xanthine oxidase (XO). 
Superoxide and NO"react to form peryoxnitrite anion (ONOOH) 
that decomposes to form deadly hydroxyl radicals ( "OH) once 
protonated. 
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Interestingly, it has been suggested that NO"may be produced 
to protect cells from superoxide mediated damage. Rubanyi et 
al [67] found that NO' decreased the reduction of cytochrome 
C by the superoxide produced in leukocytes. This reduction 
was found to be from the direct reaction between No"and Oi . 
Perhaps under conditions where large amounts of superoxide 
are produced, NO" is synthesised to act as an oxygen 
free-radical scavenger. This aspect obviously needs more 
research to establish if NO' is friend or foe! 
In type 1 diabetes, it was generally assumed that the 
cytokines IL-l and TNF were directly responsible for the 
destruction of islet cells. However, Kroncke et al [91] have 
since shown that NO"produced by cytokineactivated macrophages 
and endothelial cells, is in fact responsible. This evidence 
supports the idea that NO'may injure normal cells and 
contribute to inflammatory tissue destruction. 
Septic shock results in many hospital deaths It is 
associated with the over-production of No: by the inducible 
NOS [58,60] in cells including endothelial cells and smooth 
muscle cells [76]. A substantial fall in blood pressure 
occurs when large amounts of No' are produced in response to a 
severe bacterial infection. It has been demonstrated that 
administration of nitric oxide synthase inhibitors can 
normalise the blood pressure. Interleukin-2 treatment is 
often used to treat some forms of cancer, however it 
stimulates the production of NO~ which can result in life 
threatening low blood pressure. To avoid this side-affect 
IL-2 is given in conjunction with No' inhibitors, allowing 
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IL-2 to act on the cancer cells, without the hypotensive 
side-effects [53]. 
It is accepted that nitrite, under acidic conditions, can 
deaminate purines, pyrimidines and various forms of RNA and 
DNA. These reactions occur through the protonation of N02to 
form N2 ~, an electrophilic nitrosating agent [92]. Nguyen et 
al [92] demonstrated that NO.in combination with Oi can 
mimick the effects of No2- and damage and mutate mammalian 
DNA. No·was found to induce DNA strand breaks and cause the 
deamination of guanine. This would result in a high 
percentage of G.C-->A.T transitions in cells exposed to high 
concentrations of No: With relation to cancer formation two 
types of mutations in the P53 gene have been associated with 
cancer. These are 1) transitions at CpG dinucleotides in 
colon cancer and 2) G.C-->T.A transversions in liver and lung 
cancer. These mutations can be explained in terms of exposure 
to NO.as a result of the inflammatory response, or bacterial 
infection. 
2.1.G: REACTIONS OF NITRIC OXIDE. 
At this point the cytotoxic and neurological effects of 
nitric oxide have been attributed to No· itself, however due 
to its reactivity it has been proposed that other NO"reaction 
products may be the biologically active molecules [62]. A 
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FIGURE 29: Summary of the chemistry of the interrelated forms 
of NO'of potential biological significance [62]. 
A) Redox-interrelated forms of NO~ The primary reactions of 
NO' involve oxygen, superoxide and redox metals (M). No-
reacts with metals and sulphydryls (SH) . Nitrosation 
reactions involve electrophilic aromatic substitutions (Ar) 
and addition to bases (B). B) Summary of NO"biochemistry. The 
reaction products of No· that allow NO' to fulfill it's 
functions as a neurotransmitter and a host immune defence 
mechanism. 
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The redox state of No'seems to influence its affinity for 
different target functional groups i.e: No'reacts at the heme 
site of hemoglobin, while NO+ reacts with intramolecular 
amine and sulfhydryl centres and No· at sulphydryl centres. 
At this stage it is not exactly clear if No: NO+ or NO- is 
involved in the activation of guanylate cyclase, or what 
functional group is attacked [62]. 
Although most research has been performed on mammalian 
models, it is possible that NO' fq.nctions in other systems as 
well. The elusive endothelium relaxing factor (EDRF) has been 
demonstrated in reptiles and the key enzyme in the reactivity 
of No: guanylate cyclase, has also been found in squid giant 
axons. It is possible that the NO" pathway has an early 
evolutionary origin [51]. 
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2.2 INTRODUCTION: NITRIC OXIDE PRODUCTION, A NOVEL APPROACH 
TO STUDY NITRIC OXIDE PRODUCTION IN 
FIBROBLASTS. 
NO.is fast becoming an integral part of cellular biology and 
the understanding of its effects essential to the elucidation 
of the mechanisms underlying many diseases. The NO.story is 
not an easy one to understand, with many isoforms of NOS that 
are widely distributed among different cell types and No· 
itself demonstrating a varity of biological roles. 
Many studies on NO"production have been performed using cell 
free extracts of NOS [54,57,73,88], measuring No·production 
under in vitro conditions. More recently whole cell assay 
systems have been utilised [7,78,85], including studies on 
macrophages and a variety of human tumor cell lines. In both 
these systems NOS enzyme activity has been measured in a 
number of ways. NOS activity can be measured indirectly, by 
measuring the formation of nitrates and nitrites from No• 
[7,78,85] or somewhat more directly by measuring the 
formation of citrulline from arginine (since citrulline and 
No·are produced in equimolar quantities [63]) under various 
conditions [54,59,73,88]. The problem with whole cell assay 
systems, when analysisng No·production by the formation of 
citrulline, is that cells that contain ASS are capable of 
metabolising the citrulline, making quantitation difficult. 
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The citrullinemic 'cell-line F25 has an almost complete loss 
of ASS activity (1-5% of controls) making it a good model for 
studying the production of No· in fibroblasts. Fibroblasts 
contain several enzymes of the urea cycle: arginase, ASS, ASL 
and carbamyl phosphate synthetase [1,6]. However, ornithine 
tanscarbamylase activity 
fibroblasts, which implies 
has not been reported 
are unable 
in 
to that fibroblasts 
produce citrulline from arginine or ornithine. Inducible NOS 
activity can then be detected in fibroblasts by the formation 
of citrulline from arginine after the required cytokine 
induction. In citrullinemic fibroblasts (F25) the lack of ASS 
activity will allow this citrulline to accumulate, making it 
easy to detect. 
So far, NO" production has not been directly demonstrated in 
human fibroblasts although some evidence suggests bhat No· 
synthesis is possible. Firstly, WernerFelmayer et al [77] 
reported that BH4 synthesis in murine fibroblasts after 
treatment with cytokines is directly linked to the 
production of No· Secondly BH4, which is a cofactor of iNOS, 
has also been shown to be synthesized in response 
to interferon stimulation in human fibroblasts [82]. No 
clear function had previously 
synthesis in 
that it is 
cytokine-induced BH4 
it is possible 
co-factor for the production of 
been found for 
mammalian cells and 
mainly produced as a 
NO" [ 77]. Finally 
fibroblasts show similarites to macrophages in their ability 
to increase both IDO and BH4 synthesis in the presence of a 
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combination of cytokines (~-interferon, LPS and TNF) and it 
has been proposed that fibroblasts may in fact participate in 
the general immune response [82]. 
Fibroblasts are readily accessible for diagnostic purposes 
and the demonstration of N~production in these cells may 
allow for the development of assay systems for NO.production 
defects. 
The purpose of this study was to use the F25 model to 
investigate the production of NO*by iNOS in fibroblasts, in 
response to cytokine 











efficient method of separation of citrulline, arginine, 
ornithine and urea, all of which may be formed in fibroblasts 
from the metabolism of arginine. Section 2A deals with the 
development of the ,various separation techniques, while 
section 2B investigates the preliminary tests required to 
develop the nitric oxide detection assay in fibroblasts. 
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SECTION 2A: EVALUATION OF AMINO ACID SEPARATION TECHNIQUES. 
2.3: INTRODUCTION. 
To investigate the NO pathway in fibroblasts, it was 
necessary to study the utilisation of arginine by these 
cells. The assay for NO' detection involved the incubation of 
fibroblasts with radioactively labelled arginine ( 3H, 14c), 
preparation of cellular supernatants after the incubation 
period and then the analysis of the radiolabelled amino acid 
products of metabolism. 
There are several techniques that can be used to separate and 
quantify the amino acid products: HPLC, thin-layer 
chromatography and ion-exchange chromatography. These methods 
separate amino acids according to size and differences in the 
properties of their side chains. The most sensitive 




was not initially available 
thin-layer chromatography and 
was investigated. Upon the 
and so the 
ion-exchange 
aquisition of 
appropriate HPLC columns, the optimal separation of 
radioactive amino acid metabolites on these columns was also. 
investigated. 
2. 4: MATERIALS AND METHODS. 
2.4.A: ION-EXCHANGE CHROMATOGRAPHY. 
Ion-exchange chromatography is performed using resins such as 
Dowex-50 and separates amino acids under the influence of 
gravity rather than high pressure. Cation-exchange resins 
(Dowex-50) used in ion-exchange chromatography separate amino 
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acids according to their net charge differences at a specific 
pH. Cation-exchange resins possess negatively charged groups 
that bind the postively charged groups of the amino acids. 
The strength with which the amino acids bind to the resin 
depends upon the pKa value and the number of charged amino 
groups [93]. 
Amino acid mixtures are made acidic, so that the amino acids 
are optimally positively charged, loaded on to the column and 
then eluted with a basic solution. The acidic amino acids are 
eluted first followed by neutral and then basic amino acids. 
The procedure that was used in this study was a modification 
from the separation technique used by Windmueller and Spaeth 
[2]. 1, 2 or 2.5mls of prepared Dowex-50 (Biorad) analytical 
grade cation-exchange resin (washed several times with 
distilled water) was loaded into a column of either 0.7cm or 
0.5cm in diameter. 
Amino acid mixtures were prepared as follows: 
1ml Basal Medium Eagles (BME) containing: 
~Ci 3H-arginine (Amersham, 19Cijmmol) andjor 
1pCi 14c-citrulline (Amersham, 58mCijmmol) 
lpCi 14c-ornithine (Amersham, 208mCijmmol) 
0.5ml of the solution was adjusted to pH2 with O.lM HCl. 
The prepared amino acid solutions were loaded onto the 
Dowex-50 columns and eluted with ammonia solution (25%) 
(BDH). Fractions were collected in lml aliquots. The relative 
positions of the eluted amino acids were determined by 
measuring the radioactivity in each fraction. 100pl of each 
fraction was first neutralised with glacial acetic acid, to 
prevent the chemoluminescence that occurs 
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in alkaline 
solutions, then added to 6ml scintillation fluid (Packard 
Hionic-Fluor) and the radioactivity quantified in a 
scintillation spectrometer (Beckman LS 3801). The cpm values 
were converted to dpm by adjusting the values for background 
counts and the counting efficiency of the scintillation 
counter ( 3H in 3H window = 42%, 14c in 14c window = 72%, 14c 
in 3H window= 18%). 
2.4.8: THIN-LAYER CHROMATOGRAPHY: SILICA PLATES. 
Thin-layer chromatography is a technique that separates amino 
acids according to their mobilities in organic solvents. It 
relies on the separation of amino acids between two phases: 
stationary phase (thin layer of water on a solid support i.e: 
silica or cellulose) and a mobile organic phase. The amino 
acids are placed at the bottom of the plate and as the 
organic solvent moves across the plate, so the amino acids 
are separated by partition between aqueous and organic 
phases. Hydrophilic amino acids remain in the stationary 
aqueous phase, whereas more hydrophobic amino acids partition 
preferentially in the organic solution and move rapidly up 
the plate with the solvent front. In this way amino acids are 
separated according to the hydrophobic nature of their side 
chains [93]. 
The amino acids of interest in this study: citrulline, 
arginine and ornithine have basic side chains which, 
according to Pataki [94], are best separated using 
two-dimensional chromatography. This involves the separation 
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of an amino acid mixture in one dimension with one type of 
organic solvent (propanol), followed by the rotation of the 
plates and separation of similar amino acids using another 
solvent (phenol); see figure 30. In this way amino acids with 
similar properties are more successfully separated. 
a b 
A+B A 8 
1 







FIGURE 30: Two-dimensional thin-layer chromatography. 
Samples are placed at the bottom of the silica plate and 
separated in the first dimension with the movement of the 
first solution. The plates are air dried and placed in the 
second solvent after being rotated 90°. Amino acids with 
similar partition coefficients in solvent 1 may then be 
separated as the second solvent front progresses. AP = 
application point, A and B = amino acids. 
Standard amino acid solutions : ornithine, arginine ' 
citrulline and argininosuccinate (2.5mM in O.lM HCl) were 
neutralised before use with an equal volume of O.lM NaOH and 
then 5-lOpl of the samples were applied to the corner of a 
10 x lOcm silica plate (Merck 60F254). The amino acids were 
separated in the first dimension with propanol:water = 7:3 
(vjv) and in the second dimension with phenol:water = 75:25 
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(wjv). The plates were air-dried between solvent changes and 
developed with ninhydrin (0.2g 1 100ml). The separation of 
radioactive standards (14c) was visualised by autoradiography 
of the silica plates using hyper-film-Mp (Amersham). 
Radioactivity yields of individual amino acids were 
determined by the removal of the ninhydrin stained spot of 
interest from the silica plate and dissolving it in 6ml 
scintillation fluid (Packard Hionic-Fluor). The radioactivity 
content of the spot was then determined as in section 2.4.A, 
taking into account the quenching effects of ninhydrin and 
silica. 
2. 4. C: HIGH PERFORMANCE LIQUID CHRO~TOGRAPHY ( HPLC) • 
With HPLC, samples are driven through an ion-exchange column 
under intense hydrostatic pressure of 5000-10000 pounds per ' 
square inch. Under these conditions amino acids are separated 
with high resolution. The high pressure contributes to short 
extension times and hence little diffusion. HPLC methods are 
reproducible and easily automated [93]. 
The two columns that were used in this study were a 
C18-reverse-phase column and a cation-exchange column. The 
cation-exchange system operates by separating amino acids 
according to charge differences • Reverse-phase columns 
operate slightly differently. The column packing material is 
coated with hydrophobic hydrocarbon chains (C18), a solution 
of octane-sulphonate is then run through· the column. The 
octane interacts with the C18 via hydrophobic interactions, 
while the sulphonate interacts with the charged amino acid 
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side chains. 
C.i: Reverse-phase: octane-sulphonate 1 acetonitrile. 
The method that was used for the separation of urea cycle 
amino acids was a modification of the method used by 
Blachier et al (95]. A mixture of two buffers was used to 
separate citrulline arginine , ornithine , urea and 
argininosuccinate (96]: 
Buffer A: 0.1M Na Acetate, 10mM octane sulphonate (pH 5.5). 
Buffer B: 0.2M Na Acetate (pH 4.5): Acetonitrile 10:3, 10mM 
octane sulphonate (Sigma). 
The following program was implemented: 
Flow rate: 1mllmin 
Time(min): 0 100% A 0% B 
30 60% A 40% B 
42 0% A 100% B 
47 100% A 0% B 
53 END 
Samples were adjusted to pH7 and 100ul volumes loaded onto 
the column. The HPLC program was run on a Beckman 126 System 
Gold HPLC system, using a Beckman C18-ultrasphere cotumn 
(5u, 4.6mm x 25cm). 
c.ii: Cation exchange: Li-A 1 Li-R system. 
An abbreviated version of the separation program used on the 
amino acid analyser (Beckman 6300) was used in some cases to 
definitively separate citrulline and urea The 
cation-exchange column (Beckman system 7300 I 6300, P I N 
338050) was maintained at 67~C and equilibrated with Li-A 
(1% lithium citrate, 0.5% lithium chloride, 0.5% hydrogen 
chloride, 98% water) for 8-10 minutes prior to the loading 
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of samples (lOOpl). The samples were diluted and acidified in 
Li-s dilution buffer (1% lithium citrate, 1% thiodiglycol, 
0.7% HCl, 0.5% benzoic acid, 96.8% water) to pH 2.2 before 
loading. The sample components were separated by an isocratic 
gradient of 100% Li-A for 35 minutes at a flow rate of 
0.3mllminute, and the column rejuvenated by two minutes of 
Li-R (1% LiOH, 99% water). 
In both HPLC separation systems, individual radioactive amino 
acid peaks were located on a radio-chromatography detector 
(Flo-oneiBeta, series A-100), attached in series to the HPLC. 
FloScint IV (Packard Radiomatic) scintillation fluid was used 
in a ratio of 4:1 in this procedure. 
c.iii: Quench curves. 
The quenching effects of the solutions used in the two HPLC 
systems were evaluated to ensure that the radiochemical 
detector was sensitive enough and to enable cpm -> dpm 
conversions where necessary. 
In the case of the cation-exchange column (Li-A), the system 
operates as an isocratic gradient system and thus a static 
quenching effect could be measured [97]. The radiochemical 
detector cell was filled with scintillation fluid and Li-A 
in a 4:1 ratio. The flow was stopped and the background 
counts determined The cell was then filled with 
scintillation 1 Li-A fluid, to which 10000 dpmlml of 14t label 
had been added, after which the flow was again halted 
and the counts 1 minute determined over several minutes. The 
efficiency of the radiochemical detector was determined as 
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follows: 
average 14c countsjminute 
E = ------------------------- X 100 
dpmjcell (= 2.5x10000) 
For the reverse-phase system (octane-sulphonate), a gradient 
of buffer A and B was used to separate the amino acids, 
therefore a quench curve needed to be established to 
evaluate the effects of the concentration gradient on the 
efficiency of the radiochemical detector [97]. 8000dpmjml 
14c was added to the scintillation fluid. The HPLC system 
was then run in conjunction with the "spiked" scintillation 
fluid and the cpm at each time point determined .· The 
radiochemical detector "efficiency curve" program calculated 
the dpm at each time point, taking into account the HPLC 
flow rate, cell size, scintillation flow rate and dpmjml 
scintillation fluid. The efficiency at each time point was 
then calculated as follows: 
cpm 




2.5.A: ION-EXCHANGE CHROMATOGRAPHY. 
Citrulline and arginine were used for the initial 
studies of this separation technique, as they optimisation 
represent the greatest charge variation between the amino 
acids of interest. 
The best separation result using this method was obtained 
using a 2ml (7mm diameter) Dowex-50 cation-exchange column. 
The results are shown in figure 31A. Arginine and citrulline 
were separated sufficiently, however the other amino acids 
(i.e ornithine) were found to elute together with these 
peaks, making it difficult to successfully analyse separate 
amino acids. 
Several attempts were made to improve 
diameter 
the quality of 
separation. The effects of 
column (1 - 2.5ml, 5 - 7mm 
of the grade quality of 
the and height of the 
diameter), as well as the effects 
the eluting ammonium hydroxide 
solution were investigated. These effects were monitored by 
investigating the elution of citrulline and the results of 
changing these parameters are shown in figure 31B. Firstly, 
these results show the variation in the elution position of 
citrulline when the column parameters were altered. Secondly, 
it was found that a high quality grade ammonium hydroxide 
solution was necessary for high recovery yields and sharp 
amino acid peaks. Taking these results into account, a 2ml 
(7mm) column was found to be the most effective, resulting irt 
a sharp citrulline peak with recovery yields of 97%. 
ION-EXCHANGE CHROMOTOGRAPHY 
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FIGURE 31: Ion-exchange chromatography, separation of amino 
acid standards. 
A) Arginine (3H) and citrulline (14c) were separated on a 2ml 
(5mM diameter) Dowex-50 column. The sample mix was loaded on 
top of the column and 1ml fractions eluted with 25% ammonia 
solution. 100pl of each fraction was counted to locate the 
relative positions of the amino acids. The elution position 
of 14c-ornithine is also shown. B) The effects of column 
volume and diameter on the elution position of14c-citrulline 
were evaluated. 
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·. 2. 5.B: THIN-LAYER CHROMATOGRAPHY. 
The separation of arginine, citrulline and ornithine on 
silica thin-layer chromatography plates is shown in figure 32 
and demonstrates the efficient separation of these amino 
acids using this two-dimensional system. Argininosuccinate 
was found to migrate as two separate species on either side 
of arginine, figure 32 shows the approximate positions. 
Regarding the recovery yields from the silica plates, it was 
found that silica in combination with ninhydrin exerts a 
quenching effect on the radioactive emission of the isotopes. 
It was found 
the presence 
effect into 
that counting efficiency was reduced 
of these components. Taking this 
account, as well as the efficiency 
by 34% in 
quenching 
of the 
scintillation counter, the yield of 14c-citrulline from the 
silica spot was found to be 75% ( 3H yield= 78%). Losses 
were due to loss of silica particles in the removal of the 
ninhydrin stained amino acid spots, residual radioactivity 
remaining at the point of application and possible 
contaminants or degradation products in the isotope stock 
solutions, that elute differently during two-dimensional 
chromatography. 
Although this method gave good separation of the amino acids, 
it was time-consuming and sample volumes had to be reduced to 
5-lOpl to allow for effective separation. Inaccuracies arise 











FIGURE 32: Thin-layer chromatography, separation of amino 
acid standards. 
Arginine (A), citrulline (C) , ornithine (0), leucine (L) and 
argininosuccinate (-----) were separated on silica 
chromatography plates using two-dimensional chromatography. 
Amino acid mixtures were separated in the first dimension 
with propanol:water (7:3 vjv) and phenol:water (75:25 wjv) in 
the second dimension. Plates were air-dried and stained with 
ninhydrin. AP = application point. 
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2.5.C: HPLC. 
c.i: Reverse-phase octane-sulphonate. 
This method [95] was previously used for the analysis of urea 
cycle intermediates by Blachier et al and was therefore 
chosen as a suitable method in this study. Radioactive 
labelled citrulline,ornithine and arginine were found to be 
efficiently separated using the recommended conditions [95]: 
Buffer A = pH 4.5, Buffer B = 4.5, which is illustrated in 
figure 33. However, when argininosuccinate and urea were 
analysed, these conditions were found to be inadequate in the 
separation of these components from the afore mentioned amino 
acids. 
In solution argininosuccinate can exist in three forms A, B 
and c. A is the non-cyclic form, while B and C are cyclic 
anhydrides that are formed at high temperatures and under 
acidic conditions [98]. By varying temerature and pH, it is 
possible to change one form of argininosuccina~e into 
·another, although no method is 100% effective and two forms 
will always be present. Under alkaline conditions A and B 
forms are favoured [98]. Labelled argininosuccinate was not 
available for use, so its elution position was detected by 
separation of unlabelled argininosuccinate (15mM) from 
L-citrulline (15rnM), with fractions collected at 30 second 
intervals and the positions of the two components visualised 
by reaction with an equal volume of ninhydrin (0.2gjml). 
Figure 34B shows the poor separation achieved under the 
recommended conditions (buffer A= pH 4.5). Figure 34A, C and 
D show the results of changing the pH of buffer A in an 
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attempt to improve the separation. These results show that 
under more alkaline conditions (>pH 6), two forms of 
argininosuccinate are separated. These probably represent the 
A and B forms, with the A eluting first. Separation of the 
various forms of argininosuccinate was not favourable as the 
B form co-elutes with citrulline, so a pH of 5.5 for buffer A 
was chosen as the most effective system for separating 
argininosuccinate and citrulline. 
The pH change of buffer A from 4.5-5.5 had no effect on the 
relative positions of citrulline, arginine and ornithine, 
although the retention times altered slightly: citrulline = 
3.4 minutes, ornithine = 5.8-6.2 minutes and arginine = 26.5 
minutes. Figure 35 shows a typical profile of these 
standards. Using this method the cpm in each major amino acid 
peak represented 90-97% of the radioactivity loaded on the 
column. 
One criticism of the method of Blachier et al [95] was that 
they were unable to separate urea from citrulline, which is a 
major metabolite of arginine metabolism. To investigate this 
separation, unlabelled urea (7mM) was eluted on the 
reverse-phase system (buffer A = pH 5.5) and its position 





7 ( 30 
in 
second fraction 
fraction 8 and 
argininosuccinate in fraction 6. Upon the acquisition of 
14c-urea, the retention time of urea was found to be 2.8-3 
minutes (citrulline= 3.4 minutes). 
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FIGURE 33: Reverse-phase/octane-sulphonate HPLC ,(buffer A = 
pH 4. 5) , separ,ation __ Qf_amino acid ·standards. 
Citrulline (We), ornithine {~C) and arginine (3a) (pH 7) were 
separated on a Cl8-reverse-phase exchange column using a 
gradient system of Buffer A {0.1M Na acetate, lOmM 
octane-sulphonate, pH 4.5) and Buffer B {0.2M Na acetate: 
acetonitrile {10:3), 10mM octanA-sulphonate) with an HPLC 
flow rate of lmljminute (see section 2.4.C.i for details of 
the gradient program). Amino acids were detected using a 
Flo-one-/Beta radiochromatography detector connected in 
series to the HPLC. c =citrulline {3 minutes), o =ornithine 
{3.5 minutes) and A= arginine (12 minutes). 
THE EFFECTS OF pH ON THE ELUTION 
OF CITRULLINE AND ARGININOSUCCINATE 
A: pH4 8: pH 4.5 
1 • 3 1 2 3 
--A$ -')lf:-ciT 
C: pH 5.5 D: pH 6 
1 • 3 1 2 3 
--AS9 "*CIT -ASs ~err 
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FIGURE 34: The effects of pH on the elution of citrulline and 
argininosuccinate. 
Citrulline (CIT) and argininosuccinate (ASS) (pH 7) were 
separated on a C18-reverse-phase column (octane-sulphonate) 
using Buffer A of varying pH values (pH 4- pH 6). HPLC 
fractions were collected at 30 second intervals and the 
positions of the amino acids detected by the addition of 
ninhydrin to the fractions. When buffer A is pH 6 two forms 
of argininosuccinate are separated (A and B forms). 
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FIGURE 35: Reverse-phase/octane-sulphonate HPLC (buffer A = 
pH 5.5) standards profile. 
A mixture of arginine, ornithine and citrulline ( 14c) (pH 7) 
was separated on a C18-reverse-phase column using a gradient 
' 
of Buffer A (0.1M Na acetate, 10mM octane-sulphonate pH 5.5) 
and Buffer B (0.2M Na acetate: acetonitrile (10:3), 10mM 
octane-sulphonate). Radioactive metabolites were detected 
using a Flo-one-/Beta radiochromatography detector. The 
relative positions of argininosuccinate (AS) and urea are 
also indicated. A= arginine {26.5 min), C =citrulline (3.4 
min), 0 =ornithine (6 min), U =urea (3 min). 
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In order to utilise the HPLC information correctly, the 
quenching effects of 
investigated. It was 
the octane-sulphonate system were 
found that the efficiency of counting 
was constant throughout the run , regardless of the 
concentration gradient : 14c in the 20-160 14c window on the 
radiochemical detector [97] = 24%, while in the open window 
0-2048 efficiency of counting = 65%. 
C.ii: Cation-exchange column. 
Several problems were encountered with the separation of 
urea and citrulline from cell-supernatant fractions, with 
urea sometimes co-eluting with citrulline when using the 
reverse-phase HPLC system. In order to completely resolve 
these components and correctly identify citrulline peaks, a 
cation-exchange HPLC system was used in conjunction with the 
octane-sulphonate system. The cation-exchange system that 
was adopted was that used by the Beckman 6300 amino acid 
analyser . Several hours and a variety of buffers are 
required to separate the entire range of amino acids, so the 
method was shortened to allow for the definitive separation 
of urea and citrulline. The program was shortened to 35 
minutes of Li-A, with Li-R removing the other amino acids 
from the column. Maintaining the cation-exchange column at 
67oc was found to be necessary to achieve maximal urea I 
citrulline separation. Figure 36 shows the well-defined 
separation of these metabolites, with the retention time of 
urea at 6.9 minutes and citrulline at 29.6 minutes. Each peak 
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·FIGURE 36: Cation-exchange separation of citrulline and urea. 
A cation exchange column system (Li-A/Li-R) was used to 
separate citrulline from urea. The column was maintained at 
67°C throughout the 35 minute run (HPLC flow= 0.3ml/minute). 
Radioactively labelled metabolites (pH 2.2) were detected by 
the Flo-one-/Beta radiochromatography detector connected in 
series to the HPLC. 14c-ci trulline = 29.6 minutes, 14c-urea = 
6.9 minutes. 
The static quenching effects of 
calculating the efficiency of 
conditions. In the open window 
efficiency was 66%. 
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Li-A were determined by 
counting under the HPLC 
0-2048 [97] 1~ counting 
The HPLC methods allow for accurate quantitative and 
qualitative analysis, with minimal hands-on manipulations 
allowing less room for experimental error. 
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2.6: DISCUSSION. 
In order to study the NO" pathway in fibroblasts, an 
efficient separation system was needed to separate arginine, 
citrulline, ornithine, urea and argininosuccinate. Several 
methods are available to separate amino acids and three of 
these were analysed for their suitability to the separation 
of the components mentioned above. Thin-layer chromatography 
(silica plates), ion-exchange chromatography (Dowex-50) and 
two HPLC systems ( reverse-phase octane-sulphonate and cation 
exchange) were optimised for the separation of the urea cycle 
metabolites. 
The ion-exchange chromatography system separated arginine 
from citrulline, but the other amino acids were found to 
elute in overlapping positions making the analysis of 
separate amino acids difficult (figure 33A). The yields were 
high (97%) and the method quick and easily scaled up to allow 
for the analysis of many samples. However, the separation was 
not sufficient for the required purpose. 
Thin-layer chromatography using silica plates provided 
well-defined separation of citrulline, ornithine and arginine 
(figure 32), although argininosuccinate migrated in two 
positions. The yields were relatively low at 74%, which may 
hinder the detection of small amounts of labelled 
metabolites. This method is also time consuming and requires 
the sample volume to be reduced to 5-lOpl, which introduces a 
margin of error and adds to the low reproducibility of this 
method. 
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The most effective method with respect to separqtion 
efficiency, reproducibility and yield , was HPLC. Both 
systems gave clear, sharp standard peaks, with yields in the 
90-97% range. Volumes of up to lOOpl could be analysed, 
allowing for less loss during manipulations. HPLC also 
requires less hands-on time which ensures greater 
reproducibility and accuracy. The disadvantage of both the 
methods used here, is that the programs are fairly long, 
requiring 37-53 minutes per sample run. The reverse-phase 
aolumn gave clear separation of arginine , ornithine , 
citrulline and argininosuccinate {figure 35), while the 
cation-exchange system clearly separated urea from citrulline 
{figure 36). Although under preliminary test conditions the 
octane-sulphonate system sucessfully separated citrulline and 
urea, during cellular assay conditions it was found that the 
two HPLC systems needed to be used in conjunction with each 
other to definitively identify citrulline peaks. 
From these results the HPLC methods were found to be more 
quantitative and reproducible than the other separation 
techniques, and were thus employed to investigate the nitric 
oxide pathway in fibroblasts. However, while awaiting the 
HPLC components, the thin-layer chromotography {silica 
plates) method was used for preliminary studies. 
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SECTION 2B: NITRIC OXIDE PRODUCTION IN FIBROBLASTS -
PRELIMINARY TESTS AND THE NITRIC OXIDE ASSAY. 
2.7: INTRODUCTION. 
carbamyl phosphate 
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FIGURE 37: The Urea cycle and the Nitric Oxide pathway. 
NO' is produced when arginine is metabolised by NOS, to 
produce equimolar quantities of citrulline and NO' [63]. One 
assay system that is often used to detect iNOS activity is 
the ability of cells to form 14c-citrulline from 14c-arginine 
when stimulated by cytokines [54,59,60]. This method reiies 
on the assumption that citrulline is not formed in these 
cells by any other pathway in the cell and that it is not 
readily metabolised. 
The availability of F25, which is an ASS deficient fibroblast 
cell line, provided an interesting model to investigate No' 
synthesis in fibroblasts. Citrulline is not readily 
metabolised by these cells (< 5% residual ASS activity) and 
should therefore accumulate in cytokine activated cells, if 
iNOS is operative in fibroblasts. 
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In designing the nitric oxide assay, it was important to be 
aware of the possibility of citrulline production via the 
ornithine transcarbamylase pathway (OTC). Arginase, ASS and 
ASL activities have been reported in fibroblasts [1,6], 
therefore the substrate for the OTC reaction, ornithine, will 
be formed by arginine metabolism in fibroblasts. Several 
reports [6,99] indicate that OTC activity is not present in 
fibroblasts. However, due to the importance of the absence of 
detectable OTC activity and the fact that we were working 
with mutant cells, OTC activity in the F25 and a control cell 
line F500 was investigated. 
The majority of exogenous arginine is consumed by the cells 
to synthesize proteins, while another fraction is converted 
to urea by arginase activity. The contribution of these 
pathways to the utilisation of exogenous arginine was 
investigated, as well as ways of inhibiting these pathways 
(cycloheximide and valine treatment). This was performed to 
ensure that sufficient arginine remained in the medium to be 
utilised by iNOS and to limit the amount of radioactivity 
that needed to be used in the assay. 
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2. 8: MATERIALS AND METHODS. 
2.8.A: PRELIMINARY TESTS. 
A.i: Ornithine transcarbamylase activity. 
Confluent fibroblasts were trypsinised (section 1.3) and 
300000 cells were plated into 3ml Falcon wells. The cells 
were incubated overnight in the presence of BME (5% FCS, PSN) 
and 5% co2 and then the medium replaced with lml medium Z 
containing 0.5pCi 14c-u-argininejwell (Amersham 318mCijmmol, 
universal label). After the required incubation times (0-10 
hours), the medium was removed and the cells washed four 
times with ice cold saline to remove exogenous radioactivity. 
The cell supernatant fraction was collected by treatment with 
0.5ml ice cold 5% TCA. The protein fraction was then 
collected by the further precipitation of cellular proteins 
with three washes of 5% TCA and the addition of 0.5ml O.lM 
NaOH. 
400)11 of the protein fraction was dissolved in 6ml 
scintillation fluid (Packard Hionic-Flour) and counted in a 
liquid scintillation spectrometer {Beckman LS 60001C). SOul 
was used to determine the protein content of each sample 
(section 1.3). The cpm were normally expressed as cpmjcell 
number, however when protein levels differed significantly 
the cpm were expressed as cpmj~g protein. The dpm values were 
calculated where necessary by taking into account the 
background counts and the efficiency, which was 74% for 14c in 
the open window, 0-1000. 
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Cell supernatant fractions were neutralised with 12 washes of 
an equal volume of water-saturated ether to pH 6. The samples 
were vortexed, centrifuged and the etherlayer removed at each 
wash. The volume of the samples was reduced from 500pl to 
50-lOOpl by evaporation (Savant Speedvac SC110). The lml 
medium fraction was treated with an equal volume of 5% TCA to 
precipitate cellular proteins, ether neutralised and the 
volume reduced through evaporation. Cell supernatant and 
·medium samples were analysed using the silica; phenol/ 
propanol TLC system or the HPLC in combination with a 
(Flo-onejBeta series A100) radiochemical detector, using 
either the reverse-phase (sample pH = 7) or cation-exchange 
columns (sample pH= 2.2). 
A.ii: cycloheximide treatment. 
F500 (control) fibroblasts (300000) were incubated in 
the presence of 0, 20, 50 or 100 )Ug/ml cycloheximide 
dissolved in lml medium z. Inhibition of protein synthesis by 
cycloheximide was assayed as the cells' ability to 
incorporate o.5pCi 14c-u-arginine into acid precipitable 
material (protein), in the presence of increasing 
concentrations of cycloheximide over a 4 hour period. After 
the incubation period the medium, cell supernatant and 
protein fractions were collected and analysed as above. 
A.iii: Arginase inhibition - Valine treatment. 
F500 (control) fibroblasts (300000 cells) were incubated in 
lml medium Z (0.5pCi 14c-u-arginine) with or without 50mM 
L-valine (Sigma) for 4 hours • Again the medium, cell 
supernatant and protein fractions were collected and analysed 
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as above. Protein levels were evaluated to assess differences 
in cell number due to the incubation conditions. 
A.iv: Inhibition of 14c-citrulline consumption by the addition 
of exogenous unlabelled citrulline. 
o, 0.01, 0.1, 1 and 10mM concentrations of L-citrulline 
(Sigma) were added to the medium Z incubation medium 
(1mljwell). F500 (control) fibroblasts (300000 cells) were 
then incubated in these various solutions in the presence of 
0.005pCi (0.1pM) 14c-u-citrulline (58mCi/mmol, Amersham) for 4 
hours. The metabolism of the trace amount of 14c-citrulline by 
ASS in the presence of unlabelled citrulline was measured by 
the conversion of 14b-citrulline into 14C-arginine, which is 
then incorporated into protein. After the incubation period, 
the 14C radioactivity content of the medium (200pl) and 
protein fractions· ( 400pl) was analysed. 
2.8.B: NITRIC OXIDE ASSAY - Finalised assay. 
300000 F25 (ASS deficient) fibroblasts and a similar number 
of F500 (control) cells were plated into 3ml wells and 
allowed to grow to confluency in DMEM (10% FCS, PSN). Upon 
confluency the medium was removed and replaced with 1ml DMEM 
(10% FCS, PSN) containing 100U human, recombinant gamma 
interferon ( 1S -IFN) (Boehringer Mannheim) and lOpg 
lipopolysaccharide (LPS) (Sigma). The cells were incubated in 
the presence of these additives for 8 hours, at which time 
2pCi 14c-guanido-arginine (NEN products, 55.6mCi/mmol), lmM 
citrulline (Sigma) and 50mM valine (sigma) were added and the 
cells incubated for a further 16 hours. 
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After the 24 hour incubation period the medium was removed, 
and the cells washed 4 times with ice-cold saline. The 
cell supernatant was collected by the addition of 0.5ml 5% 
TCA and finally the protein fraction collected by 3 
washes of 5% TCA and the precipitate dissolved in 0.5ml 0.1M 
NaOH. The medium and cell-supernatant fractions were treated 
with 12 washes of water-saturated ether, freeze-dried to 
50-100pl volumes and analysed on the cation-exchange HPLC 
system. 
Amino acid analysis. 
Medium from the nitric oxide assay was also analysed on the 
amino acid analyser to monitor the levels of arginine during 
the 24 hour assay. Medium fractions (400pl of 1ml) at time o, 
8 and 24 hours were collected and 20pl of an internal amino 
acid standard added (amino-ethyl cysteine, 2500pM). Cellular 
proteins were precipitated by the addition of 
5-sulphosalicylic acid and the precipitate removed by 
centrifugation (5 minutes at 15000g) . The resulting 
supernatant was filtered through a 0.2pm millipore filter and 
adjusted to pH 2.2 with 0.1M HCL or NaOH. 
Samples were analysed on a Beckman system 6300 automated 
amino acid analyser. The amino acids were identified by the 
comparison of the trace to separations of standard amino acid 
mixtures, and their concentrations determined by their 
relative peak heights once corrected with the height of the 




2.9.A: PRELIMINARY TESTS. 
Originally all preliminary tests were performed in medium Z 
rather than DMEM. Medium z is arginine-free, thus the uptake 
f 14c .•. o -arg1n1ne and 14c-citrulline by fibroblasts is optimal 
in this medium, allowing for a more sensitive assay. 
Exogenous arginine present in BME or DMEM lowers the specific 
activity of the added 14c labelled component, making detection 





TABLE 4: THE EFFECTS OF ARGININE (0.3mM) ON 
THE UPTAKE OFIH-ARG AND't-CIT IN 
F507 CONTROL FIBROBLASTS. 
SAMPLE: 3H-DPM: 14C-DPM: I RATI014cf3H: 
F5071N 29944 2234 0.075 
IBMEI 33324 2926 0.088 
F5071N I 274750 56928 0.207 
!MEDIUM zil 274708 54374 I 0.198 
control F507 fibroblasts were incubated in the 
presence of 1uCi 3H-arginine and 0.5pCi 14c-citrulline for 
4 hours, in 1ml medium z or DMEM. The acid precipitable 
material was collected and counted. Duplicate values are 
shown here. 
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A.i: Recovery yields. 
All preliminary studies and the nitric oxide assay itself 
were based upon a basic assay to study the m~tabolism of 
14c-arginine by the fibroblasts. The assay involved the 
analysis of cellular components after specific incubations 
times in the presence of 14c-arginine. It was essential that 
medium, cell supernatant and protein fractions were collected 
separately without interfraction contamination. The losses 
incurred during ether treatment and evaporation were also 
investigated to ensure that these were at a minimum. 
A.i.a: Cellular fraction collection - Saline washing and TCA 
extraction. 
After the required incubation period in each respective 
assay, the medium fraction was removed. To ensure that all 
the extracellular.radioactity was removed from the fibroblast 
layer, the samples were washed with several washes of ice 
cold saline. lOOpl of each lml saline wash were assessed for 
their radioactivity content. It was found that 4 washes were 
sufficient to reduce the levels of extracellular 14 . . c-arg1n1ne 
radioactivity to background levels (30-50 cpm). This washing 
prevents the contamination of the cell-supernatant fraction 
with medium components. 
The precipitation of the protein fraction and the removal of 
cytoplasmic radioactivity by 3 washes of ice cold 5% TCA was 
previously described by Davidson et al [33]. This 
investigation was repeated and the carry-over of 
radioactivity to the protein fraction from a 0.5pCi solution 
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of 14c-arginine at time 0, was found to be 0.2% after 3 TCA 
washes. 
A.i.b: Water-saturated ether extraction. 
The number of ether-extractions required to neutralise the 
TCA in the cell supernatant fraction was determined by 
measuring the pH of a 0.5ml solution of 5% TCA extract of 
300000 F25 fibroblasts containing 0.5pCi 14c-citrulline, after 
each ether wash. The radioactivity loss due to this process 
was measured by counting the radioactivity content of the 
ether layers after each wash. It was shown that 12 washes 
were sufficient to obtain a pH of 6 and that the 
radioactivity content of the 12 ether washes represented 1.5% 
of the inital radioactivity in the sample. This result 
indicates that no significant loss of citrulline was incurred 
during this neutralisation process. 
A.i.c: Volume reduction: evaporation. 
The loss of radioactivity incurred during the process of 
evaporation, to reduce the sample volume from 500pl to 
50-lOOpl, was investigated by evaporating a 0.5ml TCA extract 
from F25 cells containing 0. 25pCi of 14c-citrulline. The loss 
at this stage was found to be 10% when compared to the 
duplicate sample. 
Thus the overall loss of radioactivity incurred during the 
process of neutralisation and volume reduction of cellular 
extracts was found to be approximately 12%. This reduction 
should not seriously effect the detection of 14c-citrulline, 
or effect the quantification of other arginine metabolites. 
A.ii: Ornithine transcarbamylase activity. 
A.ii.a: TLC. 
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The presence of detectable OTC activity in fibroblasts was 
initially assessed in the F25 and control F507 cell-lines 
(100000 cells) by measuring the amount of 3M-citrulline 
formed by incubation with 1pCi 3H-Arginine in 1ml medium z 
over a 24 hour period (fresh medium at 12 hours). 3H-arginine 
is generally labelled with tritium, which ensures that all 
arginine metabolites with be labelled, allowing for 
detection. Cell supernatant fractions were collected at 4, 8, 
12 and 24 hour intervals, the volumes reduced by evaporation 
and then analysed on silica plates (phenol/propanol) [94], 
after being mixed with 10pl of a standard amino acid mix, for 
identification purposes. 
The amount of radioactivity found to migrate with the 
citrulline standard (spot "C") is shown in figure 38. This 
figure shows a very slow accumulation of "C" over the 24 hour 
time period in both cell lines. If spot C represents 
citrulline, a much greater accumulation of citrulline would 
be expected in F25 (compared to the control), due to the 
argininosuccinate synthetase block. 
The location of the tritiated arginine metabolites was 
determined by the positions of ninhydrin stained unlabelled 
standards. This was probably not accurate enough, as the 
radioactive spots may have been more diffuse than the 
unlabelled amino acids. This may well have led to loss of 
radioactivity, which could explain the unexpected result 
shown in figure 38. 
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FIGURE 38: Ornithine transcarbamylase assay: Thin-layer 
chromatography analysis. Spot c formation in 
fibroblasts. 
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100000 F25 (ASS deficient) and· F507 (control) fibroblasts 
were incubated in medium z containing 1pCi 3H-arginine over a 
24 hour period. Cell supernatant fractions were collected at 
4, 8, 12 and 24 hour intervals and the components separated 
on silica plates (phenol/propanol system). Unlabelled amino 
acid standards were used to identify the citrulline migratory 
position and the 3H content of this spot (spot c) was 
determined at each time point. The error bars give an 




To prevent this loss, the 4, 8 and 12 hour incubation time 




locate the labelled 
(another generally 
the plates were 
metabolites more 
accurately. Figure 39 represents an autoradiograph of a F25 8 
hour time point and shows the formation of c-spot "C". The 
duplicate values of this experiment were poorly correlated 
however, so HPLC separation techniques were used to overcome 
the difficulties of quantitation using the silica plates. 
A.ii.b: HPLC. 
The OTC assay was repeated using 14c-u-arginine (universal 
label) (0.5pCi) and the samples analysed on the HPLC. 300000 
fibroblasts were used in the assay to increase the formation 
of the various metabolites, making them more easily 
detectable. A time course of 0-10 hours was performed and the 
medium (medium Z) as well as the cell supernatant fractions 
were collected at 2 hour intervals. The fractions were 
treated as in the methods and 14c-arginine metabolites 
separated initially on 
(octane-sulphonate) [95,96]. 
a reverse-phase column 
To assess cell viability during the experiment, several 
controls were performed: 1) The medium was analysed to assess 
the levels of 14c-u-arginine. 2) The incorporation of 
1~-arginine into 1~-protein was monitored over the time 
period to ensure continuous cell growth. 3) Glucose levels in 
the medium were also analysed to ensure that enough glucose 
was present for cell utilisation. 
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FIGURE 39: Ornithine transcarbamylase activity: Thin-layer 
chromatography analysis. Formation of 
14c-arginine metabolites. 
100000 F25 (ASS deficient) fibroblasts were incubated for 
0-12 hours in the presence of 0.5flCi 14c-u-arginine (medium 
Z). Cell supernatant fractions were collected at 4-hourly 
intervals and separated on silica plates (propanol/phenol 
system). The silica plates were autoradiographed and 
14c-arginine metabolites identified according to the migration 
positions of standards. This autoradiograph represents an 8 
hour sample, where C represents "spot C". AP = application 
point. 
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These controls were performed to ensure that the levels of 
arginine metabolites found in the medium and cell-supernatant 
fractions were due to normal cell functions, and not due to 
starvation or cell death. The results of these controls are 
shown in figure 40 and show that at 6 hours the medium 
needed to be replaced to replenish the 14c arginine levels, 
allowing for constant 14c-protein formation and an adequate 
glucose supply. The cells appeared normal under 
examination throughout the 10 hour experiment, 
signs of large scale cell death. 
microscopic 
showing no 
Initially, samples were analysed on the reverse-phase I 
preliminary tests 
showed sufficient 
octane-sulphonate system and although the 
on this column (section 2.5.C) 
citrulline/urea separation, it was found that this was not 
always the case with the actual cellular samples. Therefore, 
samples that indicated the presence of 14c-citrulline were 
analysed on the cation-exchange system (duplicate samples) to 
confirm the formation of 14c-citruiline. 
Figure 41 shows a typical amino acid profile of the 
cell-supernatant fraction from the F25 cell line analysed on 
the cation-exchange column, showing the formation of two 
distinct peaks. Peak X elutes in the predicted region for 
citrulline (29 minutes) and was initially assumed to 
represent this amino acid. Figure 42A shows the formation and 
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FIGURE 40: Ornithine transcarbamylase fibroblast assay: 
controls. 
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F25 (ASS deficient) and FSOO fibroblasts (300000) were 
incubated in medium z containing o.suci 14c-u-arginine over a 
10 hour period (FSOO = 6 hours). The medium (A) and the 
incorporation of 14b-arginine into cellular ~rotein (B) were 
monitored at 2-hourly intervals to monitor the presence of 
sufficient radioactivity in the medium and continuous cell 
proliferation during the incubation period. The medium was 
replaced at 6 hours to maintain glucose and radioactivity 
levels in the medium (>0.2pCi). The error bars represent the 
range of results in the triplicate wells. 
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FIGURE 41: Ornithine transcarbamylase assay: BPLC analysis of 
F25/F500 cellular supernatant fractions. 
This figure represents the typical separation profile of 
~c-arginine metabolites found in the cellular supernatant 
fraction of F25/F500 cells, analysed on a cation-exchange 
column (Li-A/Li-R) during the OTC 10 hour assay. 300000 F25 
(ASS deficient) fibroblasts were incubated in the presence of 
0.5pCi 14C-u-arginine over a 10 hour period in medium z and 
samples collected at 2-hourly intervals. Two major peaks were 
identified in this fraction : peak X and peakY. 
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F25 cells should accumulate 14c-citrulline due to the ASS 
blockage, however figure 42A seems to indicate "citrulline" 
depletion at 6 hours and then a gradual accumulation again, 
when the medium was relenished with 14c-arginine. Due to the 
unexpected nature of the metabolism of peak X, the OTC 
experiment was repeated for a 
only over a 6 hour period to 
control cell line, F500, but 
establish the trend of the 
curve. If the species represented by peak X was in fact 
citrulline, very low levels of this peak would be expected in 
the control due to its continual metabolism by ASS and ASL 
activity. However, it was found that peak X formation 
followed the same curve as that shown for F25, with depletion 
of metabolite X at 6 hours. Interestingly, 3 times more of 
this metabolite was produced in the control cell line, which 
further suggested that peak X did not represent citrulline. 
Proline and glycine elute very closely to citrulline on a 
typical amino acid profile from the amino acid analyser, so 
the possibility of these amino acids being represented by 
peak X was investigated. On the cation-exchange program used 
on the HPLC system, it was demonstrated that proline eluted 
very closely to citrulline, and may be a likely candidate for 
peak X in the OTC experiment. Glycine eluted somewhat earlier 
at 27 minutes. To confirm this result, 14c-proline and 
14c-citrulline standards were used to spike the OTC 
cell-supernatant samples, and the the identity of peak X was 
confirmed as proline. Figure 42B also shows the continous 
accumulation of urea and proline in the medium extracts over 
the 10 hour incubation period. 
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FIGURE 42: Ornithine transcarbamylase assay: Accumulation of 
14c-arginine metabolites in the medium and cellular 
supernatant fractions. 
300000 F25 (ASS deficient) fibroblasts were incubated in 1ml 
medium z containing o.spci Wc-u-arginine for 0-10 hours 
(medium replaced at 6 hours). Cellular supernatant and medium 
fractions were collected at 2-hourly intervals and analysed 
on a cation-exchange HPLC column (Li-A/Li-R system). A). The 
accumulation of 14c-cpm in peak X and peak Y in the cellular 
supernatant fractions. B) The accumulation of 14c-cpm in the 
identified proline and urea integrated peaks in the medium. 
The error bars represent the range of results seen in the 
duplicate wells. 
The shape of the proline curve (figure 42 
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peak X) may 
reflect the cells utilisation of proline, where a small pool 
is maintained in the cell and any excess accumulates in the 
medium. When 14c-proline formation was slowed due to the fall 
in exogenous arginine levels at 6 hours, this intracellular 
pool was diminished, explaining the dip in the curve. 
Citrulline and proline were also separated on silica TLC 
plates and were found to elute in the same position, 
explaining the earlier TLC results (section 2.9.A.ii.a), 
which suggested the formation of 3H/ ~ citrulline (spot C) 
from labelled arginine. 
These combined results show that detectable levels of 
labelled citrulline could not be demonstrated from the 
metabolism of labelled arginine over a 10 hour incubation 
period. This indicates that OTC activity is not detectable in 
human cultured fibroblasts, which is in agreement with 
previous reports [6,99]. 
The proline that was formed from the metabolism of arginine 
in the above OTC experiment, was formed by the ornithine-keto 
aminotransferase (OKT) pathway which is found in fibroblasts 
[6]. Another product of this pathway is glutamate (see figure 
43) and this was investigated as a possibility for the 
metabolite represented by peakY (17.5 minutes) in figure 41. 
The accumulation of metabolite Y in the F25 cell-supernatant 
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FIGURE 43: Intracellular amino acid metabolism [1]. 
Diagram of amino acid metabolism, demonstrating the link 
between the urea cycle and the ornithine keto-amino 
transferase (OKT, OAT) pathway. CAP = carbamyl phosphate 
synthetase, OTC = ornithine transcarbamylase. 
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HPLC and TLC analysis of glutamate's migration position 
relative to other standards, provisionally confirmed its 
identification as the metabolite in peak Y. 
From the measurement of arginine metabolites during this 
investigation, it is possible to get an approximate 
estimation of the arginine flux with respect to the urea 
cycle and the flow of arginine towards the synthesis of 
protein. Calculations were made according to the amount of 
14c-protein and 14c-urea formed after 4 hours (figures 40 and 
42B) during the OTC experiment. The cpm results were 
converted to dpm values to ensure accuracy. 
Firstly, after the 4 hour incubation period, the amount of 
14c-arginine in the medium had been reduced by 53%, with 45% of 
the available 14c-arginine having been incorporated into acid 
precipitable material. Secondly, from the amount of 14c-urea 
that was formed over the 4 hour period, it was calculated 
that only 0.8% (14nM) of the available 14C-arginine {1.6pM) 
was metabolised by arginase activity. This result shows a 
preferential flux of arginine molecules towards protein 
production rather than urea formation by a ratio of 56:1. 
These results do not accurately represent the absolute 
amounts of the various arginine metabolism pathways, but 
instead give an indication of the scale of the utilisation of 
arginine for protein synthesis after a 4 hour incubation 
period. 
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A.iii: Cycloheximide treatment. 
Due to the large consumption of 14c-u-arginine by protein 
synthesis, the possibility of blocking this pathway was 
investigated as a means of promoting the metabolism of 
arginine by other pathways. 
The effects of a cycloheximide concentration range of 
0-lOOpgjml on F500 fibroblasts were investigated, to find the 
minimal concentration necessary to halt protein synthesis in 
these cells, and maximise flux to the other metabolites. 
14c-arginine was added at the same time as cycloheximide to 
monitor the levels of protein synthesis and metabolism of 
arginine. The acid precipitable fraction was collected to 
monitor protein synthesis, medium collected to monitor 
glucose levels and cell-supernatant fractions analysed on 
both the reverse-phase and cation-exchange HPLC systems. The 
cells were also visualised throughout the incubation period 
and most of the wells showed no signs of ill effects, 
although some cell death was noted in the wells containing 
lOO~gjml cycloheximide. 
Figure 44A shows the inhibitory effects of cycloheximide on 
protein synthesis, with 20~g/ml allowing only 3.8% of the 
original protein synthesis and 50-lOO~gjml between 1 and 2%. 
This shows the effective blockage of this pathway by 
cycloheximide. Figure 44B shows the resulting increase in the 
formation of arginine metabolites (urea, proline, glutamate) 
as a result of protein synthesis inhibition. 
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FIGURE 44: The effects of cycloheximide on protein synthesis 
and arginine metabolism in control fibroblasts. 
300000 FSOO (control) fibroblasts were incubated in medium Z 
containing 0-lOOpg/ml cycloheximide. o.spci 14c-u-arginine was 
included in the medium to analyse arginine metabolism in the 
presence of the cycloheximide. (A) represents the amount of 
14c-protein formed in the presence of the various 
concentrations of cycloheximide. (B) Through the HPLC 
analysis (reverse-phase and cation-exchange) of medium and 
cellular supernatant fractions, the formation of ~-urea, 
14c-proline and 14c-glutamate was monitored. The error bars 
indicate the range of the duplicate results. 
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The glucose analysis of the medium after the incubation 
period, revealed that cells incubated with 100pgjml 
cycloheximide utilised glucose at a slightly faster rate. 
From these results, 50pg/ml cycloheximide was chosen as the 
level necessary to inhibit protein synthesis maximally and 
stimulate the increase in metabolism of arginine by other 
pathways, without detrimentally effecting cell viability. 
A.iv: Arginase inhibition - Valine treatment. 
Some researchers (88,100] have used arginase and ASS 
inhibitors to maximise the formation of citrulline by 
arginine via the nitric oxide pathway. The major enzyme of 
the urea cycle in fibroblasts that may cause .a diversion of 
~C-arginine is arginase. Knowles et al [100] reported that in 
liver cells, this enzyme could be effectively inhibited in 
the presence of 50mM L-valine, whil.e others [ 95,101] report 
that ornithine also inhibits arginase activity (43%-67%). 
The effects of valine on the arginase activity in fibroblasts 
(F500) were investigated. 50mM valine and Mc-u-arginine were 
incubated together with the fibroblasts and then the protein, 
medium and cell supernatant fractions evaluated. 
Firstly, it was shown that the presence of valine caused a 
33% reduction in protein synthesis. Secondly, arginase 
activity results in the formation of ornithine, which as can 
be seen in figure 45 leads to the formation of proline and 
glutamate by OKT. Analysis of the medium and cell-supernatant 
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fractions revealed the following results: 
TABLE 5: EFFECTS OF VALINE ON ARGINASE ACTIVIlY. 
METABOLITE: +VALINE {cern): -VALINE {cern): 
UREA 3387 6511 
ORNITHINE 2607 4500 
PROLINE 120 682 
GLUTAMATE 140 685 
F500 (control) fibroblasts were incubated in the presence of 
0.5pCi 14c-u-arginine and 50 mM L-valine for 4 hours. The 
medium and cell supernatant fractions were collected and 
analysed on the cation-exchange and reverse-phase HPLC 
systems. The amounts of 14c-cpm in each of the ornithine, 
urea, proline and glutamate integrated HPLC peaks were 









FIGURE 45: The arginase and OKT reactions. 
These results show the effect of valine on arginase activity, 
with a 50% decrease in both urea and ornithine production. 
The larger decrease in proline and glutamate may also reflect 
the inhibitory effects of valine on enzymes other than 
arginase. Although the inhibition is not 100%, 50mM L-valine 
does partially inhibit arginase activity in addition to 
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slowing protein synthesis, both of which will help promote 
the metabolism of arginine to citrulline by iNOS if this 
pathway is operative in fibroblasts. 
A.v: Inhibition of 14c-citrulline metabolism by addition of 
unlabelled citrulline. 
Although the purpose of this study was to utilise ASS 
deficient fibroblasts (F25) to investigate the potential NO" 
pathway, some difficulty was incurred in the detection of 
citrulline during the NO" assay (see 2.8.B). One of the 
possibilities to explain this result was that because only 
small levels of citrulline may be produced via the NO"pathway 
(10pM over 24 hours [77]), any residual ASS activity may 
metabolise this 14c-citrulline. Therefore to minimise 
14c-citrulline consumption in these fibroblasts, the dilution 
effects of exogenous L-citrulline on the metabolism of a 
trace amount of 14C-citrulline by ASS was investigated. The 
tests were performed on F500 (control) cells to maximise 
14c-citrulline uptake levels for detection purposes. The 
effects of 0.01, 0.1, 1 and 10mM L-citrulline on the 
utilisation of 0.005pCi 14c-citrulline (0.1pM) to form 
14c-protein was investigated. Figure 46 shows the 14c-cpm 
incorporated into acid precipitable material after the 
incubation period and shows the efficient dilution effects of 
the added citrulline. 
1mM added exogenous L-citrulline was found to be adequate to 
minimise the metabolism of trace amounts (0.1pM amounts) of 
14c-citrulline. 
COMPETITIVE INHIBITION OF 
14
C-CITRULLINE 
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FIGURE 46: Competitive inhibition of ~C-citrulline metabolism 
by ASS with unlabelled L-citrulline. 
The effects of unlabelled L-citrulline on the metabolism of 
14C-citrulline (0.1pM) were investigated in FSOO (control) 
· fibroblasts. 300000 cells were incubated with 0 .OOS.)lCi 
14b-citrulline (medium Z) in the presence of o, 0.01, 0.1, 1 
and 10mM L-citrulline for 4 hours. ASS activity was assayed 
by measuring the incorporation of 14c-cpm into acid 
precipitable cellular material (~C-citrulline-~4c-arginine-> 
~c-protein). The error bars represent the range of results 
from the triplicate wells. 
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2.9.8: NITRIC OXIDE ASSAY. 
Using the information from the preliminary studies, several 
attempts were made to induce the nitric oxide pathway in 
fibroblasts. 
B.i: Experiment 1. 
When the project was initiated little was understood about 
the mechanism by which interferon could stimulate activity of 
iNOS. It was not known whether cytokine induction was pre or 
post-translational or that exogenous arginine levels of 
between 0.2mM and 0.3mM were required for maximal iNOS 
activity [7]. So due to the preliminary findings of the large 
consumption of label by the protein synthesis pathway, ~he 
inital study utilised the blockage of this pathway by 50pgjml 
cycloheximide to try and promote NO.formation, and maintain a 
high level of 14c-arginine in the cytoplasm. 
The actual experiment involved incubation of the F25 
fibroblasts with 100U ~-IFN, in the presence or absence of 
10pg/ml LPS for 18 hours in DMEM, to activate iNOS. The 
length of the incubation period and amounts of cytokines 
needed for iNOS activation were decided upon by reference to 
other studies [7,54,58,77] .. The medium was then removed and 
replaced with medium z (to enhance 14c-arginine uptake) 
containing 0.5pCi 14c-u-arginine (universal label) and 50pgjml 
cycloheximide. The incubation was then continued for a 
further 4 hours and the cell-supernatant fractions analysed 
(HPLC) for.the formation of 14c-citrulline. No citrulline was 
detected under these incubation conditions. 
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In hindsight this result is not surprising, as several key 
elements of the experimental design were found to be 
inappropriate in the light of recent publications. Firstly, 
interferon induces iNOS at the transcriptional level, which 
then requires protein synthesis to allow the formation of the 
enzyme (60,71]. Secondly, although iNOS has been isolated and 
then assayed (similar to the method used here), the in vitro 
assays were performed over short periods of time (10-30 
minutes) [73,88,100], and at present no indication is given 
as to the half life of this enzyme. It is possible that over 




and interferon stimulation, any iNOS that was 
during the 18 hour l -IFN stimulation period was 
degraded and did not therefore allow the production 
of detectable levels of citrulline. Finally, for maximal 
activity of iNOS, exogenous arginine at levels of above 
0.25mM were shown to be required [7]. Under the assay 
conditions mentioned above, only 1.5pM arginine was added in 
the form of 14c-u-arginine, which' would not have been enough 
to allow for maximal enzyme activation. 
In light of the above, several points were noted that could 
have contributed to the absence of detectable citrulline 
under the above experimental conditions: 
1) Continual cytokine stimulation is required to allow the 
production of sufficient levels of iNOS. 
.• 
187 
2) Although IFN and LPS may stimulate transcription over the 
18 hour period, the inclusion of cycloheximide in the 
incubation medium would prevent the synthesis of iNOS 
protein. 
3) Sufficient iNOS may be produced in the 18 hour period, 
however under the incubation conditions , sufficient 
extracellular arginine 
maximal enzyme activity. 
was not available to allow for 
4) The citrulline may be produced in very small quantities 
and it is possible that even the 5% residual ASS activity 
in F25 may result in the metabolism of this ~C-citrulline 
pool. 
B.ii: Experiment 2. 
In an attempt to circumvent these problems, the assay was 
remodelled to take int9 account the above considerations. 
Firstly, the OTC experiment (section 2.9.A.ii.b) showed that 
large amounts of proline and glutamate can be formed from 
14c-arginine metabolism during the incubation, and that a 
large peak of proline may readily interfere with the 
detection of a small citrulline peak, due to the very close 
retention times of these two amino acids (cation-exchange 
column). So as to avoid this problem the NO' experiment was 
performed with · 14c-guanido-arginine. The 14c-label of this 
arginine preparation is positioned on the carbon that forms 
part of the guanido group in arginine, which is cleaved by 
arginase to form 14c-urea. Thus the only labelled metabolite 
that can be formed from the reactions of arginase, OKT and 
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OTC, is urea. The only other possible labelled metabolite 
that may arise from the metabolism of 14c-guanido arginine is 
citrulline, if it is produced by the NO'pathway. This enables 
the sensitivity of the assay to be enhanced as it prevents 
thee overlap of potentially major labelled species such as 
prolne (OKT pathway). 
Secondly, it was proposed that the incubation period of 4 
hours in the presence of 1~-arginine may not have been long 
enough to allow the accumulation of detectable levels of 
14t-citrulline. So to overcome this problem, as well as the 
need for extracellular arginine levels in the > 0.2mM range 
[7] and the requirement of the presence of IFN for continual 
iNOS production, the experiment was performed as follows: F25 
and FSOO (control) cells were incubated for 8 hours in DMEM 
(O.SmM arginine) containing 100U ~-IFN and 10mg LPS. This 
step should allow for the inital activation of iNOS. 2pCi of 
14C-guanido arginine was then added to the medium, as the iNOS 
substrate, and the incubation continued for a further 16 
hours. Cell supernatant and medium fractions were then 
collected. such large amounts of 14C-arginine were necessary 
to allow for the lagre consumption of arginine for protein 
synthesis, especially over the 16 hour incubation period. 
Due to the long incubation time of 16 hours in the presence 
of the isotope, it was important to try and limit the 
utilisation of 14c-arginine by other pathways (arginase). 
Other researchers have used urea cycle inhibitors to promote 
No· formation [88,100]. The effects of valine were 
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investigated in the preliminary studies and revealed that 
50mM L-valine was sufficient to reduce arginase activity by 
50% to 60% (section 2.9.A.iv). The added valine was also 
shown to reduce protein synthesis by 33%. Unlabelled 
citrulline (1mM) was found to be effective in minimising the 
metabolism of 14c-citrulline (section 2.9.A.v), thus promoting 
14c-citrulline accumulation. So in an attempt to maximise No" 
production and 14c-citrulline formation, 50mM valine and 1mM 
L-citrulline were added at the same time as· the 
14 'd . . . c-guan1 o-arg1n1ne 1n the above experimental profile. A 
schematic summary of this No·experiment is shown in figure 
47. 
Controls: 
To ensure that the system was operating optimally and that 
all the essential components were present, several controls 
were performed. Firstly, the extracellular arginine levels in 
the medium were measured at time o, 8 hours and 24 hours to 
ensure that arginine levels remained above the critical 
0.25mM level. Amino acid analysis showed this to be the case. 
Secondly, the inhibition of arginase activity was measured by 
comparing cells treated with and without 50mM L-valine in the 
presence of the cytokines and 14c-guanido-arginine. It was 
shown that the presence of 50mM valine over the 16 hour 
incubation period effectively reduced the amount of 14c-urea 
produced by 66%. 
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FIGURE 47: A schematic representation of the nitric oxide 
assay (experiment 2) in human fibroblasts. 
A simplified diagram of the main enzymes and metabolites that 
were considered during the design of the nitric oxide assay 
and the steps that were taken to promote the formation of NO 
by blocking these pathways. (a) = 50mM valine reduces protein 
synthesis by 33%. (b) = Arginase activity is reduced 50-70% 
by 50mM valine. (c)= OTC activity. was shown to be absent in 
fibroblasts. (d) = ASS activity is reduced in F25 (1-5%) and 
lmM citrulline prevents the metabolism of trace amounts of 
14c-citrulline by ASS. • = Possible 14c-metabolites when 
incubating with 14c-guanido arginine. 
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With regards to 14c-citrulline metabolism, cytokine stimulated 
control fibroblasts {DMEM, 0.5mM arginine) were incubated in 
the presence of 50mM L-valine with or without 1mM 
L-citrulline as well as 0.05pCi 14c-citrulline, and the amount 
of 1~-protein generated after the 16 hour incubation period 
measured. 
It was found that no significant 14c-protein was formed under 
these circumstances, indicating the effectiveness of the 
added 1mM citrulline in diluting the 14c-citrulline and 
minimising its metabolism by ASS. Amino acid analysis showed 
that both citrulline and valine were found in substantial 
amounts in the medium after the 16 hour incubation period. 
Finally, the experiment was performed in the presence and 
absence of the cytokines as a comparison and the experiment 
was performed in triplicate to ensure accuracy. ~-IFN and LPS 
were always used in conjunction with one another as this has 
been found to be the optimal stimulation in a number of 
systems [77,82]. 
The cell-supernatant and medium fractions of both the F25 and 
F500 samples were analysed on the reverse-phase and 
cation-exchange columns after the 24 hour incubation period 
of the experiment. No 14c-citrulline was detected after using 
these revised incubation conditions. 
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2.10: DISCUSSION. 
The aim of this section was to use the F25 (ASS deficient) 
fibroblast cell line to demonstrate whether induction of the 
No'' pathway ( iNOS) by cytokines could be achieved in cultured 
human fibroblasts. Several NO assay systems in other cell 
lines [54,59,60,88,100] have used the fact that equimolar 
amounts of citrulline and No'are produced by the metabolism 
of L-arginine by NOS [63]. In the F25 fibroblast cell line, 
this citrulline should accumulate due to the absence of 
significant ASS activity, allowing for the detection of 
accumulating citrulline in response to cytokine stimulation . 
.. 
NO has been shown to operate in both signal transduction and 
in host immune defense mechanisms (macrophage cytotoxicity) 
[60,63,71]. Several similarities exist between macrophages 
and fibroblasts that suggests that fibroblasts may play a 
role in the general immune response. These include the 
synthesis of BH4 [77,80,81,82], which has been directly 
linked to the production of No' in murine fibroblasts after 
cytokine stimulation [77], as well as the increased synthesis 
of IDO in response to this stimulus [82]. It is therefore 
possible that fibroblasts may participate in the general 
immune response through the production of NO' by iNOS 
activity. 
The basic No' assay system that was adopted in this study 
was as follows: Activation of the ASS deficient 
fibroblasts with ~-interferon and lipopolysaccharide, to 
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induce the expression of iNOS. The iNOS enzyme activity was 
then assayed by measuring the accumulation of 14c-citrulline 
from 14c-arginine in cell-supernatant and extracellular medium 
fractions. 14c-citrulline and other arginine metabolites were 
separated and quantified using two HPLC systems 
(reverse-phase 1 octane-sulphonate and cation-exchange). 
Preliminary studies were performed to optimise the No·assay 
and 14c-citrulline detection system. Firstly, OTC activity was 
tested in fibroblasts, with the results confirming previous 
reports [6,99] of the absence of OTC activity in fibroblasts. 
This result implied that arginine could only give rise to 
citrulline if it was metabolised by NOS, via the No·pathway. 
Secondly, ways of inhibiting other arginine metabolic 
pathways were investigated, in an attampt to maximise the 
flow of arginine to citrulline via iNOS activity. These tests 
included the inhibition of protein synthesis by cycloheximide 
(50pg/ml) and the inhibition of arginase activity by valine 
(50mM). It was later found that complete protein inhibition 
was not appropriate for the 
not used, although valine 
NO.assay so cycloheximide was 
was incorporated to reduce 
arginase activity (50-70%). Finally, although ASS activity 
in the F25 (ASS deficient) was only 1-5% of the control, it 
was proposed that this activity may allow for the 
metabolism of small amounts of accumulating 14c-citrulline 
over the long incubation periods. The addition of 1mM 
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unlabelled citrulline was found to be effective in diluting 
small amounts of 14c-citrulline (0.1pM), to prevent its 
metabolism by ASS. Valine (50mM) and citrulline {1mM) have 
previously been used in the analysis of the No· pathway in 
liver [88,100]. 
Several attempts were made to detect NO" production in 
fibroblasts, with the most comprehensive assay incorporating 
a total of 24 hours of exposure to ~-interferon and LPS to 
induce iNOS expression, with iNOS activity being measured for 
16 hours during this cytokine exposure. The iNOS activity was 
assayed by measuring the formation of 14c-citrulline from 
14t-guanido-arginine in the presence of 50mM valine and 1mM 
citrulline, over the 16 hour period. However, in all these 
experiments 14c-citrulline production was not detected. 
There are many parameters that need to be established to 
definitively answer whether human fibroblasts are able to 
express iNOS activity. Firstly, in some cell lines iNOS 
activity can be induced and detected after several . hours 
stimulation with )/-interferon (6-24 hous) [54,58,72]. 
However, human fibroblasts have shown very slow responses to 
cytokines, requiring 96 hours to show some effects of 
interferon stimulation (increased IDO synthesis) [81]. It is 
possible therefore that the 24 hour stimulation used in this 
study~ is not long enough in studies .with human fibroblasts. 
Secondly, it was not established if the cytokine combination 
was actually having any effect on the fibroblasts. It is 
essential to establish a control to ensure that these 
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additives are activating the cell. For example, by monitoring 
an increase in IDO or BH4 ·synthesis [ 77, 81,82]. 
Finally, the indirect assay of NO'production by the formation 
of ~c-citrulline from 14c-arginine may not be the best assay 
system to use if only small amounts of NO are produced. Long 
assay times (>24 hours) require very large amounts of 
radioactivity with most of the label being incorporated into 
protein. The detection of NO by the formation of nitrates and 
nitrites is more suitable to extended incubations and may be 
more suitable for this system. The number of cells used in 
this study may also not be sufficient if very small amounts 
of iNOS are induced, with the radiochemical detector system 
only being able to define peaks containing more than 300dpm 
(2.4nM of 14c-guanido-citrulline) without ambiguity. 
The implications of NO production in fibroblasts are 
fascinating, with the potential for diagnostic testing in the 
area of No· disorders. The involvement of fibroblasts in the 
general immune response by their production of NO' is also a 
new idea, that may uncover a different perspective to 
generalised immunology. However, it appears that 
identification of iNOS activity in fibroblasts requires more 
extensive investigation than was possible during the course 




The metabolic basis of inherited disease, 6th edition, 
chapter 20, pg:629. McGraw Hill publishers. 
2) Windmeuller,H.,Spaeth,A.(1974) Uptake and metabolism of 
plasma glutamine by the small intestine. Journal of 
Biological Chemistry, 249, pg:5070-5079. 
3) Windmueller,H.G.,Spaeth,A.E.(1981) Source and fate of 
circulating citrulline. American Journal of Physiology, 
241, pg:E473-E480. 
4) Featherston,W.,Rogers,Q.(1973) Relative importance of 
kidney and liver in synthesis of arginine by the rat. 
American Journal of Physiology, 224, pg:127-129. 
5) Lockwood,A.,McDonald,J.(1979) The dynamcis of ammonia 
metabolism in man. Journal of Clinical Investigations, 
63, pg:449-460. 
6) Shih,V.E.,Mandell,R.(1981) Defective ornithine metabolism 
in the syndrome of hyperorthinaemia, hyperammonaemia and 
homocitrullinuria. Journal of Inherited Metabolic 
Disease, 4, pg:95-96. 
7) Bogle,R.G.,Baydoun,A.R.,Pearson,J.D.,Moncada,S., 
Mann,G.E. (1992) L-arginine transport is increased in 
macrophages generating nitric oxide. Biochemical 
Journal, 284, pg:15-18. 
8) Su,T.,Lin,L.(1990) Analysis of a splice acceptor site 
mutation which produces multiple splicing abnormalities 
in the human argininosuccinate synthetase locus. 
Journal of biological Chemistry, 265, pg:19716-19720. 
9) Kobayashi,K.Jackson,M.J.,Tick,D.B.,O'Brien,W.E.(1990) 
Heterogeneity of mutations in argininosuccinate 
synthetase causing human citrullinemia. Journal of 
Biological Chemistry, 265, pg:11361-11367. 
10) su,T.,Beaudet,A.L.,O'Brien,W.E.(1983) Abnormal mRNA 
splicing for argininosuccinate synthetase in 
citrullinemia. Nature, 301, pg:533-534. 
11) Ratner,S.(1983) A radiochemical assay for 
argininosuccinate synthetase with [U-14C]asparate. 
Analytical Biochemistry, 135, pg:479-488. 
12) O'Brien,W.E.(1979) Isolation and characterisation of 
argininosuccinate synthetase from human liver. 
Biochemistry, 18, pg:5353-5356. 
13) Bock,H.O.,Su,T.,O'Brien.W.E.,Beaudet,A.L.(1983) Sequence 
for human argininosuccinate synthetase eDNA. Nucleic 
Acids Research, 11, pg:6505-6512. 
14) Rochovansky,O.Kodowaki,H.,and Ratner,S.(1977) 
Biosynthesis of urea. Journal of Biological 
Chemistry, 252, pg:5267-5294. 
197 
15) Kumar,S.,Lennane,J.,Ratner,S.(1985) Argininosuccinate 
synthetase: essential role of cysteine and arginine 
residues in relation to structure and mechanism of ATP 
activation. Proceedings of the National Academy of 
Science, 82, pg:6745-6749. 
16) Surh,L.C.,Beaudet,A.L.,O'Brien,W.E.(1991) Molecular 
characterisation of the murine argininosuccinate 
synthetase locus. Gene, 99, pg:181-189. 
17) Ghose,C.Raushel,F.M.(1985) Determination of the 
mechanism of the argininosuccinate synthetase reaction 
by static and dynamic quench experiments. Biochemistry, 
24, pg:5894-5898. 
18) Van Vliet,F.,Crabeel,M.,Boyen,A.,Tricot,c.,stalon,V., 
Falmagne,P.,Nakamura,Y.,Baumberg,S.,Glansdorff,N.(1990) 
Sequences of the genes encoding argininosuccinate 
synthetase in E.Coli and s.cerevisiae: comparison with 
methanogenic archaebacteria and mammals. Gene, 95, 
pg:99-104. 
19) Raushel,F.M.,Seiglie,J.L.(1983) Kinetic mechanism of 
argininosuccinate synthetase. Archives of Biochemistry 
and Biophysics, 225, pg:979-985. 
20) Chapman,T.L.,Shull,T.B.,Raushel,F.M.(1986) 
Stereochemical probes of the argininosuccinate 
synthetase reaction. Biochemistry, 25, pg:4739-4744. 
21) Freytag,S.O.,Beaudet,A.L.,Bock,H.O.,O'Brien,W.E.(1984) 
Molecular structure of the human argininosuccinate 
synthetase gene: occurrence of alternative mRNA 
splicing. Molecular and Cellular Biology, 4 (No 10), 
pg:1978-1984. 
22) Beaudet,A.L.,Su,T.,and O'Brien,W.E.(1982) Dispersion of 
argininosuccinate synthetase-like human genes to 
multiple autosomes and the X chromosome. Cell, 30, 
pg:287-293. 
23) Freytag,S.O.,Bock,H.O.,Beaudet,A.L.,O'Brien,W.E.(1984) 
Molecular structures of human argininosuccinate 
synthetase pseudogenes. Journal of Biological 
Chemistry, 259, pg:3160-3166. 
24) Su,T.,Bock,H.O.,O'Brien,W.E.,Beaudet,A.L.(1981) Cloning 
of eDNA for argininosuccinate synthetase mRNA and study 
of enzyme overproduction in a human cell line. 
Journal of Biological Chemistry, 256, pg:11826-11831. 
25) Su,T.,Beaudet,A.L.,O'Brien,W.E.(1981) Increased 
translatable messenger ribonucleic acid for 
argininosuccinate synthetase in canavanine-resistant 
human cells. Biochemistry, 20, pg:2956-2960. 
198" 
26) Boyce,F.M.,Anderson,M.,Rusk,C.D, and Freytag,S.0.(1986} 
Human argininosuccinate synthetase minigenes are subject 
to arginine-mediated repression but not to trans 
induction. Molecular and Cellular Biology, 6 (No 4), 
pg:1244-1252. 
27) Boyce,F.M.,Freytag,S.0.(1989} Regulation of human 
argininosuccinate synthetase gene: induction by 
positive-acting nuclear mechanism in 
canavanine-resistant cell variants. Somatic Cell and 
Molecular Genetics, 15, pg:113-121. ~ 
28) Kimball,M.E,Jacoby,L.B.(1980) Purification and properties 
of argininosuccinate synthetase from normal and CanR 
lymphoblasts. Biochemistry, 19, pg:705-709. 
29) Amos,J.A.,Fleming,B.C.,Gusella,J.F.,Jacoby,L.B.(1984) 
Relative argininosuccinate synthetase mRNA levels and 
gene copy number in canavaninie-resistant lymphoblasts. 
Biochemica et Biophysica Acta, 782, pg:247-253. 
30) Su,T.,O'Brien,W.E.,Beaudet,W.E.(1984) Genomic 
DNA-mediated gene transfer for argininosuccinate 
synthetase. Somatic Cell and Molecular Genetics, 10 
(No 6), pg:601-606. 
31) Rayzanov,A.G.,Rudkin,B.B.,Spirin,A.S.(1991) Regulation 
of protein synthesis at the elongation stage. FEBS 
Letters, 285, pg:170-175. 
32) Boyce,F.M.,Pogulis,R.J.,Freytag,S.0.(1989) Paradoxical 
regulation of human argininosuccinate synthetase eDNA 
minigene in opposition to endogenous gene: evidence for 
intragenic control sequences. Somatic Cell and Molecular 
Genetics, 15, pg:123-129. 
33) Davidson,J.,Baumgarten,I.,Harley,E.H.(1984) Metabolic 
cooperation between argininosuccinate synthetase and 
argininosuccinate lyase deficient human fibroblasts. 
Experimental Cellular Research, 150, pg:367-378. 
34) Bradford,M.M.(1976) A rapid and sensitive method for the 
quantitation of microgram quantities of protein using 
the principles of protein-dye binding. Analytical 
Biochemistry, 72, pg:248-254. 
35) Maniatis,T.,Fritsch,E.F.,Sambrook,J.(1982) Molecular 
Cloning a laboratory manual. Cold sping harbour, USA. 
36) Jones,J.C.,Schofield,J.P.(1990) A rapid method for 
isolating high quality plasmid DNA suitable for DNA 
sequencing. NUcleic Acids Research, 18 (No 24), 
pg:7463-7465. 
37) Kraft,R.,Tardiff,J.,Krauter,K.S.,Leinand,L.A.(1988) 
Using mini-prep plasmid DNA for sequencing double 
stranded templates with sequenase. Biotechniques, 6 




Protocols in Molecular Biology. Harvard Medical School, 
Wiley interscience. 
39) Hybond N+ protocols for nucleic acid blotting and 
hybridisation.(1990) Amersham. 
40) Marinaki,A.M.(1992) Amplification, sequencing and 
cloning of mutant HPRT eDNA from tissue culture 
material. EBG-PCR Protocols Workshop, pg:l8. 
41) Rappolee,D.A.(1990) Optimizing the sensitivity of 
RT-PCR. Amplifications (Perkin Elmer Cetus), 4, pg:6. 
42) Erlich,H.A.,Gelfand,D.,Sninsky,J.J.(1991) Recent 
advances in the polymerase chain reaction. Science, 
252, pg:643-650. 
43) Technical Bulletin: Magic PCR preps DNA purification 
system for rapid purification of DNA fragments.(1992) 
Promega corporation. (cat: A7170). 
44) Qiaex handbook: DNA extraction from agarose gels, 
purification of PCR products, desalting and 
concentration of DNA from solutions.(1992) Quiagen. 
(cat: 20020). 
45) Everett,H.(1992) PCR cloning. EBG-PCR Protocols 
Workshop, pg:27. 
46) Kushner,S.R.(1978) An improved method for transformation 
of E.coli with ColE1-derived plasmids. Genetic 
Engineering (ed.H.B.Boyer and S.Nicosia), pg:l7. 
Elsevier, Amsterdam. 
47) Technical bulletin: Taq polymerase.(1991) Boehringer 
mannheim. 
48) Russ.(1992) Dr Russ's problem corner. Ancient DNA 
Newsletter, 1 (No2), pg:4-7. 
49) Baumgarten,I.(1993) A comparison of metabolic pathway 
dynamics in man and other mammals. Cape Technicon. 
200 
50) Liew,F.Y.,Cox,F.E.G.(l991) Nonspecific defence 
mechanism: the role of nitric oxide. Immunology Today, 
12 (No 3), pg:A17-A21. 
51) Moncada,S.,Palmer,R.M.,Higgs,E.A.(l989) Biosynthesis of 
nitric oxide from L-arginine. Biochemical Pharmacology, 
38, pg:1709-1715. 
52) Palmer,R.M.J.,Ferrige,A.G.,Monacada,S.(1987) Nitric 
oxide release accounts for the biological acitvity of 
EDRF. Nature, 327, pg:524-526. 
53) Culotta,E.,Koshland,D.E.(1992) NO.news is good news. 
Science, 258, pg:1862-1865. 
54) Chenais,B.,Yapo,A.,Lepoivre,M.,Tenu,J.P.(l991) HPLC 
analysis of the unusual pathway of oxidation of 
L-arginine to citrulline and nitric oxide in mammalian 
cells. Journal of Chromatography, 539, pg:433-441. 
55) Marletta,M.A.(1989) Nitric oxide: biosynthesis and 
biological significance. Trends in Biolchemical 
Sciences, 14, pg:488-492. 
56) Castillo,L.,DeRojas,T.C.,Chapman,T.E.,Vogt,J.(l993) 
Splanchnic metabolism of dietary arginine in relation to 
nitric oxide synthesis in normal adult man. Proceedings 
of the National Academy of Science, 90, pg:193-197. 
57) Schmidt,H.,Murad,F.(1991) Purification and 
characterisation of a human No·synthase. Biochemical and 
Biophysical Research Communications, 181, pg:1372-1377. 
58) Stuehr,D.J.,Cho,H.J.,Kwon,N.S.,Weise,M.F.,Nathan,c.F. 
(1991) Purification and characterisation of the 
cytokine-induced macrophage nitric oxide synthase: an 
FAD- and FMN-containing flavoprotein. Proceedings of the 
National Academy of Science, 88, pg:7773-7777. 
59) Bush,P.A.,Gonzalez,N.E.,Ignarro,L.J.(1992) Biosynthesis 
of nitric oxide and citrulline from L-arginine by 
constitutive nitric oxide synthetase present in rabbit 
corpus cavernosum. Biochemical and Biophysical Research 
Communications, 186, pg:308-314. 
60) Knowles,R.G.,Moncada,S.(l992) Nitric oxide as a signal 
in blood vessels. Trends in Biochemical Sciences, 17, 
pg:399-402. 
61) Xie,Q.,Cho,H.J.,Calatcay,J.,Mumford,R.A.,Swiderek,K.M. 
(1992) Cloning and characterisation of inducible nitric 
oxide synthase from mouse macrophages. Science, 256, 
pg:225-228. 
62) Stamler,J.S.,Singel,D.J.,Loscalzo,J.(l992) Biochemistry 
of nitric oxide and it's redox-activated forms. Science, 
258, pg:1898-1901. 
201 
63) Snyder,S.H.,Bredt,D.S.{1992) Biological roles of nitric 
oxide. Scientific American, May, pg:28-35. 
64) Beckman,J.S.{1991) The double-edged role of nitric oxide 
in brain function and superoxide-mediated injury. 
Journal of Developmental Physiology, 15, pg:53-59. 
65) Snyder,S.H.(1992) Nitric oxide: First in a new class of 
neurotransmitters. Science, 257, pg:494-496. 
66) Crossin,K.L.(1991) Nitric oxide: a versatile second 
messenger in brain. Trends in Biochemical Sciences, 16; 
pg:81-82. 
67) Rubanyi,G.,Ho,E.H.,Cantor,E.H.,Lumma,W.C.,Botelho,L.H.P. 
{1991) Cytoprotective function of nitric oxide -
inactivation of superoxide radicals produced by human 
leukocytes. Biochemical and Biophysical Research 
Communications, 181, pg:1392-1397. 
68) Andersson,K.E.,Pascual,K.,Persson,K.,Forman,A., 
Tottrup,A.(1992) Electrically-induced, nerve-mediated 
relaxation of rabbit urethra involves nitric oxide. 
Journal of Urology, 147, pg:253-259. 
69) Luscher,T.F.{1992) Endogenous and exogenous nitrates and 
their role in myocardial ischaemia. British Journal of 
Clinical Pharmacology, 34, pg:295-395. 
70) Stevens,C.F.(1992) Just say NO. current Biology, 2, 
pg:108-109. 
71) Moncada,S.,Palmer,R.M.,Higgs,E.A.(1991) Nitric oxide: 
physiology, pathophysiology, and pharmacology. 
Pharmacological Reviews, 43, pg:109-134. 
72) Garthwaite,J.,Charles,S.L.,Chess-williams,R. {1988) EDRF 
release on activation of NMDA receptors suggests role as 
intracellular messenger in the brain. Nature, 336, 
pg:385-388. 
73) Wolff,D.J.,Datto,G.A.(1992) Identification and 
characterisation of a calmodulin-dependent nitric oxide 
synthase from GH3 pituitary cells. Biochemical Journal, 
285, pg:201-206. . 
74) Bissonette,E.Y.,Hogaboam,C.M.,Wallace,J.L.,Befus,A.D. 
{1991) Potentiation of tumour necrosis factor-alpha 
mediated cytotoxicity of mast cells by their production 




inhibition by an L-arginine-derived substance by 
IL-1beta-treated vascular smooth muscle cells. American 
Journal of Physiology, 261 (No 6}, pg:H2024-H2030. 
202 
76) Gonzalez,C.,Fernandez,A.,Martin,c.,Moncada,s.,Estrada,c. 
(1992) Nitric oxide from endothelium and smooth muscle 
modulates responses to sympathetic nerve stimulation: 
implications for endotoxin shock. Biochemical and 
Biophysical Research Communications, 186, pg:150-156. 
77) Werner-Felmayer,G.,Werner,E.,Fuchs,D.,Hausen,A., 
Reibnegger,G.,Wachter,H.(1990) Tetrahydrobiopterin 
dependent formation of nitrite and nitrate in murine 
fibroblasts. Journal of Experimental Medicine, 172, 
pg:1599-1607. 
78) Estrada,C.,Gomez,C.,Martin,C.,Moncada,S.,Gonzalez,c. 
(1992) Nitric oxide mediates tumour necrosis 
factor-alpha cytotoxicity in endothelial cells. 
Biochemical and Biophysical Research Communications, 
186, pg:475-482. 
79) Severn,A.,Wakelam,M.J.,Liew,F.Y.(1992) The role of 
protein kinase c in the induction of nitric oxide 
synthesis by murine macrophages. Biochemical and 
Biophysical Research Communications, 188 (No 3), 
pg:997-1002. 
80) Werner,E.,Werner-Felmayer,G.,Fuchs,D.,Hausen,A., 
Reibnegger,G.,Wachter,H.(1989) Parallel induction of 
tetrahydrobiopterin biosynthesis and indoleamine 
2,3-dioxygenase activity in human cells and cell lines 
by interferon-gamma. Biochemical Journal, 262, 
pg:861-866. 
81) Werner,E.,Werner-Felmayer,G.,Fuchs,D.,Hausen,A.(1991) 
Impact of tumour necrosis factor-alpha and 
interferon-gamma on tetrahydrobiopterin synthesis in 
murine fibroblasts and macrophages. Biochemical Journal, 
280, pg:709-714. 
82) Werner-Felmayer,G.,Werner.E.,Fuchs,D.,Hausen,A., 
Reibnegger,G.,Wachter,H.(1989) Tumour necrosis 
factor-alpha and lipopolysaccharide enhance 
interferon-induced tryptophan degredation and pteridine 
synthesis in human cells. Biological Chemistry 
Hoppe-Seyler, 370, pg:1063-1069. 
83) Klostergaard,J.,Leroux,M.E.,Hung,M.(1991) Cellular 
models of macrophage tumoricidal effector mechanisms in 
vitro. Journal of Immunology, 147, pg:2802-2808. 
84) de Graaf,G.C.,Banga,J.D.,Moncada,s.,Palmer,R.M.(1992) 
Nitric oxide functions as an inhibitor of platelet 
adhesion under flow conditions. Circulation, 85, 
pg:2284-2290. 
85) cunha,F.Q.,Moncada,S.,Liew,F.Y.(l992) Interleukin-10 
inhibits the induction of nitric oxide synthase by 
interferon-gamma in murine fibroblasts. Biochemical and 
Biophysical Research Communications, 182, pg:1155-1159. 
203 
86) Siebert,P.D.,Wright,S.C.,Larrick,J.(1992) Examination of 
brain-type nitric oxide synthase expression in 
non-neuronal tissue by RT-PCR. Clontechniques, 7 (No 3), 
pg:1-3. 
87) Hattori,R.,Yui,Y.(1992) Regulation of nitric oxide 
synthase. Nippon Rinsho, 50, pg:311-314. 
88) Evans,T.,Carpenter,A.,Cohen,J.(1992) Purification of a 
distinctive form of endotoxin-induced nitric oxide 
synthase from rat liver. Proceedings of the National 
Academy of science, 89, pg:5361-5365. 
89) Billiar,T.R.,Langrehr,J.M.,Curran,R.D.,Ochoa,J.B., 
Stadler,J.,Harbrecht,B.G.(1991) Two unique aspects of 
inducible NO synthase in liver cells and accessory 
cells. Research Immunology, 142, pg:584-586. 
90) Radi,R.,Beckman,J.S.,Bush,K.M.,Freeman,B.A.(1991) 
Peroxynitrite oxidation of sulfhydryls. Journal of 
Biological Chemistry, 266, pg:4244-4250. 
91) Kroncke,K.,Kolb-Bachofen,V.,Berschick,B.,Burkart,V., 
Kolb,H.(1991) Activated macrophages kill pancreatic 
syngeneic islet cells via arginine-dependent nitric 
oxide generation. Biochemical and Biophysical Research 
Communications, 175, pg:752-758. 
92) Nguyen,T.,Brunson,D.,Crespi,C.L.,Penman,b.W., 
Wishnok,J.S.,Tannenbaum,S.R.(1992) DNA damage and 
mutation in human cells exposed to nitric oxide in 
vitro. Proceedings of the National Academy of Science, 
89, pg:3030-3034. 
93) Rawn,J.D.(1989) Biochemistry, chapter 3, pg:51-73. Neil 
Patterson publishers, U.S.A. 
94) Pataki,G.(1967) Techniques of thin-layer chromatography 
in amino acid and peptide chemistry. Ann Arbor science 
publishers Inc. 
95) Blachier,F.,Darcy-Vrillon,B.,Sener,A.,Duee,P., 
Malaisse,W.J. (1991) Arginine metabolism in rat 
enterocytes. Biochimica et Biophysica Acta, 1092, 
pg:304-310. 
96) Seiler,N.,Knodgen,B.(1980) HPLC procedure for the 
simultaneous determination of the natural polyamines and 
their monoacetyl derivatives. Journal of Chromatography, 
221, pg:227-235. 
97) Flo-one/Beta series A-100, radioactivity detectors for 




98) Westall,R.G.(1960) Argininosuccinate Aciduria: 
Identification and reactions of the abnormal metabolite 
in a newly descibed form of mental disease, with some 
preliminary metabolic studies. Biochemical Journal, 77, 
pg:135-144. 
99) Nussbaum,R.L.,Boggs,B.A.,Beaudet,A.L.,Doyle,s., 
Potter,J.L.,O'Brien,W.E.(1986) New mutation and 
prenatal diagnosis in ornithine transcarbamylase 
deficiency. American Journal of Human Genetics, 38, 
pg:149-158. 
100) Knowles,R.G.,Merret,M.,Salter,M.,Moncada,s.(1990) 
Differential induction of brain, lung and liver nitric 
oxide synthase by endotoxin in the rat. Biochemical 
Journal, 270, pg:833-836. 
101) Cheung,C.,Raijman,L.(1981) Arginine, mitochondrial 
arginase, and the control of carbamyl phosphate 
synthesis. Archives of Biochemistry and 
Biophysics, 209, pg:643-649. 
